Depression and Depressive Disorders

Depression and Depressive Disorders

Last updated: 12/2020

Contributor(s): Dr. Maureen Williams, ND; Dr. Shayna Sandhaus, PhD

1 Overview

Summary and Quick Facts

  • The term “depression” can refer to a spectrum of mental health disorders ranging in severity from mild to very severe, and more than one in five adults in the United States experience an episode of major depression during their lifetime.
  • Depression is associated with a wide range of chronic health problems, which can complicate timely diagnosis and treatment.
  • Approximately one-third of depression patients fail to respond to conventional treatment with antidepressant medications and psychotherapy.
  • Integrative therapies such as omega-3 polyunsaturated fatty acids, vitamin D, probiotics, zinc, and saffron extract, along with healthy eating habits, regular exercise, stress management practices, and adequate sleep, can support mental health and positive mood.

What are Depression and Depressive Disorders?

Depression is a mood state characterized by low mood and a loss of interest in previously pleasurable activities. If a depressed mood is persistent and severe enough to interfere with normal day-to-day function, it may meet the criteria for diagnosis as a depressive disorder.

Major depressive disorder, or major depression, is the main type of depressive disorder. When episodes of major depression are chronic and recurring, the condition is called persistent depressive disorder. Other types of depressive disorders include premenstrual depressive disorder, substance- or medication-induced depressive disorder, and depressive disorder due to another medical condition.

It has long been thought depression results from a neurotransmitter imbalance, but more recent evidence suggests underlying causes such as chronic low-level inflammation, dysregulation of the stress response, altered brain cell function, and imbalance in the gut microbiome are important contributors. Some natural interventions such as omage-3 fatty acids, saffron extract, acetyl-L-carnitine, and probiotics have been shown to target these underlying mechanisms, supporting healthy brain function and mood.

What are the Risk Factors for Depressive Disorders?

  • Gender — women are about twice as likely to experience depression as men
  • Age — adolescents and young adults are more likely to develop depression than older adults, and the risk is especially high in gender- and sexual-minority, racial- and ethnic-minority, and economically disadvantaged youth
  • Family history of depression — the risk of major depression is three times greater among those who have a first-degree relative with major depression
  • Maltreatment during childhood, including neglect and abuse
  • Adverse life events, such as unemployment, financial hardship, divorce, grief and loss, and catastrophic world events such as natural disasters
  • Chronic or severe stress
  • Loneliness
  • Certain personality traits, including shyness, agreeableness, and moodiness
  • Sleep disorders, including sleep apnea
  • Other psychiatric disorders, such as substance use disorders, anxiety disorders, and post-traumatic stress disorder (PTSD)

Depression frequently co-occurs with chronic diseases: stroke survivors and people with chronic diseases like heart disease, cancer, diabetes, and respiratory disease are up to four times more likely than others to have depression, and the co-occurrence of depression worsens their prognosis.

What are the Signs and Symptoms of Major Depressive Disorder?

  • Persistent depressed mood
  • Loss of interest and pleasure
  • Change in appetite or body weight
  • Over- or under-sleeping
  • Slowness or agitation
  • Fatigue
  • Inability to concentrate or make decisions
  • Thoughts of death or suicide

What are Conventional Medical Treatments for Depressive Disorders?

  • Cognitive behavioral therapy
  • Drug therapy
    • First-line antidepressants:
      • selective serotonin reuptake inhibitors (SSRIs)
        • eg, fluoxetine (Prozac) and citalopram (Celexa),
      • serotonin-norepinephrine reuptake inhibitors (SNRIs)
        • eg, duloxetine (Cymbalta) and venlafaxine (Effexor), and
      • atypical antidepressants
        • eg, bupropion (Wellbutrin) and mirtazapine (Remeron)
    • Second-line antidepressants, including:
      • tricyclic antidepressants
        • eg, amitriptyline (Elavil) and clomipramine (Anafranil)
      • monoamine oxidase inhibitors (MAOIs)
        • eg, tranylcypromine (Parnate) and phenelzine (Nardil)
      • Atypical antipsychotics:
        • eg, aripiprazole (Abilify) and quetiapine (Seroquel)
  • Neurostimulation techniques
    • Electroconvulsive therapy
    • Vagus nerve stimulation
    • Repetitive transcranial magnetic stimulation
    • Ablative neurosurgery

What are Some Emerging Treatments for Depressive Disorders?

  • Agomelatine, a synthetic version of melatonin
  • Ketamine (Ketalar, an intravenous medication) and esketamine (Spravato, an intranasal derivative of ketamine approved for use in treatment-resistant depression)
  • Investigational neurostimulation techniques
    • Transcutaneous auricular vagus nerve stimulation
    • Magnetic seizure therapy
    • Transcranial electrical stimulation
    • Deep brain stimulation

What Dietary and Lifestyle Changes May Be Beneficial for Depressive Disorders?

  • Eat a healthy, well-balanced, anti-inflammatory diet (eg, Mediterranean-style diet)
  • Get regular exercise — consider a structured program to keep you motivated
  • Get enough sleep
  • Meditation techniques, including mindfulness meditation

What Natural Interventions May Be Beneficial for Depressive Disorders?

  • Omega-3 fatty acids. The omega-3 fatty acids eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA) reduce inflammation, promote healthy nerve function, and have been shown to reduce symptoms of depression.
  • Vitamin D. Vitamin D deficiency has been linked to depression, and supplements have been found to have a positive impact on depression symptoms.
  • Probiotics. Certain probiotic strains have been shown to improve mood in those with depression.
  • Zinc. Low zinc levels have been correlated with depression, and zinc supplements have been shown to reduce symptoms of depression when used alone or with antidepressants.
  • Saffron. Saffron extract has been found to reduce depressive symptoms in those with other health problems and improve the effectiveness of antidepressants.
  • St. John’s wort. Multiple clinical trials have shown St. John’s wort can reduce symptoms of depression.
  • Acetyl-L-carnitine. Acetyl-L-carnitine promotes healthy brain cell function and has been found to reduce depression symptoms.
  • Dehydroepiandrosterone (DHEA). DHEA contributes to mood modulation, is neuroprotective, has anti-stress activity, and has been reported to reduce depressive symptoms.
  • B complex vitamins. Clinical trials have shown supplementing with B vitamins can lower levels of perceived stress, improve mood, and reduce depressive symptoms.
  • L-tryptophan and 5-hydroxytryptophan (5-HTP). L-tryptophan has been found to reduce depression symptoms and 5-HTP, a byproduct of tryptophan metabolism, may improve the effectiveness of antidepressants.
  • Other natural interventions such as N-acteylcysteine, rhodiola, lemon balm, lavender, and SAMe may help reduce symptoms of depression.

2 Introduction

“Depression” is an amorphous term often applied to a spectrum of mental health conditions ranging in severity from mild to very severe and debilitating. Depression may refer to a normal mood state or a manifestation of a pathological psychiatric condition. When depressive symptoms fit certain criteria, they may be classified as distinct conditions such as major depressive disorder or persistent depressive disorder. While most people experience depressed mood from time to time, depressive disorders are generally distinguished by their severity and persistence.1-3

Depressive disorders are among the most common mental health conditions in the United States.4 Depression has been ranked among the leading causes of disease burden worldwide by the World Health Organization (WHO).5-7 In the United States, more than one in five adults experience a major depressive disorder at some point in their lifetime.4 Despite its high prevalence, depression often goes undiagnosed and untreated.8,9

Depression is associated with a wide range of other chronic conditions and often co-occurs with cancer, stroke, heart disease, diabetes, chronic obstructive pulmonary disease, multiple sclerosis, chronic pain, and many other medical ailments.10,11 In addition, patients with depression commonly experience other psychiatric conditions such as anxiety.12 The overlap between depression and other health conditions can make it difficult to identify a primary diagnosis and initiate the appropriate treatment.10,11,13 Although medical and psychotherapeutic interventions are available, approximately one-third of depression patients fail to respond to conventional treatments.14

In this protocol, you will learn about the different types of depression and the underlying causes of depressive disorders and why they are often so challenging to successfully treat. You will also learn about the important role of diet and lifestyle strategies in a comprehensive treatment approach, as well as many integrative therapies that have demonstrated similar efficacy to antidepressant medications. These include probiotics, herbal supplements like saffron and St. John’s wort, and nutritional supplements like omega-3 fatty acids, vitamin D, and zinc.

3 Types of Depressive Disorders

Most people experience depressed moods from time to time, usually in response to disappointments, losses, or other negative life events. A depressed mood generally comes in waves that tend to be associated with thoughts or reminders of triggering life events, pass when the situation improves, and may be interrupted by periods of positivity and humor.15 In depressive disorders, dark moods are more severe and may even include thoughts of suicide, are often unrelated to immediate circumstances, are persistent or recur in episodes lasting weeks to months or longer, and are associated with diminished ability to function in multiple realms of life, including work, school, and relationships.8 Throughout this protocol, the term “depression” will be used to indicate clinical depressive disorders rather than transient depressed moods.

Depressive disorders are defined by the Diagnostic and Statistical Manual of Mental Disorders, fifth edition, or DSM-5, published by the American Psychiatric Association. The main types of depression delineated in DSM-5 include those listed below, although there are several subtypes and qualifiers with some of these conditions3:

  • Major depressive disorder
  • Persistent depressive disorder (dysthymia)
  • Premenstrual dysphoric disorder
  • Substance/medication-induced depressive disorder
  • Depressive disorder due to another condition
  • Disruptive mood dysregulation disorder (a childhood disorder, not covered extensively in this protocol)

Major Depressive Disorder

Major depressive disorder (also called major depression or clinical depression) is characterized by one or more episodes lasting at least two weeks in which depressed mood is experienced most of the day nearly every day. A loss of interest and ability to experience pleasure is a key feature of major depression. Major depression interferes with the ability to function in day-to-day life, and often affects self-care. Other possible symptoms include an increase or decrease in appetite and body weight; increase or decrease in sleep; mental and physical agitation; fatigue; feelings of guilt or worthlessness; and inability to think clearly, concentrate, or make decisions. Many people with major depressive disorder have recurring thoughts of suicide, may have a suicide plan, or may have attempted suicide.5,8,15

In order to be diagnosed with major depressive disorder, a patient must exhibit at least five of the aforementioned symptoms, and one must be persistent depressed mood or loss of interest and pleasure.5 Episodes of major depressive disorder may be categorized as mild, moderate, or severe, depending on degree of disability and duration of symptoms.8

Major depression is more likely to occur in women than men. People in their mid-teens, 20s, and 30s are more susceptible than those in other age groups. Approximately 40% of individuals with major depressive disorder have their first episode before age 20 and many depression patients experience recurrent episodes throughout their life.5,15

Persistent Depressive Disorder

Persistent depressive disorder (aka dysthymia) is a chronic form of depression diagnosed when episodes of major depression occur over a period of at least two years, with intervals of remission lasting no longer than two months. The number and severity of symptoms and degree of functional impairment may fluctuate. In addition to depressed mood most of the time on most days, patients with persistent depressive disorder exhibit at least two of the following symptoms: changes in appetite, body weight, and sleep; fatigue or lack of energy; low self-esteem; difficulty concentrating and making decisions; and feelings of hopelessness.5,15

Specifiers: Major Depression and Persistent Depressive Disorder

Both major and persistent depressive disorders can be further described by specific patterns of symptoms, which can vary between episodes. These specifiers are described in the DSM-5 as follows3,5,15:

  • Anxious distress: feelings of restlessness, worry and fear, and a sense or fear of losing control
  • Mixed features: includes symptoms of mania or hypomania such as elevated mood, grandiosity, excessive talking, flight of ideas, and decreased sleep
  • Melancholic: feelings of despondency, despair, and guilt, with marked mental or physical slowness or agitation, early morning waking, and diminished appetite and weight loss
  • Atypical: temporary brightening of mood in response to positive events; heightened sensitivity to perceived criticism or rejection; feelings of the body being heavy or weighed down; and increased sleep, appetite, and weight gain
  • Psychotic: includes delusions that often inspire intense guilt, shame, or fear, and/or visual and auditory hallucinations
  • Catatonic: includes severe slowing of mental and physical activity, withdrawal, and engagement in purposeless movement
  • Peripartum onset: symptoms come on during pregnancy or within four weeks after childbirth, and may include delusions or hallucinations
  • Seasonal pattern: episodes come on at certain times of year, typically fall or winter

Premenstrual Dysphoric Disorder

Premenstrual dysphoric disorder is a form of depression that occurs in synchrony with the menstrual cycle. Women with this disorder have depressive symptoms severe enough to cause distress and limit functioning during a part of most of their cycles, beginning sometime after ovulation, easing within a few days of the onset of menses, and subsiding completely or near-completely in the week following menstruation. Premenstrual dysphoric disorder is marked by mood swings, irritability or anger, feelings of hopelessness or dislike for oneself, and anxiety or tension, as well as other typical depressive symptoms such as low interest in usual activities, difficulty concentrating, low energy level, changes in appetite and sleep habits, and a sense of being overwhelmed. In addition, physical symptoms like bloating, breast swelling or tenderness, muscle and joint pain, and weight gain may accompany mood symptoms.15,16

Substance- or Medication-induced Depressive Disorder

Substance- or medication-induced depressive disorder is characterized by the same symptoms as major depression, but the onset correlates with beginning, or withdrawing from, a medication or substance that can cause depression. Some substances and medications that can trigger depression during their use or withdrawal include alcohol, psychedelics such as phencyclidine (PCP), opioids, sedatives and insomnia drugs, anti-anxiety medications, and stimulants like amphetamines and cocaine.16

Depressive Disorder Due to Another Medical Condition

Depression can result from the physiologic effects of certain medical conditions. It can be very challenging to distinguish a condition-related depression from major depression, since depression is both a common symptom and contributing factor in numerous physical illnesses.10 Some conditions known to cause depression include hypothyroidism, stroke, traumatic brain injury, Parkinson disease, and Huntington disease.16 The relationship between other chronic diseases and depression is often more complicated, but it is important to note that depression frequently co-occurs with conditions such as heart disease, diabetes, respiratory diseases, cancer, and dementia.10,17

Other Depressive Disorders

This diagnostic category refers to people who have never met the diagnostic criteria for major depressive disorder yet experience debilitating depressive episodes that include fewer than five symptoms or remit in less than two weeks. In particular, people experiencing disabling depressed mood and at least one other depressive symptom for two weeks or longer can be diagnosed with having a “depressive episode with insufficient symptoms,” which is sometimes referred to as subthreshold depression.5,15,16 Recognizing subthreshold depression is important because of its high prevalence, possible prodromal relationship with major depression, and substantial negative impact on function, health, and mortality, especially in the elderly.18

4 Risk Factors

Depression is approximately twice as common in women than men; in general, adolescents and young adults have a higher chance of developing major depression than older adults.8 In the United States, Native American and white adults are more likely to have major depression than Hispanic, African-American, and Asian adults, and those with lower incomes are at greater risk than those with higher incomes.4 In adolescents, the risk of depression is higher among sexual minorities (gay, lesbian, bisexual, transgender), racial and ethnic minorities, and economically disadvantaged youth.19 In addition, the following risk factors for major depression have been identified:

  • Family history of depression
    • Risk of major depression is three times greater among people who have a first-degree relative with major depression5
  • Maltreatment during childhood, including neglect and abuse20,21
  • Adverse life events, such as unemployment, financial hardship, divorce, grief and loss, and catastrophic world events such as natural disasters8
  • Chronic or severe stress22
  • Loneliness23
  • Certain personality traits, including shyness and introversion, agreeableness, and neuroticism (moodiness with a tendency to feel emotions such as worry, fear, anger, frustration, envy, guilt, loneliness, and depressed mood)20
  • Sleep disorders24
  • Other psychiatric disorders, such as substance use disorders, anxiety disorders, and post-traumatic stress disorder (PTSD)4

Sleep Apnea and Depression

Sleep apnea is a disorder in which sleep is fragmented by repeated bouts of partial or complete cessation of breathing, usually due to airway tissue collapse that obstructs air flow. Sleep apnea is associated with fatigue and daytime sleepiness, and has also been strongly correlated with depression and anxiety.25,26 A study that included data from 2,818 people recently diagnosed with obstructive sleep apnea found they were about twice as likely to develop depression as similar people without sleep apnea during one year of monitoring.27 In addition, a study with 18,980 participants found those with major depression were over five times more likely to have sleep apnea than the general population.28

Treating sleep apnea with continuous positive airway pressure (CPAP) may help reduce symptoms of depression. In a meta-analysis of nine randomized controlled trials with a combined total of 1,052 participants, sleep apnea patients who used CPAP had lower scores on depression tests compared with those who did not.29 On the other hand, an analysis of findings from two 12-week sham-controlled trials found CPAP reduced symptoms in those with sleep apnea and major depression, but not in those without a major depression diagnosis.30

Some evidence suggests the link between sleep apnea and depression may be related to changes in hormone levels and stress signaling.31 Other research suggests sleep apnea may increase depression risk by causing brain tissue damage due to systemic inflammation and impaired blood flow.26,32 Increased sleepiness and sedentariness in individuals with sleep apnea may further contribute to the development of depression.32

5 Physiological Factors that May Contribute to Depression

Depression is a complex disorder with numerous contributing causes. Genetic factors, including those affecting neurotransmitter metabolism and receptor expression and function, are moderately heritable (up to 45%) and may account for some of the risk. Interestingly, genetics appear to have a stronger influence on depression risk in women than men.20 Environmental and experiential circumstances also contribute significantly to depression susceptibility; depression risk correlates with factors such as traumatic life events, physical illness, and chronic stress. Together, genetic and environmental/experiential factors interact with, and provide context for, one another through epigenetics, which refers to the way genes are expressed. Epigenetic gene expression changes induced by experiences and exposures are malleable, potentially reversible, and may also be heritable to some degree.5,33

The exact mechanism by which genetics, environment, and epigenetics contribute to depression is still a topic of research and debate. It is likely these complex interactions involve multiple overlapping mechanisms, including those described below.

Neurotransmitter Imbalance (The Monoamine Hypothesis)

The monoamine hypothesis is the longest-held theory of depression and has guided the development of treatment for more than 50 years.34 According to the monoamine hypothesis, decreased signaling by monoamine neurotransmitters (serotonin, norepinephrine, and dopamine) in depressed patients reduces nerve activation in regions of the brain involved in emotional processing, memory, learning, and motivation, contributing to the manifestations of depression and diminished cognitive function.35 While this theory is attractive for its simplicity, the fact that medications that increase monoamine signaling often take two to four weeks to work, and even then are effective in only 30–40% of patients with depression, suggests there is more to explain.34,36 The three primary monoamine neurotransmitters and their connections with depression are reviewed briefly below.

Serotonin. Serotonin signaling occurs in much of the nervous system and brain and is concentrated in the limbic system, a network of brain structures involved in processing emotions and memories as well as generating sensations of pleasure that reinforce behaviors.37 In addition, serotonin participates in cognition and regulation of appetite, sleep, and temperature.38 Low serotonin levels, low brain responsiveness to serotonin, and abnormal serotonin metabolism in individuals with depression have been reported.20,39 Selective serotonin reuptake inhibitors (SSRIs), which enhance serotonin signaling, are widely used in first-line treatment of depression.20

Norepinephrine. Norepinephrine, the main neurotransmitter of the sympathetic nervous system, increases nerve excitability generally and activates the stress response.40,41 Like serotonin, norepinephrine is involved in many brain functions including attention, learning, memory, mood, sleep, and appetite.20,42 Antidepressant medications that increase norepinephrine levels, called serotonin-norepinephrine reuptake inhibitors (SNRIs), are also used in first-line treatment of depression.20 It is well known that acute stress increases norepinephrine signaling, but chronic stress and stress-induced depression are associated with damage to neurons that produce norepinephrine and changes in norepinephrine receptor function in key regions of the brain. SNRI medications may work by restoring normal norepinephrine levels and balancing norepinephrine receptor function.20,41

Dopamine. Dysregulation of dopamine signaling may play an important though less-recognized role in depression. Dopamine participates in learning and memory, and mediates feelings of pleasure and motivation.43 Deficits in dopamine signaling in specific brain regions may be associated with depression and are thought to contribute particularly to the loss of interest, pleasure, and motivation that are hallmark symptoms of depression.44 Older antidepressants called monoamine oxidase inhibitors (MAOIs) increase dopamine levels, as well as levels of serotonin and norepinephrine, by blocking their breakdown.43


Stressful events and high levels of perceived stress often precipitate depressive episodes. Many patients with depression, especially those who have experienced early childhood stress, have been found to have increased signaling along the hypothalamic-pituitary-adrenal (HPA) axis.45 The HPA axis regulates the output of the stress hormone cortisol, and in the sympathetic nervous system, initiates the acute “fight-or-flight” stress response. The HPA axis and sympathetic nervous system are closely interconnected and together manage the body’s reactivity to stressful stimuli. Hyper-responsiveness to stress appears to be an important underlying factor in the development of depression, as well as the connections between depression and chronic metabolic problems such as cardiovascular disease, type 2 diabetes, metabolic syndrome, and cognitive impairment.46,47


Depression is correlated with a number of inflammatory diseases, including chronic viral and bacterial infections, allergies and asthma, autoimmune conditions, neurological and cardiovascular diseases, obesity, and diabetes.22 It is estimated that 30–50% of people with depression exhibit an increased inflammatory tendency.48 These individuals have been found to have higher levels of immune cells and immune activation, C-reactive protein, and inflammatory cytokines such as interleukin-2 (IL-2) and IL-6, and generally have more severe depression than those without increased markers of inflammation.49,50 Some evidence suggests antidepressant medications may have anti-inflammatory effects that contribute to their therapeutic benefits, and anti-inflammatory medications are currently being explored for their potential to improve the effectiveness of antidepressant therapy (see section titled “Novel and Emerging Therapies”).51

Inflammation causes increased production of cell-damaging free radicals, which can disrupt the synthesis of monoamine neurotransmitters by oxidizing tetrahydrobiopterin, a common cofactor needed for their synthesis.52 Inflammation also activates enzyme pathways that increase production of neurotoxins, alters signaling along neural networks by increasing glutamate release in the brain, and may contribute to decreased neuronal growth and plasticity by reducing production of a growth factor called brain-derived neurotrophic factor (BDNF).52,53 Furthermore, evidence suggests stress-induced inflammation may exacerbate neuroinflammation by compromising the integrity of the blood-brain barrier, which selectively controls the microenvironment of the brain.48

While stress is a known trigger of inflammatory signaling, inflammatory cytokines in turn activate the stress response, and a heightened inflammatory response to stressful circumstances has been noted in both individuals with depression and those at high risk of depression. The integration of stress and immune function is thought to have evolved as a mechanism to help injured and infected organisms avoid or escape danger.54 Depressive behaviors induced by inflammation may even have served important functions, such as allowing energy to be conserved and redirected toward fighting infection and healing wounds, avoiding psychological or emotional re-injury, and soliciting help from others.46,54 However, in the context of modern life, these adaptive strategies have become a source of pathology, with rampant immune dysregulation and long-term psychosocial stress inducing an unabating depressed state that itself contributes to chronic illness and death.54

Impaired Neuroplasticity and Neurogenesis

The formation of new nerve cells from stem cells in the brain (neurogenesis) and the ability of neurons to grow and form new connections (neuroplasticity) may be diminished in individuals with depression. Neurogenesis and neuroplasticity are regulated by growth factors, including BDNF.55,56 BDNF levels are lower and epigenetic changes related to the BDNF gene have been noted in patients with depression.36 Suppressed levels of monoamines, neuroinflammation, and stress may all contribute to diminished levels of BDNF and reduced neurogenesis and neuroplasticity.5,36,52,56 Evidence suggests medical and psychotherapeutic treatment of depression, when effective, increase BDNF levels and result in greater neuroplasticity and neurogenesis.5,35,36 In addition, exercise has been shown in multiple studies to raise plasma BDNF levels, and accumulating evidence indicates signaling molecules released by muscles during exercise cross the blood-brain barrier and promote its production in the brain.57-59

Brain Atrophy

Patients with depression have consistently been found to have substantial reductions in volumes of the hippocampus (part of the limbic system) and medial prefrontal cortex regions of the brain, affecting both emotional regulation and cognition.5,35,60 This appears to be due not only to decreased density of neurons, but also diminished numbers of glial cells, a type of brain cell that provides structural, metabolic, and functional support to neurons.35 The degree of atrophy in these brain regions reflects the duration and severity of depression, and impacts neural networks responsible for such basic brain functions as introspection and rumination, discriminating salient from background stimulation, attention, and working memory (short-term memory related to immediate activities).61 High levels of the stress hormone cortisol, brain oxidative stress, neuroinflammation, and low levels of neurotransmitters may contribute to neuron and glial cell death, and ultimately, brain atrophy.22,36,60,62

Microbiome Dysbiosis

The bidirectional communication network between microorganisms (or microbes) of the digestive tract and the brain is the basis of the concept of the microbiota-gut-brain axis.63,64 Intestinal microbes, especially bacteria, produce signaling molecules that support digestion, preserve gut barrier function, regulate immune function and the inflammatory response, and modulate metabolism.65 In the brain, the microbiome appears to affect mood and cognition through complex signaling that alters neurotransmitter release and function, levels and activity of BDNF, circadian systems, and activation of the stress response.63,66 Gut microbial imbalance may contribute to depression by dysregulating circadian control and the HPA axis, increasing neuroinflammation, altering neurotransmitter signaling, and reducing neuroplasticity and neurogenesis.63,66,67

Patients with depression have been found to have lower numbers and diversity in their gut microbiota compared with healthy controls.67 This may be significant because diversity and abundance are key characteristics of a healthy microbiome.65 Not only does a compromised microbiome likely contribute to poor mental health, it is also clear that stress, anxiety, and depression can have negative impacts on the microbiome.65 Therapies for depression that target the microbiome, such as dietary interventions, probiotic supplements, and fecal microbial transplant, have shown promise in preclinical and early clinical research.64,67

6 Health Conditions Associated with Depression

It is estimated that nearly half of people with depression have at least one chronic non-psychiatric condition.68 In addition, stroke survivors and people with chronic diseases, including heart disease, cancer, diabetes, and respiratory disease, are up to four times more likely to have depression compared to those without such conditions, and the co-occurrence of depression worsens their prognosis.10,13,68 Many chronic diseases can cause symptoms that overlap with those of depression, blurring distinctions and complicating diagnosis and treatment.10 Underlying mechanisms that may link depression to other ailments include stress, systemic immune-inflammation dysregulation, and altered microbiome.7,10,69,70

Individuals with mental health disorders such as anxiety disorders and schizophrenia have a higher risk of depression as well. Furthermore, depression worsens the prognosis for people with other psychiatric illnesses.71

The following are some of the many chronic non-psychiatric diseases that frequently co-occur with depression:

  • Cardiovascular disease. Cardiovascular disease and depression are strongly linked, and their relationship appears to be bidirectional.72 It is estimated that major depression increases the risk of cardiovascular disease and death by about 80%.73 The complex mechanisms linking depression to cardiovascular disease are likely to include genetic, biological, psychosocial, and behavioral factors, with stress playing a substantial role.72,74
  • Cerebrovascular disease. Post- stroke depression is a well-documented phenomenon and is associated with greater disability and increased likelihood of death.75 Cognitive impairment and dementia are also closely linked to depression, possibly due to changes in brain structure and neuroplasticity.17,76
  • Diabetes and obesity. People with diabetes are about twice as likely to suffer from major depression as people without diabetes. In addition, up to 25% of diabetics suffer from depressive symptoms. Distress related to diabetes may contribute to high rates of depression; however, depression also increases the risk of diabetes, suggesting they are linked by underlying mechanisms.77 This same type of bidirectional relationship exists between obesity and depression, and may reflect common mechanisms such as systemic inflammation and microbiome imbalance.78
  • Neurological disease. Chronic neurodegenerative conditions such as Parkinson disease, Huntington disease, and Alzheimer disease are highly correlated with depression. Findings such as neurotransmitter deficits, dysregulated HPA axis signaling, neuroinflammation and oxidative stress, and impaired glial cell function are shared mechanisms in these conditions.79
  • Digestive disorders. Chronic digestive problems have been associated with major depression. Irritable bowel syndrome, for example, is associated with a 2.7-fold increase in depressive disorders compared with healthy controls.80 On the other hand, individuals who self-report having depression or anxiety are twice as likely to have irritable bowel syndrome as those reporting no mood problems.81 Chronic constipation, dyspepsia, and inflammatory bowel disease are also common in depressed patients.82-84 Factors affecting gut-brain communication, such as serotonin signaling and the microbiome, are disturbed in digestive and mood disorders.78,85
  • Chronic pain. As many as 85% of people with chronic pain disorders, such as fibromyalgia and migraines, also suffer from depression.86-88 Interestingly, individuals with depression also appear to have a greater likelihood of developing chronic pain syndromes, suggesting bi-directionality due to a common mechanism, possibly rooted in chronic or extreme stress and reduced neuroplasticity.86,88
  • Cancer. The prevalence of major depression is up to four times higher in cancer patients than the general population and is a predictor of worse outcomes. It is thought that psychological distress related to having cancer is an underlying factor.89 In addition, having depression has been associated with greater risk of cancer.90
  • Allergic and autoimmune disease. Allergic conditions including asthma and atopic dermatitis and autoimmune diseases including multiple sclerosis, rheumatoid arthritis, and celiac disease have all been found to correlate with depression, which can complicate their course.91-94
  • Chronic fatigue. Chronic fatigue syndrome and major depression share many symptoms and often co-occur. It is thought stress and neuro-inflammatory pathways are mechanisms linking them.95,96

Depression During the COVID-19 Health Crisis

The 2019-2020 COVID-19 pandemic has been a source of extreme psychological distress in the United States and around the world. Fear and anxiety due to rising numbers of deaths, mass unemployment, and disruption of life, a condition dubbed by some as “coronaphobia,” has been linked to elevated prevalence of depression, anxiety, hopelessness, suicidality, and functional impairment.97 A report from the US Census Bureau stated that depressive and anxiety disorders were three times more prevalent in 2020 compared with 2019. By mid-2020, using screening questionnaires administered to a nationally representative sample of 336,525 participants, the Census Bureau found more than 23% of participants screened positive for depression and 30% for anxiety.98 In mid-July, another Census Bureau survey found a majority of adults living in large American cities felt down, depressed, or hopeless at least several days the previous week.99 Alarmingly, nearly 15% of respondents to an online survey performed in March 2020 were noted to have high suicide risk.100

People directly impacted by COVID-19 may be at particularly high risk. A small study performed in Wuhan, China, where depression and anxiety rates were each found to exceed 35%, noted that family members of people who became sick or died from COVID-19 were more greatly impacted by depressive and anxiety disorders.101 Another study found, in patients with COVID-19 in isolation hospitals in China, the prevalence of depression was 43.1%, and the risk of depression was higher in those who relied more on social media for COVID-19-related information.102

Factors such as younger age, female gender, being unemployed or a student, social isolation, being food-insecure, and having had a previous psychiatric disorder are factors that have been associated with increased risk of pandemic-related depression and anxiety.103-106 On the other hand, eating a healthy diet, not reading news updates about COVID-19 very often, following a routine, taking time to pursue hobbies, and spending time being or looking outdoors were habits associated with lower depression risk among respondents to a survey in Spain.105

7 Diagnosis

Diagnosing major depressive disorder involves screening through careful history-taking to identify risk factors, ruling out other causes for depressive symptoms, and the use of diagnostic surveys.


The U.S. Preventive Services Task Force (USPSTF) and American Academy of Family Physicians recommend screening all adults for depression during routine health visits.107 It is especially important for those at high risk of depression—those who have a prior depressive episode, family history of depression, recent major stressful event, one or more chronic medical conditions, cognitive impairment or dementia, or anxiety or substance abuse—to undergo a screening process with their healthcare provider.68 In addition, because depression can manifest as physical symptoms, it is important to screen patients presenting to their healthcare provider with multiple physical complaints, vague complaints, or unexplained physical symptoms.68

Screening questions and surveys can help distinguish ordinary variations in mood from major depressive disorder, which is severe or enduring enough to interfere with realms of life such as work, school, and relationships.15 When depression is suspected, it is critical to also evaluate the risk of suicide.15 The two-item and nine-item Patient Health Questionnaires (PHQ-2 and PHQ-9) are the most widely used screening tools. Some healthcare providers use PHQ-9 following a positive result on PHQ-2 before proceeding with the diagnostic process.107

Table 1: PHQ-2 Depression Screening Tool

Over the past two weeks, how often have you been bothered by the following problems?

Not at all

Several days

More than half the days

Nearly every day

Little interest or pleasure in doing things





Feeling down, depressed, or hopeless





Scoring: a score of 3 or higher is considered a positive result and indicates the need for further evaluation.68,107

Table 2: PHQ-9 Depression Screening Tool

Over the past two weeks, how often have you been bothered by the following problems?

Not at all

Several days

More than half the days

Nearly every day

Little interest or pleasure in doing things





Feeling down, depressed, or hopeless





Trouble falling or staying asleep, or sleeping too much





Feeling tired or having little energy





Poor appetite or overeating





Feeling bad about yourself, or that you are a failure or have let yourself or your family down





Trouble concentrating on things such as reading the newspaper or watching television





Moving or speaking so slowly that other people could have noticed, or the opposite: being so fidgety or restless that you have been moving around a lot more than usual





Thoughts that you would be better off dead, or hurting yourself in some way





Scoring: a score of 1–4 indicates minimal depression; 5–9 indicates mild depression; 10–14 indicates moderate
depression; 15–19 indicates moderately severe depression; 20–27 indicates severe depression.68,107

Ruling Out Other Causes

Depressed mood is a common symptom in a broad array of medical conditions, including cardiovascular, neurological, hormonal, metabolic, infectious, autoimmune, and psychiatric ailments.15,107 Substance abuse disorders may be particularly difficult to distinguish from depression, and the close relationship between anxiety and depression can make accurate diagnosis complicated.68 Nutritional deficiencies, especially of B vitamins or iron, are also associated with depressive symptoms.107

Although there are no blood tests for diagnosing depression, the following may help rule out other causes of depression:

  • Complete blood count (CBC)15
  • Ferritin108
  • Basic chemistry, including electrolytes, glucose, liver enzymes, blood urea nitrogen (BUN), and creatinine107
  • Vitamin B12 and folate15
  • Homocysteine109
  • Thyroid stimulating hormone (TSH)15
  • Testosterone in men15

Cortisol testing may be helpful in assessing stress-related depression. Cortisol levels in saliva, blood, urine, and hair have been shown to be reliable markers of adrenal cortisol output and may be useful in detecting dysfunctional HPA axis signaling.45,110-112

Urine neurotransmitter tests are widely available and promoted as a method of assessing mood disorders and guiding treatment. Levels of neurotransmitters in urine reflect their levels in peripheral blood; however, it is not yet clear whether these levels are correlated with brain neurotransmitter levels or clinical disorders like depression.113,114

It is important to note that certain medications may cause depressive symptoms, including some blood pressure lowering drugs, corticosteroids, and progesterone implants, as well as interferon alfa-2b (Intron-A, used to treat some viral infections and some cancers), montelukast (Singulair, an asthma medication), finasteride (Propecia or Proscar, used to treat non-cancerous prostate enlargement and male-pattern hair loss), isotretinoin (Accutane, used to treat severe acne), and varenicline (Chantix or Champix, used to assist in smoking cessation).115,116 Drug-induced depression should be ruled out before diagnosing depression.

Diagnostic Criteria

According to the DSM-5, in order to be diagnosed with major depressive disorder, a patient must exhibit at least five of the following symptoms at the same time for two weeks or longer107:

  • Depressed mood most of the day, nearly every day, as indicated by either subjec­tive report (eg, feels sad, empty, hopeless) or observation made by others (eg, appears tearful). (Note: In children and adolescents, can be irritable mood.)
  • Markedly diminished interest or pleasure in all, or almost all, activities most of the day, nearly every day (as indicated by either subjective account or observation).
  • Significant weight loss when not dieting, or weight gain (eg, a change of more than 5% body weight in a month), or decrease or increase in appetite nearly every day. (Note: In children, consider failure to make expected weight gain.)
  • Insomnia or hypersomnia (excessive sleeping) nearly every day.
  • Mental or physical agitation or slowness nearly every day (observable by others, not merely subjective feelings of restlessness or being slowed down).
  • Fatigue or loss of energy nearly every day.
  • Feelings of worthlessness or excessive or inappropriate guilt (which may be delu­sional) nearly every day (not merely self-reproach or guilt about being sick).
  • Diminished ability to think or concentrate, or indecisiveness, nearly every day (either by subjective account or as observed by others).
  • Recurrent thoughts of death (not just fear of dying), recurrent suicidal ideation without a specific plan, or a suicide attempt or specific plan for committing suicide.

Furthermore, either persistent depressed mood or loss of interest and pleasure must be one of the five symptoms; the symptoms must cause clinically significant distress or impairment in social, occupational or other important areas of function; and, the episode must not be attributable to the physiologic effects of a substance or another medical condition.107

Severity of depression is determined by its duration and degree of disability it causes. The Hamilton Rating Scale for Depression (HAM-D) is used by healthcare providers to assess depression before, during, and after treatment, and the Beck Depression Inventory (BDI) is widely used for self-assessing depression symptoms.117 Many other depression rating scales have been developed and validated for their ability to measure major depression. Tools specific to children, adolescents, and the elderly are also available. It is vital for healthcare providers to assess suicide risk in patients with depression by questioning them about thoughts or plans to harm themselves or others and previous suicide attempts.15

The Risk of Overdiagnosis

The medicalization of depression has helped reduce stigma around this debilitating condition, but some argue it has also led to overdiagnosis and overprescribing of psychiatric medications, especially in adolescents and the elderly.118-120 The number of prescriptions for antidepressants grew 4- to 10-fold in the 1990s after the first SSRIs became available and is still on the rise,120,121 and research suggests the high rate of antidepressant use exceeds the prevalence of the psychological disorders they treat.119 Pressure to increase screening in primary care settings may have compounded the problem; in one study, 57% of elderly patients in Australia given a new prescription for antidepressants from their primary care physician to treat depression did not meet the criteria for major depressive disorder.122 Another study analyzed 3,199 new antidepressant prescriptions given to elderly patients in a single county in the United States during a 7-year period. The study found 18% of prescriptions were for patients with nonspecific psychiatric symptoms or symptoms not meeting the diagnostic criteria for a psychiatric disorder, and 6% were for specific psychiatric or medical disorders that are not acceptable indications for antidepressant treatment.123 In addition, many patients remain on antidepressants for decades, despite a lack of research on long-term use.120

The cost of overprescribing antidepressants goes beyond financial costs since these medications can cause significant side effects as well as withdrawal symptoms when discontinued.124,125 In youth between 12 and 17 years old, a reported connection between SSRI use and increased risk of suicidality and self-harm raises concern, especially since the likelihood of benefit from SSRIs, relative to placebo, is marginal.118,126,127 Furthermore, the rationale driving increased SSRI use is based on the premise that depression is simply a biochemical imbalance that can be adequately addressed with medical treatment, a notion that is clearly erroneous in a substantial proportion of individuals with depression and that diverts attention and resources away from the complex set of psychosocial and public health issues that contribute to depression’s prevalence.118,120

8 Conventional Treatment

Since the emergence of evidence suggesting a biological basis (in addition to a psychological basis) for major depressive disorder, pharmaceutical companies have been developing and promoting medications targeting neurotransmitter activity.124 Despite the number and variety of approved drugs, it is estimated up to 70% of people with major depression receiving evidence-based treatment with antidepressants continue to experience depressive symptoms, and over a third of cases are deemed treatment-resistant after having not responded to two or more drug trials.128

Psychotherapeutic interventions such as cognitive behavioral therapy (CBT) have proven efficacy as stand-alone treatment for mild depression and alongside drug therapy in moderate-to-severe cases.5 Neurostimulation therapies have a long history of effective use and may be a reasonable option for some patients, particularly those with treatment-resistant depression.129

Cognitive Behavioral Therapy

Cognitive behavioral therapy (CBT) is a type of psychotherapy in which patients develop cognitive and behavioral strategies for changing harmful or counterproductive patterns of thinking and acting. Brain imaging studies suggest individuals with depression treated with CBT experience changes in signaling in brain regions involved in emotional regulation and cognitive function.130,131 Including CBT or other types of psychotherapy in depression treatment results in a higher chance of recovery.132

CBT has been shown to be as effective as antidepressant medications when used as a first-line intervention for major depression, and has also been shown to reduce symptoms in those with subthreshold depression.133,134 Although it is widely accepted that those with severe depression require drug treatment, controlled trials and meta-analyses have found CBT results in similar response and remission rates as antidepressant medications, regardless of the severity of depression.135,136 CBT works faster and has fewer side effects than antidepressant drugs, and has demonstrated efficacy even in patients who have not responded to drug therapy.137 Meta-analyses of controlled clinical trials have found CBT can produce lasting benefits in depression patients, whether delivered in individual therapy, group therapy, or therapist-guided self-help formats.134,138

The Placebo Effect in Depression

The placebo effect is a phenomenon in which a person given a sham intervention experiences improvement (or, in some cases, harm) that would be expected from the real intervention. This response is the result of the person’s beliefs, perceptions, and expectations about the intervention, and is thus a mind-body occurrence.139

Depression and anxiety are conditions that are especially sensitive to the effects of placebo. Response rates in placebo groups in trials of antidepressant drugs are typically 30–40%, and can be as high as 50%, particularly in those with mild depression.140,141 This makes it challenging to identify a genuine treatment effect. In fact, an analysis of antidepressant trials found 25% of medication response rate can be attributed to natural history and spontaneous improvement, and 50% can be attributed to a placebo effect, leaving only 25% of the response attributable to the medication.126

Psychotherapy and natural therapies are also subject to placebo effects. These types of interventions have, in many cases, been shown to have similar efficacy to drug therapies; however, pharmacologic interventions pose many possible adverse side effects, some of which are serious, while most integrative and psychotherapy interventions have relatively high safety profiles. When choosing among therapeutic options with similar efficacy, the safest is always the preferred choice; among equally safe therapies, individual preference should be the guide.126

Pharmacologic Approaches

Antidepressants. Antidepressants are indicated for treating moderate-to-severe depression. Today, antidepressants are among the most commonly prescribed drugs in the world, and the majority of antidepressant prescriptions are for SSRIs.5,125 There are a number of individual drugs within the SSRI and other classes of antidepressants, each with slightly different mechanisms of action and side effects. Taking into account the symptom expression, co-occurring health issues, tolerance of side effects, and other individual factors will help in selecting among the many drug options and increasing the chance of a positive response.124

SSRIs and several other newer classes of antidepressants have better safety profiles than older antidepressants and are modestly effective, with treatment response rates ranging from 15–55%.142 Although these medications have demonstrated superiority over placebo, the differences between medication and placebo effects are small, and their clinical relevance has been widely questioned.126,143,144 Nevertheless, drugs in these classes are considered appropriate for first-line treatment of severe major depression5,142,145:

  • Selective serotonin reuptake inhibitors (SSRIs). SSRIs increase the activity of serotonin by interfering with its being taken up by a transport molecule after its release into the synapse. These medications can cause adverse side effects such as headache, digestive upset, insomnia, fatigue, anxiety, sexual dysfunction, and weight gain.124 Examples of drugs in this class are:
    • Fluoxetine (Prozac)
    • Paroxetine (Paxil)
    • Sertraline (Zoloft)
    • Citalopram (Celexa)
    • Escitalopram (Cipralex or Lexapro)
  • Serotonin-norepinephrine reuptake inhibitors (SNRIs). SNRIs increase the activities of serotonin and norepinephrine (also called noradrenaline) by interfering with their transport once they are released. The side effect profile of SNRIs is similar to SSRIs but also includes dry mouth and increased blood pressure.124 Drugs in this class are:
    • Venlafaxine (Effexor)
    • Desvenlafaxine (Pristiq)
    • Duloxetine (Cymbalta)
    • Levomilnacipran (Fetzima)
  • Atypical antidepressants
    • Bupropion (Wellbutrin), a norepinephrine-dopamine reuptake inhibitor (NDRI), increases the activities of norepinephrine and dopamine by inhibiting transport molecules. Bupropion causes side effects such as headache, agitation, insomnia, sweating, appetite loss, and weight loss.124
    • Mirtazapine (Remeron) increases the actions of norepinephrine and serotonin on nerve endings. Mirtazapine can cause sedation, increased appetite, and weight gain.124
    • Trazodone (Oleptro) has complex actions affecting serotonin, norepinephrine, and histamine. Possible side effects of trazodone include sedation, nausea, and, rarely, priapism (painful, persistent erection of the penis).124,146
    • Vortioxetine (Trintellix) and vilazodone (Viibryd) are recent additions to the antidepressant arsenal. They affect serotonin metabolism and receptor function, and have been associated with side effects such as nausea, diarrhea, insomnia, and dizziness.124,147

Second-line antidepressants include tricyclic antidepressants (TCAs) (ie, amitriptyline [Elavil], clomipramine [Anafranil], and doxepin [Silenor]) and MAOIs (ie, tranylcypromine [Parnate] and phenelzine [Nardil]). Partly because they are less selective in their actions, these older classes of antidepressants cause many adverse side effects, some of which are dangerous. Their use has largely been replaced by newer options; however, they have higher response rates than many first-line antidepressants and are still prescribed in some cases of treatment-resistant depression.5,124

Antidepressants and the Gut Microbiome

In light of the important influence of the gut microbiome on psycho-emotional health, researchers have begun exploring the effects of depression therapies on microbiome composition. A growing body of evidence indicates a complex two-way relationship through which intestinal microbes affect metabolism of medications and medications alter the composition of the gut microbial community.476

Preclinical studies have shown various classes of antidepressants have antimicrobial effects against some normal inhabitants of the human gut.477,478 In one study, the tricyclic antidepressant desipramine (Norpramin), the atypical antipsychotic aripiprazole (Abilify), and the SSRI citalopram demonstrated antimicrobial effects against beneficial bacteria normally found in the human gut, while the atypical antidepressant bupropion and the SNRI venlafaxine did not.479

Some evidence suggests interactions with the microbiome may contribute to the effects of antidepressants. In one study, mice subjected to chronic unpredictable stress developed dysbiosis, but fluoxetine lessened the stress-induced alteration of the microbiome.480 Another study found the effect of fluoxetine was blunted in mice whose microbiome was altered due to chronic stress.481 In another study in mice, various antidepressants, including SSRIs, SNRIs, and tricyclic antidepressants, reduced the abundance of certain bacterial species in the gut microbiome, and restoring levels of one of the affected bacteria reduced the effect of the antidepressant on depressive behaviors.482 Antidepressant-induced microbiome changes may also contribute to adverse side effects of antidepressants: one study found mice treated with fluoxetine for 29 days had reductions in abundance of Lactobacillus and Bacteroidales species known to help regulate metabolism and experienced weight gain.483

Observational reports have noted correlations between antidepressant use and microbiome composition in humans.484,485 In a pilot trial, six patients with irritable bowel syndrome and depression were treated with duloxetine. This treatment reduced abdominal and depressive symptoms, altered microbiome composition, reduced blood levels of inflammatory cytokines, and slightly increased fecal levels of anti-inflammatory short-chain fatty acids produced by healthy gut bacteria.324 Antipsychotics, but not antidepressants or anti-anxiety medications, were found to reduce microbiome diversity (a marker of microbiome health) in a study that followed 40 patients initiating treatment for depression or anxiety disorders, with higher doses causing greater loss of diversity.486

The composition of the gut microbiome has been found to be different in individuals with treatment-resistant versus treatment-responsive depression.487 An uncontrolled trial monitored microbiome changes in 15 patients with depression from pre-treatment until six months after the initiation of treatment with citalopram or escitalopram. Those who responded to treatment had greater microbiome diversity throughout the study than those who did not respond. In addition, treatment altered microbiome composition in responders, but not non-responders. These findings suggest microbiome composition affects treatment responsiveness, and a positive treatment effect may be reflected in changes in the microbiome.488

Serotonin Syndrome

One of the most serious adverse side effects of antidepressant medications is serotonin syndrome. This rare condition, which occurs in an estimated 0.09–0.23% of patients treated with serotonin-enhancing drugs, results from excessive serotonin signaling and is associated with an array of mental and physical symptoms that can rapidly progress and be fatal.148,149 Mild symptoms, which may be mistaken for flu or other illness, include fever and sweating, confusion, agitation, anxiety, physical restlessness, rapid heartbeat, diarrhea, discoordination, and tremors. Patients with severe serotonin syndrome can experience very high fever, muscle rigidity, seizures, and coma, which may lead to death.149 The condition is treated by discontinuing serotonin-raising medications, implementing supportive treatments, and in some cases using serotonin-blocking agents; however, the challenge lies in recognizing it before it becomes life-threatening.148

Serotonin syndrome is frequently the result of polypharmacy—the use of multiple drugs to treat the same condition.149 It can be due to a drug side effect, drug-drug-interaction, or an overdose.150 Antidepressant combinations that include one or more MAOI are the most common triggers of serotonin syndrome, but any medication that increases serotonin activity can cause or contribute to serotonin syndrome.149,151 In addition to antidepressants, antipsychotics, opioid analgesics, stimulants, and hallucinogens have all been implicated,149 and patients taking multiple medications are at higher risk.152 In addition, supplements that raise serotonin levels such as L-tryptophan and 5-hydroxytryptophan are thought to have the potential to contribute to serotonin syndrome, especially when combined with medications that alter serotonin metabolism; however, to date, there are no reports of serotonin syndrome as a result of use of these supplements.149

Augmentation. Many patients with depression do not respond to first- or second-line antidepressants. Unfortunately, the course of illness is more severe and risk of suicide higher for these patients.128 There are several treatment options for those who do not have an adequate response after four to eight weeks of antidepressant therapy: increase the dose, switch to a different antidepressant, combine antidepressants, or use another type of medication to augment the effect of the antidepressant.128,153

Augmentation strategies are usually used after two failures with antidepressants. Atypical antipsychotics such as aripiprazole (Abilify), quetiapine (Seroquel), olanzapine (Zyprexa), and brexpiprazole (Rexulti) are the most common drugs used in augmentation strategies.153 While there is mounting evidence that augmenting antidepressant therapy with atypical antipsychotics can increase treatment efficacy, these drugs add another layer of problematic side effects; in particular, atypical antipsychotics can cause metabolic disturbances leading to weight gain and increased risks of heart disease and type 2 diabetes.128,153

Antidepressant Adverse Effects and Withdrawal Syndrome

Finding an effective antidepressant can be challenging, since their effects often take weeks to manifest, efficacy rates are marginal, and individual responses can vary considerably. Moreover, common adverse side effects from SSRIs and SNRIs, the most widely prescribed antidepressants, include weight gain, gastrointestinal upset, sexual dysfunction, headaches, fatigue, insomnia, anxiety, dry mouth, and increased blood pressure.124

While clinical trials focus primarily on biological side effects, one study that used an online survey also explored psychological and emotional symptoms antidepressant users experience yet may have difficulty describing or quantifying: 1,431 antidepressant users in 38 countries participated in the study, and 61% reported at least 10 of the 20 adverse effects listed on the survey. The most common were emotional numbness, feeling foggy, feeling “not myself,” and sexual difficulties. Alarmingly, 50% of responders reported feeling suicidal due to their antidepressant therapy. Taking more than one antidepressant, using an antipsychotic along with antidepressants, being younger, and longer duration of treatment were factors associated with more adverse side effects.154 Because the participants in this study were self-selected, it is not possible to estimate the true prevalence of adverse side effects from this data; the findings nonetheless indicate that antidepressant therapy causes substantial psychological and emotional side effects in many patients.

As difficult as antidepressant therapy can be in some cases, discontinuation sometimes poses yet another set of serious challenges. Withdrawal symptoms commonly occur in patients after discontinuing or reducing dosages of antidepressants, particularly SSRIs and SNRIs. Among SSRIs and SNRIs, paroxetine, venlafaxine, and desvenlafaxine appear to be more likely than others to trigger withdrawal syndrome, while fluoxetine and agomelatine pose the least risk.125 It has been estimated that roughly 50% of antidepressant-treated patients experience a withdrawal phenomenon that is now recognized as antidepressant withdrawal syndrome.155 The duration of withdrawal syndrome is variable, lasting weeks or months for most, but persisting even longer in some cases.156 It has been suggested that slow, gradual reductions in dosage or medication-switching (often to fluoxetine) during the likely withdrawal period can reduce the likelihood or severity of symptoms, but little information is available regarding the tolerability and effectiveness of these strategies.125,155

It is necessary to distinguish withdrawal syndrome from relapse and rebound phenomena, as well as disease recurrence. Withdrawal is defined as a set of new symptoms brought on by reduced medication exposure, but in some cases these symptoms overlap with those of the disorder that was originally being treated, making it more difficult to recognize.125,155 A wide range of withdrawal symptoms have been reported, including heart palpitations, arrhythmias, chest pain, dizziness, vertigo, fainting, ringing in the ears, numbness, sensations of pricking or crawling, electric shock sensations (sometimes called zaps), tremors, spasms, discoordination, disorientation or confusion, decreased concentration and attention, digestive problems, blurry vision, irritability, anxiety, depressive mood, hallucinations, insomnia, vivid dreams and nightmares, aggression, and impulsiveness. In addition, general symptoms such as headache, fatigue, sweating, flushing, chills, lack of thirst, pain, and flu-like symptoms can occur.125,157

Despite the common occurrence of adverse effects and withdrawal symptoms, many antidepressant users report never having received warning by the prescriber prior to beginning antidepressant therapy. Surveys of antidepressant users suggest 33% recall no warning about the possibility of adverse effects, and only 1% recall being informed about the potential for withdrawal effects.154,158

Neurostimulation Therapies

Electroconvulsive therapy (ECT). ECT is the oldest type of neurostimulation therapy and has been used to treat depression for over 75 years. It is currently used to treat severe and recurrent major depressive disorder that is unresponsive to drug therapies. ECT is performed under general anesthesia and involves applying a mild electrical current to specific brain regions via electrodes placed on the scalp. The electrical stimulation causes a seizure that is thought to be important to its therapeutic effect; however, ECT’s exact mechanism of action is still unknown.153

Patients undergoing ECT typically receive treatments three times per week for 2–4 weeks, for a total of 6–12 treatments, followed by long-term drug therapy. Although ECT is associated with remission rates as high as 80%, the majority of patients experience relapse. In some cases, ECT is continued for six months, and possibly longer as a maintenance therapy.153

ECT is associated with serious side effects, including confusion and memory deficits that may be brief or protracted, dangerous sustained seizure, and transient changes in heart rhythm and increased blood pressure. Nevertheless, ECT is one of the most effective treatment options for treatment-resistant major depression, and its potential benefits outweigh its risks in some cases.153

Vagus nerve stimulation (VNS). VNS is an invasive therapy in which an electrode placed around the vagus nerve is connected to an electrical impulse generator implanted in the chest wall.129 The vagus nerve is a major nerve connecting the brain to the rest of the body, particularly the gut, and helps regulate normal resting body functions. Although the mechanisms underlying the antidepressant effect of VNS have not been established, one contributing factor may be its ability to reduce inflammation. The vagus nerve has been shown to communicate with the immune system by activating the cholinergic anti-inflammatory pathway and thereby inhibiting production of inflammatory cytokines.159 It also appears to modulate the gut microbiome in part through its effects on immune signaling.160,161

VNS has been found to induce long-term remission in some depression patients who have not responded to other forms of treatment, including ECT.162,163 In one study, approximately half of patients treated with VNS had a clinical response (defined as a 50% or greater reduction in depression scores) and nearly 40% were in remission after two years.164 As an add-on to drug treatment in patients with highly treatment-resistant depression, VNS has been shown to have faster and longer lasting positive impacts on depression and quality of life than drug treatment alone.165,166 Surgery-related infection is the most common complication; others include vocal cord and facial muscle weakness, changes in heart rhythm, cough, hoarseness, and throat pain.167 VNS is approved for use in those with major depression who have been unresponsive to at least four antidepressant interventions.165

Repetitive transcranial magnetic stimulation (rTMS). rTMS is a noninvasive neurostimulation technique in which a magnetized coil placed on the scalp generates an electrical current that passes through the brain’s cortex. rTMS is performed daily for several days to weeks, and does not require anesthesia.129 In some cases, therapy is continued through periodic maintenance sessions.168 rTMS specifically targeting the dorsolateral prefrontal cortex of the brain has been shown to have positive effects in patients with major depression that is unresponsive to other types of treatment.169-171 Findings from animal research suggest rTMS may increase neuroplasticity and improve cognitive function.169 It has even been found to be safe and effective in pregnant and elderly patients.172 Although its ability to induce long-term remission is not known, its safety and fast action have led to calls for its inclusion as a first-line intervention.168

Ablative neurosurgery. Ablative neurosurgery is a rarely used technique for intractable major depression in which neural connections in specific brain regions are surgically cut. The seriousness of potential harm, coupled with the irreversible nature of this approach, limit its use to the most chronic, debilitating, and intractable cases.129

9 Novel and Emerging Therapies

Emerging Medications

Agomelatine. Agomelatine (Valdoxan) is a synthetic version of the neurohormone melatonin. Like melatonin, agomelatine activates MT1 and MT2 receptors, which play an important role in regulating circadian cycles and serotonin signaling, affecting sleep, mood, and cognition. In addition, agomelatine interacts with 5-HT2C serotonin receptors. When 5-HT2C receptors are activated by serotonin, the result is inhibition of dopamine and norepinephrine signaling; on the other hand, agomelatine interacts with 5-HT2C receptors as a neutral antagonist, preventing their over-activation without suppressing their normal function.173 Meta-analyses of controlled trials have found agomelatine is similar in efficacy to other antidepressant drugs, but is more tolerable than most, mainly due to its lower likelihood of causing sexual side effects and weight gain.142,174-176 Possible adverse side effects include headache, dizziness, sleepiness, fatigue, and digestive upset. Its long-term safety is yet to be explored, but rare cases of liver toxicity have been reported.177 Agomelatine is approved for treating depression in Europe and Australia, but not in the United States.

Ketamine and esketamine. Ketamine (Ketalar) is a drug with wide ranging effects on the central nervous system due to its inhibition of glutamate receptors, known as N-methyl D-aspartate (NMDA) receptors, in the brain.178 Ketamine rapidly enhances neuronal activity in some brain regions and may ultimately reverse depression-related brain atrophy and diminished neuroplasticity.153 Although approved for use as a general anesthetic, ketamine has recently attracted interest for its effects in psychiatric disturbances, including substance use, depression, and anxiety disorders.

Ketamine, used intravenously in sub-anesthetic doses, has been reported to trigger rapid and long-term antidepressant effects.179 Multiple clinical trials have found an intranasal version of ketamine, called esketamine (Spravato), increased response and remission when used alone or in combination with oral antidepressants in patients with treatment-resistant depression.128,180 This led to esketamine’s approval by the US Food and Drug Administration (FDA) in 2019 for use in patients with treatment-resistant depression.181 It was the first antidepressant with a new mechanism of action to be approved by the FDA in 30 years.180

Ketamine is typically administered in single intravenous doses. In most patients, substantial antidepressant effects are noted within four hours and may last a week or longer.153,178,179 Esketamine is also administered in single doses under the supervision of a certified healthcare provider.182 As with ketamine, esketamine’s effects come on within hours of administration and have been reported to last four weeks or longer.183 Despite their increasing use, the long-term safety and effectiveness of ketamine and esketamine are still being explored.181,184 For example, ketamine is known to raise blood pressure for a few hours after administration, and may pose a safety risk in patients with high blood pressure or aneurysm.185 In addition, ketamine and esketamine can cause drowsiness, dizziness, and blurred vision, as well as altered perceptions and hallucinations that many find intolerably uncomfortable.153,183 Due to the potential for dissociation and perceptual changes, patients administered esketamine must be monitored by a qualified healthcare provider for at least two hours after receiving a dose.182

Psychedelic Therapy

Psychedelic drugs are increasingly being explored for their potential antidepressant effects. Psychedelics may have unique effects on emotional processing and the development of new neural networks in brain regions involved in mood.186 Many people treated with psychedelics report experiencing mystical awakening, a sense of connectedness, and access to new ways of thinking, leading to enduring improvements in mood, attitude, and well-being.187

According to meta-analyses of clinical trials, psychedelic therapy appears to induce rapid and lasting improvement in depression patients.188,189 In placebo-controlled clinical trials in cancer patients and patients with terminal illness, a single high dose of psilocybin (a psychoactive substance from mushrooms in the Psilocybe family) administered in the context of an intensive psychotherapy setting rapidly reduced depression and anxiety and improved spiritual well-being and quality of life.190,191 Not only were these changes sustained for more than six months after treatment, a second follow-up 4.5 years later found most participants had persistent antidepressant or anti-anxiety effects related to the psilocybin-assisted psychotherapy.192 Because of the strength of evidence for its potential to bring about enormous improvement in depression treatment, the FDA designated psilocybin a “breakthrough therapy” in 2018 for its use in treatment-resistant depression and in 2019 for its use in major depression.193 This designation allows researchers to accelerate clinical research and drug development.

Ayahuasca is an Amazonian herbal combination containing two primary active constituents: the psychedelic substance dimethyltryptamine (DMT) and a monoamine oxidase inhibiting compound called harmaline that prevents the immediate breakdown of DMT.194 A study surveying ceremonial ayahuasca users found 80% of those diagnosed with depression and 79% of those diagnosed with anxiety reported improvement following its use.195 Observational studies and clinical trials have found ayahuasca reduces symptoms in patients with depression and may decrease suicidality.194,196-198 Patients treated with ayahuasca report effects such as increased mindfulness, greater cognitive flexibility, and behavioral changes.199,200 Ayahuasca has also been shown to reduce levels of inflammatory markers and increase levels of BDNF.201,202

Lysergic acid diethylamide (LSD) is a well-known psychedelic substance that has shown promising antidepressant effects in animal research and human trials.203 Hundreds of papers have been published (the majority before 1967, when its use was banned by the FDA) describing its positive effects as an adjunct to psychotherapy, particularly for those struggling with alcoholism and those with life-threatening diseases.194,204,205 More recently, in a study in healthy volunteers, a single dose of LSD led to increased optimism and openness, markers of psychological well-being, two weeks later.206 However, another trial in healthy subjects found LSD did not impact negative attitudes or mood symptoms despite inducing an experience most participants deemed highly meaningful after 12 months.207 At least one clinical trial evaluating the effect of LSD in patients with major depression is currently underway.208

Despite their ongoing use in research settings, psilocybin, DMT, and LSD are still classified as Schedule 1 drugs in the United States, making their unauthorized possession and distribution illegal.194 Moreover, because psychedelic use outside the medical context poses many potential problems and adverse effects, these substance should not be used to treat depression or other conditions except under supervision of an experienced healthcare provider.209

Anti-inflammatory drugs. Cytokine inhibitors (eg, etanercept [Enbrel] and infliximab [Remicade]) and non-steroidal anti-inflammatory drugs (eg, aspirin and celecoxib [Celebrex]) are categories of anti-inflammatory drugs being investigated for their possible use in depression treatment, mainly as adjuncts (add-ons) to antidepressant drugs.

An uncontrolled trial that included 24 depression patients who had not responded to four weeks of SSRI treatment found the addition of 160 mg aspirin per day resulted in a 52.4% response rate and a 43% remission rate.210 Controlled trials have been less promising: one trial found aspirin did not improve the effectiveness of either the SNRI duloxetine or the SSRI escitalopram,211 and another found the combination of 160 mg aspirin per day plus the SSRI citalopram led to severe anxiety and physical restlessness in eight of the 10 participants receiving this combination.212 Further research indicates aspirin does not have a role in preventing depression.213,214 Several randomized controlled trials found that celecoxib, as an adjunct to antidepressant therapy, improved symptom reduction in patients with depression, but its possible association with increased cardiovascular risk must be taken into consideration.215

Findings from clinical trials using cytokine inhibitors have not been consistently positive, but a growing body of evidence suggests there may be a subset of depression patients with elevated inflammatory cytokine levels, such as those with co-occurring autoimmune or other inflammatory conditions, who are likely to benefit from the addition of cytokine-blocking agents to their treatment regimen.216-218 More research is needed to clarify the potential utility of these drugs in these patient groups.

Investigational Neurostimulation Techniques

Transcutaneous auricular vagus nerve stimulation (tVNS), in which electrical stimulation is applied through the skin at a location behind the ear, is a non-invasive variation on VNS. A meta-analysis of four randomized controlled trials with a combined total of 222 subjects with major depression found tVNS, applied twice daily or at least five days per week for 2–4 weeks, effectively reduced depression symptoms.219

Magnetic seizure therapy is a non-invasive technique involving the application of a magnetic field across the head in high enough intensity to induce a seizure. Like ECT, magnetic seizure therapy is performed under general anesthesia at a series of sessions over several days or weeks. Magnetic seizure therapy may be somewhat less effective than ECT, but appears to cause fewer general and cognitive side effects.129

Transcranial electrical stimulation involves the use of a battery-operated device that delivers weak electrical impulses via electrodes placed on the scalp, earlobes, behind the ears, or on the face.129 Transcranial electrical stimulation devices are widely available and appealing because they are non-invasive and self-administered. One form of transcranial electrical stimulation, called transcranial direct current stimulation, has shown some positive effects in patients with major depressive disorder.220 However, more remains to be learned about whether and how this neurostimulation method works and its long-term consequences on mood and cognitive function.129,220

Other non-invasive neurostimulation techniques under investigation include129,221,222:

  • Focal electrically administered seizure therapy
  • Transcranial low-voltage pulsed electromagnetic fields
  • Trigeminal nerve stimulation
  • Low field magnetic stimulation
  • Transcranial focused ultrasound

Deep brain stimulation (DBS) is a highly invasive neurostimulation therapy being investigated for possible use in patients with severe treatment-resistant depression. In DBS, electrodes are surgically placed in specific deep regions of the brain (below the cortex) and pulses of electricity are administered to alter the activity of neurons in these brain regions.129 DBS is gaining interest and showing clinical promise in patients with treatment-resistant major depression.223-225 Its mechanism of action is still not completely understood: in addition to activating local neurons, DBS also appears to stimulate neurogenesis and neuroplasticity and may slow the progression of neurodegenerative conditions such as Parkinson disease (for which DBS is approved) and Alzheimer disease.226 Surgical complications are a risk associated with DBS, and, although most side effects are reportedly mild, about 50% of individuals receiving DBS experience some stimulation-related side effects.225

Hormone Therapy and Menopause-Related Depression

Fluctuating hormone levels, such as during menstrual cycles, pregnancy and postpartum, and menopause, increase women’s risk of depression. Some studies indicate women are more than twice as likely to be diagnosed with depression during the menopausal transition than prior to menopause, and the risk is greater in those who experience menopause before age 40.227 Depression in perimenopausal women typically co-occurs with other menopausal symptoms, such as hot flashes and sleep disturbance, and is often associated with psychosocial stressors.228,229

Although hormone therapy is not an approved treatment for depression, some studies show transdermal bioidentical estradiol, the estrogen produced in greatest amounts prior to menopause, may have antidepressant activity comparable to commonly prescribed antidepressant drugs in perimenopausal women.227,228 In one controlled trial that included 172 perimenopausal or early postmenopausal women, those receiving treatment with 0.1 mg per day transdermal estradiol (delivered via a patch), along with 200 mg oral micronized progesterone daily for 12 days every three months, for one year were less likely to develop clinically meaningful depressive symptoms compared with those receiving placebo: 17.3% of women in the hormone therapy group and 32.3% in the placebo group developed significant symptoms of depression.230

10 Diet and Lifestyle Interventions


Evidence consistently supports the notion that healthy dietary patterns with low inflammatory potential are associated with better mental health and less depression risk. The Mediterranean diet and similar diets that limit inflammatory foods (like those high in saturated fats, trans fats, and processed sugars) and emphasize anti-inflammatory foods (like fruits and vegetables and other plant-based unprocessed foods high in phytonutrients, mono- and poly-unsaturated fats, and fiber) have been associated with reduced risk of depression.231-240

A meta-analysis of 16 randomized controlled trials with over 45,000 participants combined, most of which included participants with depressive symptoms but not major depression, found dietary interventions can effectively reduce symptoms of depression, and women may benefit more than men.241 One trial included 67 individuals with moderate-to-severe depression who were randomly assigned to receive nutritional counseling or general social support for 12 weeks. The purpose of nutritional counseling was to improve adherence to a Mediterranean-like diet, high in whole grains, vegetables, fruit, legumes, low-fat unsweetened dairy products, nuts, fish, lean meat and poultry, eggs, and olive oil. Those in the nutritional support group had more improvement in depression symptoms and a higher rate of remission (32%) compared with those in the social support group (8%).242 Another important trial included 76 young adults with high levels of depression symptoms and poor dietary habits assigned to either a three-week dietary intervention or no intervention. Those in the dietary intervention group received guidance encouraging adherence to a more Mediterranean-style diet and discouraging consumption of refined carbohydrates, sugar, soft drinks, and fatty or processed meat. Not only did those in the diet intervention group have decreased depression scores at the end of the trial, their improvement in mood was sustained three months after the trial ended.243


Physical activity has well established benefits on mood and depression, while being sedentary worsens mental and physical health.244-246 The efficacy of exercise in depression is comparable to that of antidepressant medications and CBT, yet has additional benefits on fitness and physical health.247 Exercise has been shown to be beneficial in patients with major depression as well as conditions associated with depression such as alcohol and substance use disorders,248 cardiovascular disease,249 neurodegenerative diseases,250 and other psychiatric illnesses.251

Aerobic exercise, strength training, and mind-body exercise (such as yoga, tai chi, and qigong) have all been found to improve depression.252-254 A meta-analysis of 11 trials with a total of 455 participants with major depression found aerobic exercise, for an average of 45 minutes three times weekly for nine weeks, reduced symptoms by 21%.255 A meta-analysis of nine clinical trials with a combined total of 366 participants found both high-intensity interval training (HIIT) and moderate intensity continuous training can be beneficial in patients with depression and other psychiatric disorders, but HIIT may have a stronger effect.256 A meta-analysis of 15 trials with a total of 596 older adult participants found, among the different types of exercise, mind-body exercise had the greatest positive impact on depression in this demographic.257 Furthermore, multiple randomized controlled trials have shown mind-body exercise can reduce depression and anxiety severity in adults of all ages.258

Despite the wealth of evidence that exercise can play a substantial role in treating depression, depression itself is an obstacle to self-care. Structured exercise programs that provide ongoing supervision, support, and motivation are more likely to engage patients with depression and increase the chance of successful adherence.259

More information is available in our Exercise Enhancement protocol.


Circadian signaling between the brain’s master “clock” and cells throughout the body regulates biological cycles that impact every aspect of physiology and health, modulating metabolism, temperature regulation, appetite, sleep, cognition, behavior, social activity, and mood.260,261 Circadian rhythms become disrupted due to factors such as nighttime activity or light exposure, atypical eating patterns, alcohol overconsumption, shift work, and travel through time zones.262 Circadian disruption is a common feature of many chronic and metabolic diseases, as well as mood disorders.262 In people with major depression, circadian desynchronization has been noted to manifest as altered sleep patterns, increased core temperature, and blunted circadian changes.263,264

Chronotherapy involves modifying or limiting exposure to environmental stimuli that affect circadian rhythms. The goal of chronotherapy is to restore normal circadian control and synchronize rhythmic cycles.265 In depression treatment, chronotherapy strategies include bright light therapy, sleep deprivation (also called wake therapy), and sleep phase advance. Evidence from clinical research suggests combinations of these therapies with or without antidepressants may have positive impacts on depression.266

Bright light therapy generally involves use of white light at an intensity of 2,000–10,000 lux for 30 to 120 minutes per day. Although it is best known as a first-line treatment for seasonal depression, multiple controlled trials indicate bright light therapy can reduce depressive symptoms and improve sleep quality in healthy subjects and patients with non-seasonal major depression.265 One sleep deprivation method involves awakening well before usual rising time one morning followed by normal awakening the next morning, in a set of three for a total of six mornings. Another method involves total sleep deprivation for one night, followed by morning light therapy. Sleep phase shifting usually involves normalizing bedtime over a period of weeks. Sleep deprivation and phase shifting are generally done together to treat sleep and mood disorders.267

Chronotherapy has been found to be helpful in cases of moderate-to-severe treatment-resistant depression, and some evidence suggests those with evening chronotypes (a preference to function and conduct activities in the evening) and whose mood is best in the evening may be more likely to benefit.268 A meta-analysis of 16 studies noted chronotherapies improve depression more quickly than antidepressants, psychotherapy, or exercise, reducing symptoms by 50% or more in 33% of patients after 5–7 days.269 In one open study, 35 hospitalized patients with moderately severe major depression underwent chronotherapy as follows: sleep deprivation via 4 a.m. awakening on three mornings with simultaneous light therapy of increasing intensity from 4 a.m. to 8 a.m., alternating with three nights of uninterrupted sleep with one hour of bright light therapy in the morning; a sleep phase shift of one hour earlier was targeted. Participants experienced improvements in depression and energy after the first night and throughout the 6-day trial, and were successful in shifting bedtime to 30–40 minutes earlier. Participants given glasses to filter out blue light during light therapy did slightly worse than those exposed to full spectrum white light.270 In another trial, 27 patients underwent one night of total sleep deprivation followed by morning light therapy; this chronotherapy program led to improvement in depression after one week that was sustained three months after the end of treatment.271 In one study, 29 adolescents with major depression underwent a four-day chronotherapy intervention that included one night of sleep deprivation followed by three days of sleep phase advancement (going to bed earlier) and morning bright light therapy. The intervention led to symptom reduction of 50% or more in 26 subjects (84%) and remission in 24 (77%), and the benefits were sustained one month after treatment.272


Mindfulness meditation, which emphasizes focused attention on the present moment, has been shown to be helpful in reducing the severity of major depression.254,273,274 Having a regular practice at home may also reduce the risk of relapse.275 Research suggests mindfulness training may have lasting positive effects on stress resilience that may reduce the risk and symptoms of depression.276,277 Other types of meditation, such as breathing-based and mantra-based meditation practices, have also been found to improve depression symptoms.278,279 Studies in healthy volunteers and subjects with major depression suggest meditation may alter signaling and connectivity in regions of the brain involved in depression and anxiety.280,281

11 Integrative Interventions

Omega-3 Fatty Acids

The long-chain polyunsaturated omega-3 fatty acids, eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), are important components of nerve cell membranes, affecting their fluidity and ability to send and receive signals.282 They are also used in the body to produce anti-inflammatory metabolites, as well as endocannabinoids, compounds that regulate nerve function by interacting with cannabinoid receptors. These effects have been correlated with improvement in major depression.283,284 Preclinical research further suggests EPA and DHA enhance neuroplasticity.285

Eating moderate amounts of fatty fish, the main dietary source of EPA, DHA, and other omega-3 fatty acids, may reduce the risk of depression.284,286 In people with depression and other psychiatric illnesses, higher levels of omega-3 fatty acids have been correlated with less severe symptoms.287,288

Numerous randomized controlled trials using supplements with EPA and DHA in proportions of 2:1 or 3:1 and at doses of 1–2 grams per day have found positive effects on depression.289,290 Omega-3 fats may also have metabolic benefits in patients with depression and metabolic disorders such as type 2 diabetes, obesity, and cardiovascular disease.291-294 Based on the abundance of evidence, the International Society for Nutritional Psychiatry Research recommends the use of EPA in the treatment and prevention of major depression.295 The unique role of DHA in supporting emotional health should also be recognized. DHA is the most prevalent fatty acid in the central nervous system. Not only is DHA incorporated into nerve cell membranes, where it is necessary for normal structure and function, it is also a critical component of other brain cells that use it to support neuronal growth and formation of nerve connections. Furthermore, DHA is a source for critical anti-inflammatory molecules called resolvins and protectins.284,296

Vitamin D

A number of observational studies have noted an association between low vitamin D levels and depression risk,297-299 and several studies have noted a link between vitamin D deficiency and suicidality.300,301 Furthermore, low vitamin D status may also be associated with cognitive impairment in depression patients.302 The connection between vitamin D and depression may be related to vitamin D’s immune-regulating anti-inflammatory effects, ability to promote neuroplasticity and neurogenesis, and its influence on neurotransmitter levels.299,303

A randomized placebo-controlled trial with 18,353 participants aged 50 years and older (16,657 of whom had never had depression and 1,696 of whom had had depression but had not been treated for at least two years) found taking 2,000 IU vitamin D daily for a median of 5.3 years did not reduce the risk of developing depression or clinically relevant depressive symptoms.304 However, the methodology and rigor of this study has been questioned.305 Moreover, vitamin D has been found to be effective in reducing symptoms in patients with depression in clinical trials using doses from 2,800 to 5,600 IU daily for 1–12 months.299 A meta-analysis of four randomized controlled trials with a combined total of 948 patients with major depression found vitamin D supplementation can have a substantial positive impact on depression symptoms.306 Another meta-analysis that included nine studies found vitamin D supplementation can reduce depression symptoms and improve some markers of inflammation and oxidative stress in patients with a variety of psychiatric diagnoses.307

Vitamin D has broader health benefits and may reduce depression in those with other chronic conditions. In one trial, subjects with type 2 diabetes and mild-to-moderate depressive symptoms treated with 4,000 IU vitamin D daily had greater improvement in mood, as well as markers of metabolic health, compared with those treated with placebo after 12 weeks.308 An open-label trial found 10,000 IU vitamin D daily for 12 months reduced depressive symptoms in 35 patients with multiple sclerosis. Blood tests showed subjects’ vitamin D levels were deficient or borderline-deficient at the beginning of the study and became sufficient during the course of the study. In addition, higher vitamin D levels were correlated with lower scores on depression tests throughout the study.309


The gut microbiome has a close relationship with the brain and plays a fundamental role in regulating mood and cognitive function. People with depression have been found to have reduced gut microbial abundance and diversity, a pattern associated with poorer health in general.63 Eating probiotic-rich fermented foods was correlated with lower risk of major depression in one study.310

Multiple clinical trials, reviews, and meta-analyses indicate probiotic supplements can be effective in treating depression.311-315 In an 8-week trial that included 110 patients being treated with antidepressant drugs for mild-to-moderate depression, those receiving a probiotic with 10 billion colony forming units (CFUs) of combined Lactobacillus helveticus R00052 and Bifidobacterium longum R00175 had greater reductions in scores on a test for depression than those receiving placebo.316 These same probiotic strains have previously been shown to reduce psychological distress in healthy volunteers.317 A placebo-controlled trial that enrolled 90 subjects with mild-to-moderate depression found taking a probiotic supplement providing 1 billion CFUs of L. plantarum, along with 200 mg SAMe, daily for six weeks effectively reduced depression symptom scores as well as depression-related anxiety and cognitive changes.318 A probiotic supplement with 2 billion CFUs per day each of L. acidophilus, L. casei, and B. bifidum reduced depression symptoms and improved some markers of insulin resistance, oxidative stress, and inflammation better than placebo in 40 subjects with major depression after eight weeks.319

The addition of a probiotic supplement containing Clostridium butyricum, at 60 mg per day, to standard antidepressant therapy resulted in a 70% response rate and 35% remission rate in an open trial in 40 patients with treatment-resistant depression.320 Another small open trial in treatment-resistant depression patients found the addition of a mixed probiotic with a total of 20 billion CFUs of L. acidophilus, B. bifidum, and Streptococcus thermophilus, plus 1,600 mg per day magnesium orotate, to antidepressant therapy led to improvement in depression and quality of life scores in eight of 12 participants (67%) after eight weeks.321

Probiotics may reduce depressive symptoms in patients with other chronic conditions. A placebo-controlled trial that included 54 participants with type 2 diabetes and coronary heart disease showed taking a mixed probiotic with 2 billion CFUs each of L. acidophilus, L. reuteri, L. fermentum, and B. bifidum, along with 200 mcg selenium, daily for 12 weeks decreased depression scores and improved metabolic markers.322 Similarly, a placebo-controlled trial in 44 post-heart attack patients found 1.6 billion CFUs L. rhamnosus per day for 12 weeks reduced depression, decreased markers of inflammation and oxidative stress, and improved quality of life.323 Findings from other clinical trials suggest probiotics may reduce symptoms of depression in patients with irritable bowel syndrome.324,325

In a noteworthy clinical trial, 155 healthy individuals and 156 patients with major depression were studied to identify differences in bacterial landscapes and metabolic signatures of their gut microbiome and fecal metabolites.489

Trial participants had notable differences in the abundance of three bacteriophages (viruses that infect bacteria), 50 fecal metabolites, and 47 bacterial species. The bacterial species were mainly classified in one of the three genera (taxonomic category): Bacteroides, Blautia, and Eubacterium. Bacterial species in these genera are diverse but can play critical roles in the body including regulating inflammation.489,490 Those in the major depression group had significantly increased abundance of Bacteroides and significantly decreased abundance of Blautia and Eubacterium.

Based on these findings, the authors suggest certain species in these genera might be responsible for the inflammatory imbalances commonly seen in major depression patients. Importantly, this research helps pave the way for using gut microbiome signatures in the assessment of major depression.


Zinc has a multitude of functions in the body, including reducing oxidative stress, modulating neurotransmitter receptor function, and regulating gene expression.326,327 Importantly, zinc may inhibit neuronal NMDA glutamate receptors, which are dysregulated in those with depression, and raise BDNF levels, which can promote neuroplasticity.328,329 A meta-analysis of nine studies found low zinc intake was associated with increased depression risk.330 In addition, people with depression have been reported to have lower zinc levels compared with non-depressed individuals, and zinc deficiency has been correlated with increased depression severity and treatment resistance.328,331 Zinc supplementation has been found to improve depression as a stand-alone therapy and in conjunction with antidepressant therapy, even in cases of treatment-resistant depression.329,332

A controlled trial in 50 overweight and obese subjects found symptoms of depression were correlated with lower blood BDNF levels, and supplementing with 30 mg zinc daily for 12 weeks increased BDNF levels and reduced depression symptoms more effectively than placebo.333 In 30 healthy young women, adding 7 mg zinc to a daily multivitamin supplement for 10 weeks led to lower scores assessing anger and hostility compared with the multivitamin alone.334 A 12-week trial that included 44 participants with major depression found those receiving zinc sulfate (providing 25 mg elemental zinc per day) in addition to their usual SSRI had greater improvement in depression compared with those receiving placebo plus SSRI.335 This same dose of zinc was found to be more beneficial than placebo for lowering depression scores in a trial with 14 patients with major depression being treated with SSRIs or tricyclic antidepressants.336 In 60 patients with treatment-resistant depression, adding 25 mg zinc daily to treatment with the tricyclic antidepressant imipramine (Tofranil) for 12 weeks led to a more rapid and robust treatment response compared with placebo.337


Saffron (Crocus sativus) and its active constituents have been widely studied for their effects on depression. Saffron’s antidepressant effects may be due to its anti-inflammatory action, ability to raise dopamine levels, and interactions with endogenous opioid receptors.338 Multiple controlled clinical trials and meta-analyses have shown saffron extract, typically at a dose of 30 mg per day, is more effective than placebo and comparable to antidepressant drugs for improving mild-to-moderate depression.339-342 One meta-analysis that included findings from 21 controlled trials found saffron extract can reduce self-reported depression and anxiety scores and improve sleep quality.343

In a placebo-controlled trial in 40 patients with major depression, combined treatment with antidepressant therapy plus 30 mg crocin (an active compound from saffron) per day for four weeks was more effective for reducing symptoms than antidepressant therapy alone.344 In 54 patients with type 2 diabetes and mild-to-moderate combined depression and anxiety, mood symptoms and sleep improved more after taking 30 mg saffron extract daily for eight weeks compared with placebo.345 In 139 patients with persistent depression despite treatment with antidepressant drugs, adding a standardized saffron extract, at a dose of 28 mg per day, for eight weeks reduced practitioner-assessed depression scores, but not self-assessment score, better than placebo.346

Saffron extracts have been shown to lower depression symptoms in overweight women,347 healthy women with menopausal symptoms,348 patients with HIV/AIDS in substance abuse recovery,349 individuals with metabolic syndrome,350 patients with coronary artery disease,351 and those with fibromyalgia syndrome. Placebo-controlled clinical trials further show saffron, when used in conjunction with antidepressants, may mitigate antidepressant side effects related to sexual function in both men and women.352,353

St. John’s wort

Multiple clinical trials have shown St. John’s wort ( Hypericum perforatum) can reduce symptoms of major depression with a similar efficacy to first-line antidepressant therapy, but with fewer adverse side effects.354-357 One meta-analysis including 35 randomized controlled trials with a combined total of 6,993 participants confirmed St. John’s wort’s benefits in mild-to-moderate depression; however, little is known about its effects in severe depression.358

Some active compounds from St. John’s wort have a weak inhibitory effect on monoamine oxidase, an enzyme that breaks down neurotransmitters, while other constituents have anti-inflammatory and free radical-scavenging effects.359,360 It is thought its antidepressant properties are related to synergistic effects of multiple active compounds.361 Standardized extracts typically contain 0.1–0.3% hypericin and up to 6% hyperforin.362

Extracts of St. John’s wort, particularly those high in hyperforin, can promote increased detoxification activity in the intestinal wall and liver, which can impact metabolism of a number of drugs; therefore, individuals who take medications and want to add St. John’s wort will be safest using low-hyperforin preparations and carefully monitoring conditions for which they take medications.362


Acetyl-L-carnitine is a form of the amino acid L-carnitine, which is important for normal mitochondrial energy metabolism. Acetyl-L-carnitine readily crosses the blood-brain barrier and enhances neuronal mitochondrial metabolism.363 It is thought to have brain-protective effects related to anti-inflammatory and antioxidative stress mechanisms, and promote neuroplasticity.364,365 Acetyl-L-carnitine levels in the blood have been reported to be lower in depressed than non-depressed subjects, and levels were noted to drop with decreasing age of depression onset and increasing severity; patients with treatment-resistant depression and a history of childhood trauma had the lowest levels.366

A meta-analysis of 12 randomized controlled trials with a combined total of 791 participants found acetyl-L-carnitine was more effective than placebo and had similar efficacy to widely-prescribed antidepressant drugs for reducing depression symptoms.367 A 7-week placebo-controlled trial in 80 elderly patients with subthreshold depression found acetyl-L-carnitine was as effective as the antidepressant fluoxetine for reducing symptoms, but symptomatic improvements were more rapid with acetyl-L-carnitine than fluoxetine.368 Acetyl-L-carnitine in doses of 1,500 mg per day has been found to reduce depression symptoms and pain and improve quality of life in patients with fibromyalgia syndrome more effectively than placebo and similarly to duloxetine (Cymbalta).369,370


Dehydroepiandrosterone (DHEA) is an adrenal hormone that can be used to produce testosterone and estradiol. It also has immune-modulating and metabolic effects independently of its role as a sex hormone precursor.371 DHEA contributes to mood modulation, is neuroprotective, and has anti-stress activity.372 Patients with depression have been found to have low DHEA-sulfate (DHEA-s) levels, and the ratio of cortisol:DHEA-s has been suggested to be a measure of stress hormone activity in depression.373 Persistent disturbance of the cortisol:DHEA ratio during remission from depression may be an indicator of recurrence risk.374

In a randomized controlled trial that included 17 participants with midlife-onset non-major depression, taking 90 mg DHEA daily for three weeks resulted in greater improvement in depression symptoms compared with placebo.375 Similarly, a placebo-controlled trial involving 46 participants with major or non-major midlife-onset depression also noted the antidepressant effect of DHEA.376 In another trial, 22 participants with major depression, some of whom were being treated with antidepressant therapy, received either 90 mg DHEA per day for six weeks or placebo. Compared with the control group, more participants in the DHEA group experienced a treatment response, defined as a 50% reduction in depression symptoms.377 DHEA has also been reported to reduce depressive symptoms in patients with schizophrenia378 and HIV/AIDS.379

B Vitamins

The vitamin B complex consists of nine water-soluble B vitamins that have related roles as cofactors in a diverse array of biochemical reactions, and are necessary for normal cellular metabolism and energy production.380 Vitamins B1 (thiamine), B3 (niacin), B6 (pyridoxine), B9 (folate), and B12 (cobalamin) are needed for normal nerve function, and deficiencies have been linked to depression.381 Adequate amounts of the trio of methylators, B6, B9, and B12, are required for the conversion of homocysteine into S-adenosyl methionine, or SAMe, a form of methionine involved in the synthesis of many critical biomolecules, including neurotransmitters. Deficiencies of any of these three B vitamins can raise homocysteine levels. High homocysteine levels have been associated with increased risk of depression, as well as cardiovascular, neurological, and other chronic diseases.109

Clinical trials have shown supplementing with B vitamins can lower levels of perceived stress and improve mood in healthy individuals.382 Long-term folate and B12 supplementation has been found to reduce the risk of relapse in individuals with major depression, and may help prevent the onset of major depression in people at high risk.383 In patients with major depression and a genetic mutation that causes disruption in homocysteine metabolism, taking a multivitamin-mineral supplement with the metabolized forms of B vitamins reduced homocysteine levels and was more effective than placebo at reducing depression symptoms, resulting in a 42% remission rate after eight weeks.384 A combination of 200 mg L-tryptophan, 8 mg B6, and 8 mg B3 per day taken between meals was found to reduce symptoms better than placebo in a 7-day trial that included 30 young adults with severe depression symptoms that did not reach the threshold for a major depression diagnosis.385

Although findings from studies in patients with depression have been mixed, placebo-controlled trials indicate folate, particularly in the form methylfolate, may improve the response to antidepressant therapy.386,387 Vitamin B12 supplementation has also been found to reduce symptoms in patients being treated with antidepressants: in a trial that included 73 patients taking antidepressants for major depression, 100% of participants who received intramuscular injections of 1,000 mcg B12 weekly for six weeks had 20% or greater improvement in depression scores, while only 69% of those not receiving B12 had the same degree of improvement.388 In a placebo-controlled trial in 51 hospitalized patients with major depression, the addition of 300 mg B1 per day to antidepressant therapy led to faster symptom reduction.389

L-Tryptophan and 5-Hydroxytryptophan

L-tryptophan, the amino acid precursor to serotonin in the intestines and brain, is an important mediator of communication between the gut and the central nervous system.38,390,391 L-tryptophan is also a precursor to melatonin and vitamin B3, as well as several other metabolites. Altered tryptophan metabolism that enhances production of inflammatory metabolites may be a contributing factor in depression risk and connect depression to other chronic conditions.392-394 Some evidence suggests stress can disrupt normal tryptophan metabolism, interfering with serotonin production and leading to increased inflammation and risk of depression.395,396 L-tryptophan levels have been noted to diminish with age.397

A meta-analysis of studies found patients with major depression have lower levels of circulating tryptophan.398 Increased tryptophan intake is associated with reduced depressive symptoms and increased sociability, and randomized controlled trials indicate supplementing with up to 3 grams L-tryptophan daily may improve positive mood in healthy adults.399-402 Genetic factors that influence tryptophan metabolism appear to determine in part individual responsiveness to L-tryptophan supplementation.403

5-hydroxytryptophan (5-HTP) is a byproduct of tryptophan metabolism and the immediate precursor to serotonin. Supplementing with 5-HTP instead of L-tryptophan may avoid the production of other L-tryptophan metabolites and may bypass the rate-limiting step in the conversion of tryptophan to serotonin. Randomized controlled trials have found 5-HTP, mainly in doses of 200–300 mg per day, is more effective than placebo and comparable to first-line antidepressants in treating major depression.404,405 Some evidence suggests 5-HTP may also increase responsiveness to antidepressant therapy.406 5-HTP can cause digestive upset but has not been linked to serotonin syndrome or serious adverse effects.406,407


N-acetylcysteine (NAC) is a derivative of the amino acid cysteine. As a source of cysteine, it helps build levels of glutathione, which is needed to metabolize toxins and reduce oxidative stress throughout the body. NAC has important functions in the brain, decreasing oxidative stress and neuroinflammation, enhancing mitochondrial activity, modulating dopamine and glutamate signaling, and promoting neuroplasticity.408

A controlled trial in 252 participants with major depression compared standard of care plus 2,000 mg NAC daily with standard of care plus placebo. Among those with the most severe depression, NAC use resulted in statistically significant improvement in symptoms beginning at week six and continuing until the end of the study. In addition, NAC users had greater improvement in functional impairment at a follow-up four weeks after the end of the trial.409 Another trial found 1,800 mg NAC per day reduced symptoms of depression and anxiety in bipolar or major depression patients with elevated baseline levels of C-reactive protein, a marker of systemic inflammation.410 In a trial of 35 female youths with a history of non-suicidal self-injury, treatment with NAC in doses that were gradually increased to 3,600 mg per day reduced depression symptoms and self-injurious behaviors.411 NAC has been found in multiple clinical trials to reduce depressive symptoms in patients with depression and other psychiatric and neurological conditions.412


Rhodiola (Rhodiola rosea) is a plant that flourishes in northern climates and has been used medicinally as an adaptogen. Adaptogens are therapeutics that increase stress resilience and have been used historically to treat fatigue, build stamina, and promote longevity.413 Preclinical evidence indicates rhodiola modulates neurotransmitter signaling and normalizes the stress response. It also has anti-inflammatory and oxidative stress-reducing effects that may contribute to its antidepressant activity, and has been shown to inhibit depression-like signaling in brains of healthy volunteers.414-416

A controlled trial in 89 patients with mild-to-moderate depression found rhodiola extract, in doses of 340 mg and 680 mg daily, reduced depression symptoms compared with placebo after 42 days. Although the overall effects of the two dosages were similar, those receiving the higher dose were noted to have experienced a marked improvement in self-esteem, which was not observed in those receiving the lower dose.417 In a randomized controlled trial, 100 patients with mild-to-moderate depression were treated with the SSRI sertraline plus either 300 mg per day rhodiola, 600 mg per day rhodiola, or placebo. After 12 weeks, those receiving the higher dose of rhodiola had the greatest symptom improvement.418 In addition, results from a number of open trials add to the evidence that rhodiola has meaningful antidepressant activity.419 In a 12-week comparison trial in 57 patients with mild-to-moderate depression, a dose-escalation of rhodiola extract (ranging from 340–1,360 mg daily) led to slightly lower likelihood of improvement than sertraline, relative to placebo, but caused fewer adverse side effects.416

Lemon Balm (Melissa officinalis)

Lemon balm is a perennial herb in the mint family; it is native to southern Europe, Asia Minor, and Africa. Lemon balm has been used historically to treat mood disorders, including depression and anxiety, and for managing stress and promoting restful sleep.420,421 Contemporary preclinical research has shown that lemon balm possesses some pharmacological properties that may partly explain its ability to influence mood. Extracts of lemon balm have been shown in vitro to inhibit monoamine oxidase A (MAO-A),422 an action that can modulate the metabolism of monoamine neurotransmitters involved in mood regulation.

In a small pilot study, 45 adults with major depression were randomized to fluoxetine, lemon balm, or another herb, English lavender (Lavandula angustifolia).421 Subjects’ mood was assessed at baseline, two, four, and eight weeks using the HAM-D. Lemon balm and lavender were both as effective as fluoxetine in reducing subjects’ HAM-D scores over the course of the study. The authors of this study acknowledged the preliminary nature of this work: “Although in our study effects of M. officinalis and L. angustifolia was equal to fluoxetine, a meta-analysis has revealed that these effects [are comparable to those attributable to the] placebo effect.126 Regarding to this controversy, larger trials with longer duration of follow up and including placebo group are needed to evaluate the long-standing safety and efficacy of these herbal medications.”

An earlier randomized placebo-controlled trial evaluated the effects of lemon balm on mood and sleep disorders in 80 subjects with chronic stable angina. Participants were randomized to receive either 3 grams lemon balm or placebo daily for eight weeks. Mood was assessed using a standardized questionnaire. At the end of the study period, subjects taking the lemon balm had significant reductions in scores for depression, anxiety, stress, and sleep disturbance compared with those taking placebo.423 Another small trial found lemon balm helped relieve depression in people with insomnia. In this study, lemon balm was combined with another herb, Nepeta menthoides, and the combination improved mood-related scores more than placebo after four weeks of treatment.424

Lavender (Lavandula angustifolia)

Lavender is a common herb in the Mediterranean region; its pleasant scent makes it a popular ingredient in perfumes and essential oil infusions. Lavender aromatherapy has been shown to alleviate depressive symptoms in preliminary research. Oral supplementation with lavender preparations, as extracts, teas, or tinctures, has been shown to ameliorate depression symptoms in a few small studies.425

In a single-blind clinical trial, 60 elderly subjects were assigned to consume lavender tea twice daily or no treatment for two weeks. Mood scores were assessed using standardized questionnaires. Scores for depression declined significantly in the lavender tea group compared with those who did not consume any lavender tea.426 In a trial that enrolled 318 adults with mixed anxiety and depression, a lavender extract (Silexan, 80 mg daily) improved scores on a standardized depression rating scale significantly more than placebo after 70 days of treatment.427 In a separate open-label trial in which this same extract was studied in people reporting anxiety and restlessness, depression scores decreased significantly from baseline after six weeks of treatment.428

In another trial, 45 adults with major depression were randomized to receive a lavender tincture (1:5 extract in 50% alcohol) plus placebo, lavender tincture plus the antidepressant imipramine, or imipramine plus placebo for four weeks. The combination of lavender plus imipramine was found to be more effective than imipramine alone in reducing depression, but lavender alone was less effective than imipramine alone. The researchers concluded that “The main overall finding from this study is that [lavender] tincture may be of therapeutic benefit in the management of mild to moderate depression as adjuvant therapy.”429

S-adenosyl methionine

S-adenosyl methionine (SAMe) is an important source of single-carbon methyl groups needed for the synthesis of many critical biomolecules, including neurotransmitters and hormones. The production of SAMe from the amino acid methionine requires adequate amounts of folate and vitamin B12, which act as cofactors in that chemical reaction. SAMe levels have been found to be reduced in people with depression.430

Findings from clinical trials examining the use of SAMe for depression have been mixed, and most studies of SAMe in the context of depression have suffered from low methodological quality, design flaws, or small sample size.431 A systematic review of the research from 2005 and two meta-analyses published in 2003 and 1994 all found evidence supportive of SAMe’s antidepressant effect432-434; however, more recent trials have been unable to clearly corroborate these findings.431

In a placebo-controlled trial that included 49 patients with mild-to-moderate depression, 800 mg SAMe per day for eight weeks led to substantial reductions in depression symptoms, particularly in those with milder depression; however, due to the small number of participants in the study and a very strong placebo response, the improvements seen with SAMe were not statistically significant.435 Similarly, SAMe added to antidepressant therapy in patients who did not respond sufficiently to medication alone led to improvements that were clinically meaningful but not statistically significant due to a 50% response rate in those receiving placebo.436

A 2016 systematic review of eight trials that included a combined total of 934 subjects found SAMe had similar efficacy to certain antidepressant therapies, but the overall quality of evidence was weak.437 A 12-week randomized controlled trial in which 189 patients with major depression were given either 1,600–3,200 mg SAMe per day, 10–20 mg escitalopram per day, or placebo found all three were equally effective438; however, a second analysis of these findings revealed that SAMe was superior to placebo in men but not women.439 A potential influence of gender could partly explain the inconsistency of findings from clinical trials over the years.

Overall, the available evidence is insufficient to allow conclusions to be drawn as to the efficacy of SAMe in the treatment of depression. Adjunctive therapy with SAMe in people taking antidepressants might be effective, but higher-quality studies are needed to clarify the degree of benefit, if any.431,440

SAMe is contraindicated in patients with bipolar disorder since it has been reported to induce mania in some cases.441


Creatine is an organic acid made from the amino acids glycine, arginine, and methionine and is found in meat and fish. It plays a critical role in modulating energy production in highly active cells, such as muscle and brain cells. Low dietary intake of creatine has been correlated with increased risk of depression, and altered brain creatine metabolism has been identified as a potential factor in depression.442,443

A randomized controlled trial in 52 women with major depression found combined treatment with escitalopram plus creatine monohydrate, at 3 grams daily for one week followed by 5 grams daily for seven weeks, led to better treatment responsiveness than escitalopram plus placebo.444 A follow-up study found creatine supplementation also increased formation of nerve connections in the brain.445 In an open trial in 15 women with treatment-resistant depression, adding 5 grams creatine monohydrate plus 100 mg 5-HTP daily for eight weeks decreased depression symptom scores by 60%.446 An open trial in five adolescent girls with major depression that was unresponsive to fluoxetine found the addition of 4 grams creatine daily for eight weeks led to symptom score reductions of 56%.447 However, a controlled trial in 18 depressed women who were unresponsive to antidepressant therapy after three weeks found the addition of 5 or 10 grams creatine daily was no more effective than placebo at improving the response rate.448 Further studies with creatine are necessary to elucidate whether it offers benefit over placebo in patients with major depression.


Inositol (sometimes referred to as myo-inositol) is a sugar alcohol derived from glucose in the body. It is found in many plant and animal foods. Inositol is stored in cell membranes in the form of phosphatidylinositol and its derivatives. In the central nervous system, inositol helps regulate neuronal signaling: activation of neurotransmitter receptors on a nerve cell stimulates delivery of inositol from the cell membrane into the cell where it modulates signal perpetuation via neurotransmitter release.449 Brain levels of inositol have been reported to be lower in individuals with depression, and may normalize as a result of successful therapy.449,450 Oral inositol supplementation may help normalize brain inositol levels.449,451

A randomized controlled trial in 28 participants with depression found 12 grams inositol per day for four weeks was more effective than placebo for reducing symptoms.452 Inositol has also been found to reduce depression symptoms marginally better than placebo in several controlled trials.453 However, researchers have failed to find a benefit from inositol compared with placebo in depressed patients being treated unsuccessfully with SSRIs.454,455


Magnesium has many important functions in the brain, including participating in regulation of nerve signal transmission.456 Some studies have reported higher magnesium intake and serum levels are associated with lower likelihood of depression and decreased depressive symptoms.457,458 Several uncontrolled trials have found magnesium supplementation is effective for reducing depressive symptoms.459 In one crossover trial that included 126 patients with mild-to-moderate depression, supplementing with 248 mg elemental magnesium (as magnesium chloride) per day for six weeks resulted in a significant reduction in symptoms compared with no treatment.460 Although most placebo-controlled trials have found magnesium’s therapeutic effect is not different from placebo,459 one trial noted 500 mg magnesium oxide daily for eight weeks reduced symptoms significantly more than placebo in 60 depressed patients with magnesium deficiency.461

It is thought that magnesium’s poor ability to cross the blood-brain barrier may be responsible for its weak performance in clinical trials.462 In cell and animal research, magnesium L-threonate, a magnesium salt that more readily permeates the central nervous system, has been found to raise brain magnesium levels, improve brain structure and function, prevent nerve damage due to toxicity or low oxygen levels, and reduce symptoms of neurological diseases.463-468 In a study in rats, magnesium L-threonate reduced depression-like symptoms and improved memory more than other forms of magnesium.469


The central nervous system is a site of high concentrations of the amino acid taurine, which reduces brain oxidative stress, stimulates nerve growth and development, and participates in regulation of nerve signal transmission.470 Diminished levels of taurine, along with aspartate, glycine, and gamma aminobutyric acid (GABA), have been noted in the brains of animals with experimentally-induced depression.471 One research group identified an antidepressant action of taurine in diabetic laboratory animals, and noted taurine supplementation reversed diabetes-related decreases in GABA signaling and BDNF production, prevented brain atrophy, and improved memory.472,473 Taurine has also been reported to decrease depression-like symptoms in animals exposed to chronic stress by regulating stress hormone levels and promoting nerve growth, nerve survival, and formation of new nerves.474 In a randomized controlled trial, 86 patients being treated for a first psychotic episode were given 4 grams taurine or placebo daily along with standard medical treatment for 12 weeks; those receiving taurine had greater improvement in psychiatric symptoms, including depression symptoms, as well as overall functioning.475

Disclaimer and Safety Information

This information (and any accompanying material) is not intended to replace the attention or advice of a physician or other qualified health care professional. Anyone who wishes to embark on any dietary, drug, exercise, or other lifestyle change intended to prevent or treat a specific disease or condition should first consult with and seek clearance from a physician or other qualified health care professional. Pregnant women in particular should seek the advice of a physician before using any protocol listed on this website. The protocols described on this website are for adults only, unless otherwise specified. Product labels may contain important safety information and the most recent product information provided by the product manufacturers should be carefully reviewed prior to use to verify the dose, administration, and contraindications. National, state, and local laws may vary regarding the use and application of many of the therapies discussed. The reader assumes the risk of any injuries. The authors and publishers, their affiliates and assigns are not liable for any injury and/or damage to persons arising from this protocol and expressly disclaim responsibility for any adverse effects resulting from the use of the information contained herein.

The protocols raise many issues that are subject to change as new data emerge. None of our suggested protocol regimens can guarantee health benefits. Life Extension has not performed independent verification of the data contained in the referenced materials, and expressly disclaims responsibility for any error in the literature.

  1. Lyness JM, Roy-Byrne PP, Solomon D. Unipolar depression in adults: Clinical features. UpToDate. Updated 02/12/2020. Accessed 07/24/2020.
  2. Lyness JM, Roy-Byrne PP, Solomon D. Unipolar minor depression in adults: Epidemiology, clinical presentation, and diagnosis. UpToDate. Updated 10/10/2018. Accessed 07/24/2020.
  3. American Psychiatric Association. Depressive Disorders: DSM-5® Selections. American Psychiatric Publishing; 2015.
  4. Hasin DS, Sarvet AL, Meyers JL, et al. Epidemiology of Adult DSM-5 Major Depressive Disorder and Its Specifiers in the United States. JAMA Psychiatry. 2018;75(4):336-346.
  5. Malhi GS, Mann JJ. Depression. Lancet. 2018;392(10161):2299-2312.
  6. Marcus M, Yasamy MT, Ommeren M, Chisholm D, Saxena S. Depression: A global public health concern. World Health Organization Paper on Depression. 2012:6-8.
  7. Flux MC, Lowry CA. Finding intestinal fortitude: Integrating the microbiome into a holistic view of depression mechanisms, treatment, and resilience. Neurobiology of disease. 2020;135:104578.
  8. McKeever A, Agius M, Mohr P. A Review of the Epidemiology of Major Depressive Disorder and of its consequences for Society and the individual. Psychiatr Danub. 2017;29(Suppl 3):222-231.
  9. Thornicroft G, Chatterji S, Evans-Lacko S, et al. Undertreatment of people with major depressive disorder in 21 countries. Br J Psychiatry. 2017;210(2):119-124.
  10. Li H, Ge S, Greene B, Dunbar-Jacob J. Depression in the context of chronic diseases in the United States and China. Int J Nurs Sci. 2019;6(1):117-122.
  11. Thom R, Silbersweig DA, Boland RJ. Major Depressive Disorder in Medical Illness: A Review of Assessment, Prevalence, and Treatment Options. Psychosomatic medicine. 2019;81(3):246-255.
  12. Hirschfeld RMA. The Comorbidity of Major Depression and Anxiety Disorders: Recognition and Management in Primary Care. Primary care companion to the Journal of clinical psychiatry. 2001;3(6):244-254.
  13. Anwar N, Kuppili PP, Balhara YPS. Depression and physical noncommunicable diseases: The need for an integrated approach. WHO South East Asia J Public Health. 2017;6(1):12-17.
  14. Rush AJ, Trivedi MH, Wisniewski SR, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):1905-1917.
  15. Coryell W. Merck Manual: Depressive Disorders. Available at Last updated 03/2020. Accessed 06/13/2020. 2020.
  16. American Psychiatric Association. Depressive Disorders: DSM-5® Selections. American Psychiatric Publishing; 2015.
  17. Linnemann C, Lang UE. Pathways Connecting Late-Life Depression and Dementia. Frontiers in pharmacology. 2020;11:279.
  18. Biella MM, Borges MK, Strauss J, Mauer S, Martinelli JE, Aprahamian I. Subthreshold Depression Needs A Prime Time In Old Age Psychiatry? A Narrative Review Of Current Evidence. Neuropsychiatr Dis Treat. 2019;15:2763-2772.
  19. Perrino T, Beardslee W, Bernal G, et al. Toward scientific equity for the prevention of depression and depressive symptoms in vulnerable youth. Prev Sci. 2015;16(5):642-651.
  20. Shao X, Zhu G. Associations Among Monoamine Neurotransmitter Pathways, Personality Traits, and Major Depressive Disorder. Frontiers in psychiatry. 2020;11:381.
  21. Braithwaite EC, O'Connor RM, Degli-Esposti M, Luke N, Bowes L. Modifiable predictors of depression following childhood maltreatment: a systematic review and meta-analysis. Translational psychiatry. 2017;7(7):e1162.
  22. Kalkman HO. Novel Treatment Targets Based on Insights in the Etiology of Depression: Role of IL-6 Trans-Signaling and Stress-Induced Elevation of Glutamate and ATP. Pharmaceuticals (Basel). 2019;12(3).
  23. Beutel ME, Klein EM, Brähler E, et al. Loneliness in the general population: prevalence, determinants and relations to mental health. BMC psychiatry. 2017;17(1):97.
  24. Franzen PL, Buysse DJ. Sleep disturbances and depression: risk relationships for subsequent depression and therapeutic implications. Dialogues in clinical neuroscience. 2008;10(4):473-481.
  25. Vanek J, Prasko J, Genzor S, et al. Obstructive sleep apnea, depression and cognitive impairment. Sleep Med. 2020;72:50-58.
  26. Kerner NA, Roose SP. Obstructive Sleep Apnea is Linked to Depression and Cognitive Impairment: Evidence and Potential Mechanisms. Am J Geriatr Psychiatry. 2016;24(6):496-508.
  27. Chen YH, Keller JK, Kang JH, Hsieh HJ, Lin HC. Obstructive sleep apnea and the subsequent risk of depressive disorder: a population-based follow-up study. Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine. 2013;9(5):417-423.
  28. Ohayon MM. The effects of breathing-related sleep disorders on mood disturbances in the general population. The Journal of clinical psychiatry. 2003;64(10):1195-1200; quiz, 1274-1196.
  29. Yang X, Yang J, Yang C, Niu L, Song F, Wang L. Continuous positive airway pressure can improve depression in patients with obstructive sleep apnoea syndrome: a meta-analysis based on randomized controlled trials. The Journal of international medical research. 2020;48(3):300060519895096.
  30. Mok Y, Melehan KL, Phillips CL, et al. Does CPAP treat depressive symptoms in individuals with OSA? An analysis of two 12-week randomized sham CPAP-controlled trials. Sleep Med. 2020;73:11-14.
  31. Zhang H, Yuan J, Zhang Y, et al. Neuroendocrine abnormalities associated with untreated first episode patients of major depressive disorder with comorbid obstructive sleep apnea. Psychiatry research. 2020;291:113248.
  32. Campos-Rodriguez F, Cordero-Guevara J, Asensio-Cruz MI, et al. Interleukin 6 as a marker of depression in women with sleep apnea. J Sleep Res. 2020:e13035.
  33. Heim C, Binder EB. Current research trends in early life stress and depression: review of human studies on sensitive periods, gene-environment interactions, and epigenetics. Experimental neurology. 2012;233(1):102-111.
  34. Blackburn TP. Depressive disorders: Treatment failures and poor prognosis over the last 50 years. Pharmacology research & perspectives. 2019;7(3):e00472.
  35. Marathe SV, D'Almeida P L, Virmani G, Bathini P, Alberi L. Effects of Monoamines and Antidepressants on Astrocyte Physiology: Implications for Monoamine Hypothesis of Depression. Journal of experimental neuroscience. 2018;12:1179069518789149.
  36. Boku S, Nakagawa S, Toda H, Hishimoto A. Neural basis of major depressive disorder: Beyond monoamine hypothesis. Psychiatry and clinical neurosciences. 2018;72(1):3-12.
  37. Hensler JG. Serotonergic modulation of the limbic system. Neuroscience and biobehavioral reviews. 2006;30(2):203-214.
  38. Jenkins TA, Nguyen JC, Polglaze KE, Bertrand PP. Influence of Tryptophan and Serotonin on Mood and Cognition with a Possible Role of the Gut-Brain Axis. Nutrients. 2016;8(1).
  39. Yohn CN, Gergues MM, Samuels BA. The role of 5-HT receptors in depression. Molecular brain. 2017;10(1):28.
  40. Ranjbar-Slamloo Y, Fazlali Z. Dopamine and Noradrenaline in the Brain; Overlapping or Dissociate Functions? Frontiers in molecular neuroscience. 2020;12(334).
  41. Seki K, Yoshida S, Jaiswal M. Molecular mechanism of noradrenaline during the stress-induced major depressive disorder. Neural Regeneration Research. 2018;13(7):1159-1169.
  42. Mammarella N, Di Domenico A, Palumbo R, Fairfield B. Noradrenergic modulation of emotional memory in aging. Ageing Res Rev. 2016;27:61-66.
  43. Belujon P, Grace AA. Dopamine System Dysregulation in Major Depressive Disorders. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). 2017;20(12):1036-1046.
  44. Grace AA. Dysregulation of the dopamine system in the pathophysiology of schizophrenia and depression. Nature reviews Neuroscience. 2016;17(8):524-532.
  45. Ceruso A, Martínez-Cengotitabengoa M, Peters-Corbett A, Diaz-Gutierrez MJ, Martínez-Cengotitabengoa M. Alterations of the HPA Axis Observed in Patients with Major Depressive Disorder and Their Relation to Early Life Stress: A Systematic Review. Neuropsychobiology. 2020:1-11.
  46. Patten SB. The "Clinician's illusion" and the epidemiology, diagnosis and treatment of depressive disorders. BMC psychiatry. 2018;18(1):395.
  47. Bondoc EN, Marinescu D, Marinescu I, Mălin RD, Stanca L, Zăvoi RE. Current understanding of psycho-neurobiology in depressive disorders with suicidal thoughts - translational models. Romanian journal of morphology and embryology = Revue roumaine de morphologie et embryologie. 2019;60(2):389-402.
  48. Felger JC, Miller AH. Identifying Immunophenotypes of Inflammation in Depression: Dismantling the Monolith. Biological psychiatry. 2020;88(2):136-138.
  49. Lynall ME, Turner L, Bhatti J, et al. Peripheral Blood Cell-Stratified Subgroups of Inflamed Depression. Biological psychiatry. 2020;88(2):185-196.
  50. Nowak W, Grendas LN, Sanmarco LM, et al. Pro-inflammatory monocyte profile in patients with major depressive disorder and suicide behaviour and how ketamine induces anti-inflammatory M2 macrophages by NMDAR and mTOR. EBioMedicine. 2019;50:290-305.
  51. Vojvodic J, Mihajlovic G, Vojvodic P, et al. The Impact of Immunological Factors on Depression Treatment - Relation Between Antidepressants and Immunomodulation Agents. Open Access Maced J Med Sci. 2019;7(18):3064-3069.
  52. Felger JC. Imaging the Role of Inflammation in Mood and Anxiety-related Disorders. Curr Neuropharmacol. 2018;16(5):533-558.
  53. Jeon SW, Kim YK. The role of neuroinflammation and neurovascular dysfunction in major depressive disorder. J Inflamm Res. 2018;11:179-192.
  54. Miller AH, Raison CL. The role of inflammation in depression: from evolutionary imperative to modern treatment target. Nat Rev Immunol. 2016;16(1):22-34.
  55. Leal G, Bramham CR, Duarte CB. BDNF and Hippocampal Synaptic Plasticity. Vitamins and hormones. 2017;104:153-195.
  56. Numakawa T, Odaka H, Adachi N. Actions of Brain-Derived Neurotrophic Factor and Glucocorticoid Stress in Neurogenesis. International journal of molecular sciences. 2017;18(11).
  57. Guerrera CS, Furneri G, Grasso M, et al. Antidepressant Drugs and Physical Activity: A Possible Synergism in the Treatment of Major Depression? Frontiers in psychology. 2020;11:857.
  58. Miranda M, Morici JF, Zanoni MB, Bekinschtein P. Brain-Derived Neurotrophic Factor: A Key Molecule for Memory in the Healthy and the Pathological Brain. Frontiers in cellular neuroscience. 2019;13:363.
  59. Pedersen BK. Physical activity and muscle-brain crosstalk. Nature reviews Endocrinology. 2019;15(7):383-392.
  60. Kim HK, Nunes PV, Oliveira KC, Young LT, Lafer B. Neuropathological relationship between major depression and dementia: A hypothetical model and review. Progress in neuro-psychopharmacology & biological psychiatry. 2016;67:51-57.
  61. Duman RS, Sanacora G, Krystal JH. Altered Connectivity in Depression: GABA and Glutamate Neurotransmitter Deficits and Reversal by Novel Treatments. Neuron. 2019;102(1):75-90.
  62. Wigner P, Czarny P, Galecki P, Sliwinski T. Oxidative and Nitrosative Stress as Well as the Tryptophan Catabolites Pathway in Depressive Disorders. Psychiatr Danub. 2017;29(4):394-400.
  63. Du Y, Gao XR, Peng L, Ge JF. Crosstalk between the microbiota-gut-brain axis and depression. Heliyon. 2020;6(6):e04097.
  64. Capuco A, Urits I, Hasoon J, et al. Gut Microbiome Dysbiosis and Depression: a Comprehensive Review. Curr Pain Headache Rep. 2020;24(7):36.
  65. Lach G, Schellekens H, Dinan TG, Cryan JF. Anxiety, Depression, and the Microbiome: A Role for Gut Peptides. Neurotherapeutics. 2018;15(1):36-59.
  66. Li Y, Hao Y, Fan F, Zhang B. The Role of Microbiome in Insomnia, Circadian Disturbance and Depression. Front Psychiatry. 2018;9:669.
  67. Liang S, Wu X, Hu X, Wang T, Jin F. Recognizing Depression from the Microbiota⁻Gut⁻Brain Axis. International journal of molecular sciences. 2018;19(6).
  68. Ng CW, How CH, Ng YP. Major depression in primary care: making the diagnosis. Singapore medical journal. 2016;57(11):591-597.
  69. van Agtmaal MJM, Houben A, Pouwer F, Stehouwer CDA, Schram MT. Association of Microvascular Dysfunction With Late-Life Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2017;74(7):729-739.
  70. Benatti C, Blom JM, Rigillo G, et al. Disease-Induced Neuroinflammation and Depression. CNS & neurological disorders drug targets. 2016;15(4):414-433.
  71. Upthegrove R, Marwaha S, Birchwood M. Depression and Schizophrenia: Cause, Consequence, or Trans-diagnostic Issue? Schizophrenia bulletin. 2017;43(2):240-244.
  72. Halaris A. Inflammation-Associated Co-morbidity Between Depression and Cardiovascular Disease. Curr Top Behav Neurosci. 2017;31:45-70.
  73. Penninx BW. Depression and cardiovascular disease: Epidemiological evidence on their linking mechanisms. Neuroscience and biobehavioral reviews. 2017;74(Pt B):277-286.
  74. Esler M. Mental stress and human cardiovascular disease. Neuroscience and biobehavioral reviews. 2017;74(Pt B):269-276.
  75. Robinson RG, Jorge RE. Post-Stroke Depression: A Review. The American journal of psychiatry. 2016;173(3):221-231.
  76. Hu M, Shu X, Wu X, et al. Neuropsychiatric symptoms as prognostic makers for the elderly with mild cognitive impairment: a meta-analysis. J Affect Disord. 2020;271:185-192.
  77. Sartorius N. Depression and diabetes. Dialogues in clinical neuroscience. 2018;20(1):47-52.
  78. Slyepchenko A, Maes M, Jacka FN, et al. Gut Microbiota, Bacterial Translocation, and Interactions with Diet: Pathophysiological Links between Major Depressive Disorder and Non-Communicable Medical Comorbidities. Psychother Psychosom. 2017;86(1):31-46.
  79. Galts CPC, Bettio LEB, Jewett DC, et al. Depression in neurodegenerative diseases: Common mechanisms and current treatment options. Neuroscience and biobehavioral reviews. 2019;102:56-84.
  80. Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: the prevalence of anxiety and depression in patients with irritable bowel syndrome. Alimentary pharmacology & therapeutics. 2019;50(2):132-143.
  81. Sibelli A, Chalder T, Everitt H, Workman P, Windgassen S, Moss-Morris R. A systematic review with meta-analysis of the role of anxiety and depression in irritable bowel syndrome onset. Psychol Med. 2016;46(15):3065-3080.
  82. Walker MM, Potter MD, Talley NJ. Tangible pathologies in functional dyspepsia. Best Pract Res Clin Gastroenterol. 2019;40-41:101650.
  83. Nowakowski J, Chrobak AA, Dudek D. Psychiatric illnesses in inflammatory bowel diseases - psychiatric comorbidity and biological underpinnings. Psychiatria polska. 2016;50(6):1157-1166.
  84. McCormick D. Managing costs and care for chronic idiopathic constipation. The American journal of managed care. 2019;25(4 Suppl):S63-s69.
  85. Agrawal L, Korkutata M, Vimal SK, Yadav MK, Bhattacharyya S, Shiga T. Therapeutic potential of serotonin 4 receptor for chronic depression and its associated comorbidity in the gut. Neuropharmacology. 2020;166:107969.
  86. Sheng J, Liu S, Wang Y, Cui R, Zhang X. The Link between Depression and Chronic Pain: Neural Mechanisms in the Brain. Neural plasticity. 2017;2017:9724371.
  87. Løge-Hagen JS, Sæle A, Juhl C, Bech P, Stenager E, Mellentin AI. Prevalence of depressive disorder among patients with fibromyalgia: Systematic review and meta-analysis. J Affect Disord. 2019;245:1098-1105.
  88. Amoozegar F. Depression comorbidity in migraine. International review of psychiatry (Abingdon, England). 2017;29(5):504-515.
  89. Bortolato B, Hyphantis TN, Valpione S, et al. Depression in cancer: The many biobehavioral pathways driving tumor progression. Cancer treatment reviews. 2017;52:58-70.
  90. Jia Y, Li F, Liu YF, Zhao JP, Leng MM, Chen L. Depression and cancer risk: a systematic review and meta-analysis. Public health. 2017;149:138-148.
  91. Paller A, Jaworski JC, Simpson EL, et al. Major Comorbidities of Atopic Dermatitis: Beyond Allergic Disorders. American journal of clinical dermatology. 2018;19(6):821-838.
  92. Tay TR, Hew M. Comorbid "treatable traits" in difficult asthma: Current evidence and clinical evaluation. Allergy. 2018;73(7):1369-1382.
  93. Busby E, Bold J, Fellows L, Rostami K. Mood Disorders and Gluten: It's Not All in Your Mind! A Systematic Review with Meta-Analysis. Nutrients. 2018;10(11).
  94. Bialek K, Czarny P, Strycharz J, Sliwinski T. Major depressive disorders accompanying autoimmune diseases - Response to treatment. Progress in neuro-psychopharmacology & biological psychiatry. 2019;95:109678.
  95. Chaves-Filho AJM, Macedo DS, de Lucena DF, Maes M. Shared microglial mechanisms underpinning depression and chronic fatigue syndrome and their comorbidities. Behav Brain Res. 2019;372:111975.
  96. Larkin D, Martin CR. The interface between chronic fatigue syndrome and depression: A psychobiological and neurophysiological conundrum. Neurophysiol Clin. 2017;47(2):123-129.
  97. Lee SA, Jobe MC, Mathis AA, Gibbons JA. Incremental validity of coronaphobia: Coronavirus anxiety explains depression, generalized anxiety, and death anxiety. J Anxiety Disord. 2020;74:102268.
  98. Twenge JM, Joiner TE. U.S. Census Bureau-assessed prevalence of anxiety and depressive symptoms in 2019 and during the 2020 COVID-19 pandemic. Depression and anxiety. 2020.
  99. Tanzi A. Bloomberg: Economics. Majority of Americans in Largest Cities Report Covid Depression. Available at Published 07/16/2020. Accessed 07/17/2020. 2020.
  100. Fitzpatrick KM, Harris C, Drawve G. How bad is it? Suicidality in the middle of the COVID-19 pandemic. Suicide Life Threat Behav. 2020.
  101. Nie XD, Wang Q, Wang MN, et al. Anxiety and depression and its correlates in patients with coronavirus disease 2019 in Wuhan. International journal of psychiatry in clinical practice. 2020:1-6.
  102. Ma YF, Li W, Deng HB, et al. Prevalence of depression and its association with quality of life in clinically stable patients with COVID-19. J Affect Disord. 2020;275:145-148.
  103. Solomou I, Constantinidou F. Prevalence and Predictors of Anxiety and Depression Symptoms during the COVID-19 Pandemic and Compliance with Precautionary Measures: Age and Sex Matter. International journal of environmental research and public health. 2020;17(14).
  104. Palgi Y, Shrira A, Ring L, et al. The loneliness pandemic: Loneliness and other concomitants of depression, anxiety and their comorbidity during the COVID-19 outbreak. J Affect Disord. 2020;275:109-111.
  105. Fullana MA, Hidalgo-Mazzei D, Vieta E, Radua J. Coping behaviors associated with decreased anxiety and depressive symptoms during the COVID-19 pandemic and lockdown. J Affect Disord. 2020;275:80-81.
  106. Fitzpatrick KM, Harris C, Drawve G. Living in the midst of fear: Depressive symptomatology among US adults during the COVID-19 pandemic. Depression and anxiety. 2020.
  107. Maurer DM, Raymond TJ, Davis BN. Depression: Screening and Diagnosis. American family physician. 2018;98(8):508-515.
  108. Al-Jafar HA. HWA: Hypoferritinemia without anemia a hidden hematology disorder. Journal of family medicine and primary care. 2017;6(1):69-72.
  109. Zaric BL, Obradovic M, Bajic V, Haidara MA, Jovanovic M, Isenovic ER. Homocysteine and Hyperhomocysteinaemia. Curr Med Chem. 2019;26(16):2948-2961.
  110. Turpeinen U, Hämäläinen E. Determination of cortisol in serum, saliva and urine. Best Pract Res Clin Endocrinol Metab. 2013;27(6):795-801.
  111. Wosu AC, Valdimarsdóttir U, Shields AE, Williams DR, Williams MA. Correlates of cortisol in human hair: implications for epidemiologic studies on health effects of chronic stress. Ann Epidemiol. 2013;23(12):797-811.e792.
  112. Shapero BG, Curley EE, Black CL, Alloy LB. The interactive association of proximal life stress and cumulative HPA axis functioning with depressive symptoms. Depression and anxiety. 2019;36(11):1089-1101.
  113. Hinz M, Stein A, Uncini T. Validity of urinary monoamine assay sales under the "spot baseline urinary neurotransmitter testing marketing model". International journal of nephrology and renovascular disease. 2011;4:101-113.
  114. Brigitta B. Pathophysiology of depression and mechanisms of treatment. Dialogues in clinical neuroscience. 2002;4(1):7-20.
  115. Rogers D, Pies R. General medical with depression drugs associated. Psychiatry (Edgmont). 2008;5(12):28-41.
  116. Shader RI. COVID-19, interferons, and depression: A commentary. Psychiatry research. 2020;291:113198.
  117. APA. American Psychological Association. Depression Assessment Instruments. Available at Published 08/2019. Accessed 06/19/2020. 2019.
  118. Cosgrove L, Morrill Z, Yusif M, et al. Drivers of and Solutions for the Overuse of Antidepressant Medication in Pediatric Populations. Frontiers in psychiatry. 2020;11:17.
  119. Alduhishy M. The overprescription of antidepressants and its impact on the elderly in Australia. Trends Psychiatry Psychother. 2018;40(3):241-243.
  120. Spence D. Bad Medicine: The rise and rise of antidepressants. The British journal of general practice : the journal of the Royal College of General Practitioners. 2016;66(652):573.
  121. Jureidini J, Tonkin A. Overuse of antidepressant drugs for the treatment of depression. CNS drugs. 2006;20(8):623-632.
  122. Maust DT, Sirey JA, Kales HC. Antidepressant Prescribing in Primary Care to Older Adults Without Major Depression. Psychiatr Serv. 2017;68(5):449-455.
  123. Bobo WV, Grossardt BR, Lapid MI, et al. Frequency and predictors of the potential overprescribing of antidepressants in elderly residents of a geographically defined U.S. population. Pharmacology research & perspectives. 2019;7(1):e00461.
  124. Santarsieri D, Schwartz TL. Antidepressant efficacy and side-effect burden: a quick guide for clinicians. Drugs Context. 2015;4:212290.
  125. Henssler J, Heinz A, Brandt L, Bschor T. Antidepressant Withdrawal and Rebound Phenomena. Dtsch Arztebl Int. 2019;116(20):355-361.
  126. Kirsch I. Placebo Effect in the Treatment of Depression and Anxiety. Frontiers in psychiatry. 2019;10:407.
  127. Plöderl M, Hengartner MP. Antidepressant prescription rates and suicide attempt rates from 2004 to 2016 in a nationally representative sample of adolescents in the USA. Epidemiol Psychiatr Sci. 2019;28(5):589-591.
  128. Ruberto VL, Jha MK, Murrough JW. Pharmacological Treatments for Patients with Treatment-Resistant Depression. Pharmaceuticals (Basel). 2020;13(6).
  129. Holtzeimer PER-B, P. P.; SOlomon, D. Up-to-Date: Depression in Adults: Overview of neuromodulation procedures. Available at Last reviewed 05/2020. Accessed 06/29/2020. . 2020.
  130. Chalah MA, Ayache SS. Disentangling the Neural Basis of Cognitive Behavioral Therapy in Psychiatric Disorders: A Focus on Depression. Brain sciences. 2018;8(8).
  131. Sankar A, Melin A, Lorenzetti V, Horton P, Costafreda SG, Fu CHY. A systematic review and meta-analysis of the neural correlates of psychological therapies in major depression. Psychiatry Res Neuroimaging. 2018;279:31-39.
  132. Li X, Wang Q. Psychological Treatment for Depressive Disorder. Adv Exp Med Biol. 2019;1180:233-265.
  133. Gartlehner G, Gaynes BN, Amick HR, et al. Comparative Benefits and Harms of Antidepressant, Psychological, Complementary, and Exercise Treatments for Major Depression: An Evidence Report for a Clinical Practice Guideline From the American College of Physicians. Ann Intern Med. 2016;164(5):331-341.
  134. Santoft F, Axelsson E, Öst LG, Hedman-Lagerlöf M, Fust J, Hedman-Lagerlöf E. Cognitive behaviour therapy for depression in primary care: systematic review and meta-analysis. Psychol Med. 2019;49(8):1266-1274.
  135. Weitz ES, Hollon SD, Twisk J, et al. Baseline Depression Severity as Moderator of Depression Outcomes Between Cognitive Behavioral Therapy vs Pharmacotherapy: An Individual Patient Data Meta-analysis. JAMA Psychiatry. 2015;72(11):1102-1109.
  136. Furukawa TA, Weitz ES, Tanaka S, et al. Initial severity of depression and efficacy of cognitive-behavioural therapy: individual-participant data meta-analysis of pill-placebo-controlled trials. Br J Psychiatry. 2017;210(3):190-196.
  137. Li JM, Zhang Y, Su WJ, et al. Cognitive behavioral therapy for treatment-resistant depression: A systematic review and meta-analysis. Psychiatry research. 2018;268:243-250.
  138. Cuijpers P, Noma H, Karyotaki E, Cipriani A, Furukawa TA. Effectiveness and Acceptability of Cognitive Behavior Therapy Delivery Formats in Adults With Depression: A Network Meta-analysis. JAMA Psychiatry. 2019;76(7):700-707.
  139. Munnangi S, Angus LD. Placebo Effect. In: StatPearls. Treasure Island (FL): StatPearls Publishing Copyright © 2020, StatPearls Publishing LLC.; 2020.
  140. Brown WA. Placebo as a treatment for depression. Neuropsychopharmacology. 1994;10(4):265-269; discussion 271-288.
  141. Parker G, Ricciardi T, Hadzi-Pavlovic D. Placebo response rates in trials of antidepressant drugs in adults with clinical depression: Increasing, decreasing, constant or all of the above? J Affect Disord. 2020;271:139-144.
  142. Cipriani A, Furukawa TA, Salanti G, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. Lancet. 2018;391(10128):1357-1366.
  143. Munkholm K, Paludan-Müller AS, Boesen K. Considering the methodological limitations in the evidence base of antidepressants for depression: a reanalysis of a network meta-analysis. BMJ open. 2019;9(6):e024886.
  144. Jakobsen JC, Gluud C, Kirsch I. Should antidepressants be used for major depressive disorder? BMJ Evid Based Med. 2019.
  145. Gartlehner G, Wagner G, Matyas N, et al. Pharmacological and non-pharmacological treatments for major depressive disorder: review of systematic reviews. BMJ open. 2017;7(6):e014912.
  146. Fagiolini A, Comandini A, Catena Dell'Osso M, Kasper S. Rediscovering trazodone for the treatment of major depressive disorder. CNS drugs. 2012;26(12):1033-1049.
  147. McIntyre RS. The role of new antidepressants in clinical practice in Canada: a brief review of vortioxetine, levomilnacipran ER, and vilazodone. Neuropsychiatr Dis Treat. 2017;13:2913-2919.
  148. Uddin MF, Alweis R, Shah SR, et al. Controversies in Serotonin Syndrome Diagnosis and Management: A Review. Journal of clinical and diagnostic research : JCDR. 2017;11(9):Oe05-oe07.
  149. Francescangeli J, Karamchandani K, Powell M, Bonavia A. The Serotonin Syndrome: From Molecular Mechanisms to Clinical Practice. International journal of molecular sciences. 2019;20(9).
  150. Jurek L, Nourredine M, Megarbane B, d'Amato T, Dorey JM, Rolland B. [The serotonin syndrome: An updated literature review]. La Revue de medecine interne / fondee par la Societe nationale francaise de medecine interne. 2019;40(2):98-104.
  151. Bartlett D. Drug-Induced Serotonin Syndrome. Critical care nurse. 2017;37(1):49-54.
  152. Heitmiller DR. Serotonin syndrome: a concise review of a toxic state. R I Med J (2013). 2014;97(6):33-35.
  153. Kutzer T, Dick M, Scudamore T, Wiener M, Schwartz T. Antidepressant efficacy and side effect burden: an updated guide for clinicians. Drugs in context. 2020;9.
  154. Read J, Williams J. Adverse Effects of Antidepressants Reported by a Large International Cohort: Emotional Blunting, Suicidality, and Withdrawal Effects. Curr Drug Saf. 2018;13(3):176-186.
  155. Fava GA, Cosci F. Understanding and Managing Withdrawal Syndromes After Discontinuation of Antidepressant Drugs. The Journal of clinical psychiatry. 2019;80(6).
  156. Hengartner MP, Davies J, Read J. Antidepressant withdrawal - the tide is finally turning. Epidemiol Psychiatr Sci. 2019;29:e52.
  157. Fava GA, Benasi G, Lucente M, Offidani E, Cosci F, Guidi J. Withdrawal Symptoms after Serotonin-Noradrenaline Reuptake Inhibitor Discontinuation: Systematic Review. Psychother Psychosom. 2018;87(4):195-203.
  158. Read J, Cartwright C, Gibson K. How many of 1829 antidepressant users report withdrawal effects or addiction? Int J Ment Health Nurs. 2018;27(6):1805-1815.
  159. Bonaz B, Sinniger V, Pellissier S. The Vagus Nerve in the Neuro-Immune Axis: Implications in the Pathology of the Gastrointestinal Tract. Front Immunol. 2017;8:1452.
  160. Bonaz B, Bazin T, Pellissier S. The Vagus Nerve at the Interface of the Microbiota-Gut-Brain Axis. Front Neurosci. 2018;12:49.
  161. Tanaka S, Hammond B, Rosin DL, Okusa MD. Neuroimmunomodulation of tissue injury and disease: an expanding view of the inflammatory reflex pathway. Bioelectron Med. 2019;5:13.
  162. Senova S, Rabu C, Beaumont S, et al. [Vagus nerve stimulation and depression]. Presse medicale (Paris, France : 1983). 2019;48(12):1507-1519.
  163. Aaronson ST, Conway CR. Vagus Nerve Stimulation: Changing the Paradigm for Chronic Severe Depression? Psychiatr Clin North Am. 2018;41(3):409-418.
  164. Bajbouj M, Merkl A, Schlaepfer TE, et al. Two-year outcome of vagus nerve stimulation in treatment-resistant depression. J Clin Psychopharmacol. 2010;30(3):273-281.
  165. Conway CR, Kumar A, Xiong W, Bunker M, Aaronson ST, Rush AJ. Chronic Vagus Nerve Stimulation Significantly Improves Quality of Life in Treatment-Resistant Major Depression. The Journal of clinical psychiatry. 2018;79(5).
  166. Kumar A, Bunker MT, Aaronson ST, et al. Durability of symptomatic responses obtained with adjunctive vagus nerve stimulation in treatment-resistant depression. Neuropsychiatr Dis Treat. 2019;15:457-468.
  167. Yang J, Phi JH. The Present and Future of Vagus Nerve Stimulation. Journal of Korean Neurosurgical Society. 2019;62(3):344-352.
  168. Baeken C, Brem AK, Arns M, et al. Repetitive transcranial magnetic stimulation treatment for depressive disorders: current knowledge and future directions. Current opinion in psychiatry. 2019;32(5):409-415.
  169. Zorzo C, Banqueri M, Higarza SG, Pernía AM, Arias JL. Current State of Transcranial Magnetic Stimulation and its use in Psychiatry. Actas espanolas de psiquiatria. 2019;47(3):110-120.
  170. Trevizol AP, Blumberger DM. An Update on Repetitive Transcranial Magnetic Stimulation for the Treatment of Major Depressive Disorder. Clin Pharmacol Ther. 2019;106(4):747-762.
  171. Burke MJ, Fried PJ, Pascual-Leone A. Transcranial magnetic stimulation: Neurophysiological and clinical applications. Handbook of clinical neurology. 2019;163:73-92.
  172. Somani A, Kar SK. Efficacy of repetitive transcranial magnetic stimulation in treatment-resistant depression: the evidence thus far. Gen Psychiatr. 2019;32(4):e100074.
  173. Guardiola-Lemaitre B, De Bodinat C, Delagrange P, Millan MJ, Munoz C, Mocaër E. Agomelatine: mechanism of action and pharmacological profile in relation to antidepressant properties. Br J Pharmacol. 2014;171(15):3604-3619.
  174. Taylor D, Sparshatt A, Varma S, Olofinjana O. Antidepressant efficacy of agomelatine: meta-analysis of published and unpublished studies. BMJ : British Medical Journal. 2014;348:g1888.
  175. Kennedy SH, Grouin JM, Cadour S, Robert V, Picarel-Blanchot F. Relative short-term efficacy and acceptability of agomelatine versus vortioxetine in adult patients suffering from major depressive disorder. Human psychopharmacology. 2018;33(1).
  176. Plesničar BK. Efficacy and tolerability of agomelatine in the treatment of depression. Patient Prefer Adherence. 2014;8:603-612.
  177. Carvalho AF, Sharma MS, Brunoni AR, Vieta E, Fava GA. The Safety, Tolerability and Risks Associated with the Use of Newer Generation Antidepressant Drugs: A Critical Review of the Literature. Psychotherapy and psychosomatics. 2016;85(5):270-288.
  178. Camargo A, Rodrigues ALS. Novel Targets for Fast Antidepressant Responses: Possible Role of Endogenous Neuromodulators. Chronic Stress (Thousand Oaks). 2019;3:2470547019858083.
  179. Corriger A, Pickering G. Ketamine and depression: a narrative review. Drug design, development and therapy. 2019;13:3051-3067.
  180. Peng FZ, Fan J, Ge TT, Liu QQ, Li BJ. Rapid anti-depressant-like effects of ketamine and other candidates: Molecular and cellular mechanisms. Cell proliferation. 2020;53(5):e12804.
  181. Kryst J, Kawalec P, Pilc A. Efficacy and safety of intranasal esketamine for the treatment of major depressive disorder. Expert opinion on pharmacotherapy. 2020;21(1):9-20.
  182. FDA. US Food and Drug Administration. News and Events: FDA approves new nasal spray medication for treatment-resistant depression; available only at a certified doctor’s office or clinic. Available at Published 03/05/2019. Accessed 09/13/2020. . 2019.
  183. Zheng W, Cai DB, Xiang YQ, et al. Adjunctive intranasal esketamine for major depressive disorder: A systematic review of randomized double-blind controlled-placebo studies. J Affect Disord. 2020;265:63-70.
  184. Park LT, Falodun TB, Zarate CA, Jr. Ketamine for Treatment-Resistant Mood Disorders. Focus (Am Psychiatr Publ). 2019;17(1):8-12.
  185. Szarmach J, Cubała WJ, Włodarczyk A, Wiglusz MS. Short-term ketamine administration in treatment-resistant depression: focus on cardiovascular safety. Psychiatr Danub. 2019;31(Suppl 3):585-590.
  186. Mertens LJ, Wall MB, Roseman L, Demetriou L, Nutt DJ, Carhart-Harris RL. Therapeutic mechanisms of psilocybin: Changes in amygdala and prefrontal functional connectivity during emotional processing after psilocybin for treatment-resistant depression. Journal of psychopharmacology (Oxford, England). 2020;34(2):167-180.
  187. Aday JS, Mitzkovitz CM, Bloesch EK, Davoli CC, Davis AK. Long-term effects of psychedelic drugs: A systematic review. Neurosci Biobehav Rev. 2020;113:179-189.
  188. Romeo B, Karila L, Martelli C, Benyamina A. Efficacy of psychedelic treatments on depressive symptoms: A meta-analysis. Journal of psychopharmacology (Oxford, England). 2020:269881120919957.
  189. Luoma JB, Chwyl C, Bathje GJ, Davis AK, Lancelotta R. A Meta-Analysis of Placebo-Controlled Trials of Psychedelic-Assisted Therapy. J Psychoactive Drugs. 2020:1-11.
  190. Ross S, Bossis A, Guss J, et al. Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial. J Psychopharmacol. 2016;30(12):1165-1180.
  191. Griffiths RR, Johnson MW, Carducci MA, et al. Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial. J Psychopharmacol. 2016;30(12):1181-1197.
  192. Agin-Liebes GI, Malone T, Yalch MM, et al. Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer. Journal of psychopharmacology (Oxford, England). 2020;34(2):155-166.
  193. Saplakoglu Y. Live Science: FDA Calls Psychedelic Psilocybin a 'Breakthrough Therapy' for Severe Depression. Available at Published 11/25/2019. Accessed 09/14/2020. 2019.
  194. Nutt D. Psychedelic drugs-a new era in
. Dialogues Clin Neurosci. 2019;21(2):139-147.
  195. Davis AK, So S, Lancelotta R, Barsuglia JP, Griffiths RR. 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT) used in a naturalistic group setting is associated with unintended improvements in depression and anxiety. Am J Drug Alcohol Abuse. 2019;45(2):161-169.
  196. Zeifman RJ, Palhano-Fontes F, Hallak J, Arcoverde E, Maia-Oliveira JP, Araujo DB. The Impact of Ayahuasca on Suicidality: Results From a Randomized Controlled Trial. Frontiers in pharmacology. 2019;10:1325.
  197. Dos Santos RG, Hallak JEC. Ayahuasca, an ancient substance with traditional and contemporary use in neuropsychiatry and neuroscience. Epilepsy Behav. 2019:106300.
  198. Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: A systematic review. J Affect Disord. 2019;258:11-24.
  199. Mian MN, Altman BR, Earleywine M. Ayahuasca's Antidepressant Effects Covary with Behavioral Activation as Well as Mindfulness. J Psychoactive Drugs. 2020;52(2):130-137.
  200. Murphy-Beiner A, Soar K. Ayahuasca's 'afterglow': improved mindfulness and cognitive flexibility in ayahuasca drinkers. Psychopharmacology. 2020;237(4):1161-1169.
  201. Galvão-Coelho NL, de Menezes Galvão AC, de Almeida RN, et al. Changes in inflammatory biomarkers are related to the antidepressant effects of Ayahuasca. Journal of psychopharmacology (Oxford, England). 2020:269881120936486.
  202. de Almeida RN, Galvão ACM, da Silva FS, et al. Modulation of Serum Brain-Derived Neurotrophic Factor by a Single Dose of Ayahuasca: Observation From a Randomized Controlled Trial. Frontiers in psychology. 2019;10:1234.
  203. Fuentes JJ, Fonseca F, Elices M, Farré M, Torrens M. Therapeutic Use of LSD in Psychiatry: A Systematic Review of Randomized-Controlled Clinical Trials. Frontiers in psychiatry. 2019;10:943.
  204. Reiche S, Hermle L, Gutwinski S, Jungaberle H, Gasser P, Majić T. Serotonergic hallucinogens in the treatment of anxiety and depression in patients suffering from a life-threatening disease: A systematic review. Progress in neuro-psychopharmacology & biological psychiatry. 2018;81:1-10.
  205. Ross S. Therapeutic use of classic psychedelics to treat cancer-related psychiatric distress. International review of psychiatry (Abingdon, England). 2018;30(4):317-330.
  206. Carhart-Harris RL, Kaelen M, Bolstridge M, et al. The paradoxical psychological effects of lysergic acid diethylamide (LSD). Psychol Med. 2016;46(7):1379-1390.
  207. Schmid Y, Liechti ME. Long-lasting subjective effects of LSD in normal subjects. Psychopharmacology. 2018;235(2):535-545.
  208. NIH. National Institutes of Health: US National Library of Medicine: Clinical LSD Therapy for Persons Suffering From Major Depression (LAD). Available at Last updated 01/18/2020. Accessed 09/13/2020. 2020.
  209. Bienemann B, Ruschel NS, Campos ML, Negreiros MA, Mograbi DC. Self-reported negative outcomes of psilocybin users: A quantitative textual analysis. PLoS One. 2020;15(2):e0229067.
  210. Mendlewicz J, Kriwin P, Oswald P, Souery D, Alboni S, Brunello N. Shortened onset of action of antidepressants in major depression using acetylsalicylic acid augmentation: a pilot open-label study. Int Clin Psychopharmacol. 2006;21(4):227-231.
  211. Zdanowicz N, Reynaert C, Jacques D, Lepiece B, Dubois T. Selective Serotonergic (SSRI) Versus Noradrenergic (SNRI) Reuptake Inhibitors with and without Acetylsalicylic Acid in Major Depressive Disorder. Psychiatr Danub. 2017;29(Suppl 3):270-273.
  212. Ghanizadeh A, Hedayati A. Augmentation of citalopram with aspirin for treating major depressive disorder, a double blind randomized placebo controlled clinical trial. Antiinflamm Antiallergy Agents Med Chem. 2014;13(2):108-111.
  213. Kim HB, Kim JS, Jung JG. The association between aspirin use and depression: a systematic review and meta-analysis of observational studies. Pharmacoepidemiol Drug Saf. 2020;29(6):613-622.
  214. Berk M, Woods RL, Nelson MR, et al. Effect of Aspirin vs Placebo on the Prevention of Depression in Older People: A Randomized Clinical Trial. JAMA Psychiatry. 2020;77(10):1012-1020.
  215. Colpo GD, Leboyer M, Dantzer R, Trivedi MH, Teixeira AL. Immune-based strategies for mood disorders: facts and challenges. Expert Rev Neurother. 2018;18(2):139-152.
  216. Shariq AS, Brietzke E, Rosenblat JD, Barendra V, Pan Z, McIntyre RS. Targeting cytokines in reduction of depressive symptoms: A comprehensive review. Prog Neuropsychopharmacol Biol Psychiatry. 2018;83:86-91.
  217. Boufidou F, Nikolaou C. [Αnti-Inflammatory medication as adjunctive antidepressive treatment]. Psychiatriki. 2016;27(2):106-117.
  218. Bavaresco DV, Uggioni MLR, Ferraz SD, et al. Efficacy of infliximab in treatment-resistant depression: A systematic review and meta-analysis. Pharmacol Biochem Behav. 2020;188:172838.
  219. Wu C, Liu P, Fu H, et al. Transcutaneous auricular vagus nerve stimulation in treating major depressive disorder: A systematic review and meta-analysis. Medicine. 2018;97(52):e13845.
  220. Philip NS, Nelson BG, Frohlich F, Lim KO, Widge AS, Carpenter LL. Low-Intensity Transcranial Current Stimulation in Psychiatry. The American journal of psychiatry. 2017;174(7):628-639.
  221. Vlaicu A, Bustuchina Vlaicu M. New neuromodulation techniques for treatment resistant depression. International journal of psychiatry in clinical practice. 2020;24(2):106-115.
  222. Sanguinetti JL, Hameroff S, Smith EE, et al. Transcranial Focused Ultrasound to the Right Prefrontal Cortex Improves Mood and Alters Functional Connectivity in Humans. Frontiers in human neuroscience. 2020;14(52).
  223. Voineskos D, Daskalakis ZJ, Blumberger DM. Management of Treatment-Resistant Depression: Challenges and Strategies. Neuropsychiatr Dis Treat. 2020;16:221-234.
  224. Gouveia FV, Hamani C. Deep brain stimulation as a treatment for depressive disorder. Braz J Psychiatry. 2020.
  225. Cagnan H, Denison T, McIntyre C, Brown P. Emerging technologies for improved deep brain stimulation. Nat Biotechnol. 2019;37(9):1024-1033.
  226. McKinnon C, Gros P, Lee DJ, et al. Deep brain stimulation: potential for neuroprotection. Ann Clin Transl Neurol. 2019;6(1):174-185.
  227. Stute P, Spyropoulou A, Karageorgiou V, et al. Management of depressive symptoms in peri- and postmenopausal women: EMAS position statement. Maturitas. 2020;131:91-101.
  228. Maki PM, Kornstein SG, Joffe H, et al. Guidelines for the Evaluation and Treatment of Perimenopausal Depression: Summary and Recommendations. Journal of women's health (2002). 2019;28(2):117-134.
  229. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Leserman J, Girdler SS. Estradiol variability, stressful life events, and the emergence of depressive symptomatology during the menopausal transition. Menopause (New York, NY). 2016;23(3):257-266.
  230. Gordon JL, Rubinow DR, Eisenlohr-Moul TA, Xia K, Schmidt PJ, Girdler SS. Efficacy of Transdermal Estradiol and Micronized Progesterone in the Prevention of Depressive Symptoms in the Menopause Transition: A Randomized Clinical Trial. JAMA Psychiatry. 2018;75(2):149-157.
  231. Lassale C, Batty GD, Baghdadli A, et al. Healthy dietary indices and risk of depressive outcomes: a systematic review and meta-analysis of observational studies. Molecular psychiatry. 2019;24(7):965-986.
  232. Gibson-Smith D, Bot M, Brouwer IA, Visser M, Giltay EJ, Penninx B. Association of food groups with depression and anxiety disorders. Eur J Nutr. 2020;59(2):767-778.
  233. Jorgensen D, White GE, Sekikawa A, Gianaros P. Higher dietary inflammation is associated with increased odds of depression independent of Framingham Risk Score in the National Health and Nutrition Examination Survey. Nutr Res. 2018;54:23-32.
  234. Sánchez-Villegas A, Álvarez-Pérez J, Toledo E, et al. Seafood Consumption, Omega-3 Fatty Acids Intake, and Life-Time Prevalence of Depression in the PREDIMED-Plus Trial. Nutrients. 2018;10(12).
  235. Ljungberg T, Bondza E, Lethin C. Evidence of the Importance of Dietary Habits Regarding Depressive Symptoms and Depression. International journal of environmental research and public health. 2020;17(5).
  236. Głąbska D, Guzek D, Groele B, Gutkowska K. Fruit and Vegetable Intake and Mental Health in Adults: A Systematic Review. Nutrients. 2020;12(1).
  237. Jesus M, Silva T, Cagigal C, Martins V, Silva C. Dietary Patterns: A New Therapeutic Approach for Depression? Current pharmaceutical biotechnology. 2019;20(2):123-129.
  238. Angelino D, Godos J, Ghelfi F, et al. Fruit and vegetable consumption and health outcomes: an umbrella review of observational studies. International journal of food sciences and nutrition. 2019;70(6):652-667.
  239. Li Y, Lv MR, Wei YJ, et al. Dietary patterns and depression risk: A meta-analysis. Psychiatry research. 2017;253:373-382.
  240. Molendijk M, Molero P, Ortuño Sánchez-Pedreño F, Van der Does W, Angel Martínez-González M. Diet quality and depression risk: A systematic review and dose-response meta-analysis of prospective studies. J Affect Disord. 2018;226:346-354.
  241. Firth J, Marx W, Dash S, et al. The Effects of Dietary Improvement on Symptoms of Depression and Anxiety: A Meta-Analysis of Randomized Controlled Trials. Psychosom Med. 2019;81(3):265-280.
  242. Jacka FN, O'Neil A, Opie R, et al. A randomised controlled trial of dietary improvement for adults with major depression (the 'SMILES' trial). BMC Med. 2017;15(1):23.
  243. Francis HM, Stevenson RJ, Chambers JR, Gupta D, Newey B, Lim CK. A brief diet intervention can reduce symptoms of depression in young adults - A randomised controlled trial. PLoS One. 2019;14(10):e0222768.
  244. Cunningham C, R OS, Caserotti P, Tully MA. Consequences of physical inactivity in older adults: A systematic review of reviews and meta-analyses. Scandinavian journal of medicine & science in sports. 2020;30(5):816-827.
  245. Ashdown-Franks G, Firth J, Carney R, et al. Exercise as Medicine for Mental and Substance Use Disorders: A Meta-review of the Benefits for Neuropsychiatric and Cognitive Outcomes. Sports medicine (Auckland, NZ). 2020;50(1):151-170.
  246. Wang X, Li Y, Fan H. The associations between screen time-based sedentary behavior and depression: a systematic review and meta-analysis. BMC Public Health. 2019;19(1):1524.
  247. Ignácio ZM, da Silva RS, Plissari ME, Quevedo J, Réus GZ. Physical Exercise and Neuroinflammation in Major Depressive Disorder. Molecular neurobiology. 2019;56(12):8323-8335.
  248. Giménez-Meseguer J, Tortosa-Martínez J, Cortell-Tormo JM. The Benefits of Physical Exercise on Mental Disorders and Quality of Life in Substance Use Disorders Patients. Systematic Review and Meta-Analysis. International journal of environmental research and public health. 2020;17(10).
  249. Béland M, Lavoie KL, Briand S, White UJ, Gemme C, Bacon SL. Aerobic exercise alleviates depressive symptoms in patients with a major non-communicable chronic disease: a systematic review and meta-analysis. British journal of sports medicine. 2020;54(5):272-278.
  250. Dauwan M, Begemann MJH, Slot MIE, Lee EHM, Scheltens P, Sommer IEC. Physical exercise improves quality of life, depressive symptoms, and cognition across chronic brain disorders: a transdiagnostic systematic review and meta-analysis of randomized controlled trials. J Neurol. 2019.
  251. Brinsley J, Schuch F, Lederman O, et al. Effects of yoga on depressive symptoms in people with mental disorders: a systematic review and meta-analysis. British journal of sports medicine. 2020.
  252. Saeed SA, Cunningham K, Bloch RM. Depression and Anxiety Disorders: Benefits of Exercise, Yoga, and Meditation. Am Fam Physician. 2019;99(10):620-627.
  253. Guo L, Kong Z, Zhang Y. Qigong-Based Therapy for Treating Adults with Major Depressive Disorder: A Meta-Analysis of Randomized Controlled Trials. International journal of environmental research and public health. 2019;16(5).
  254. Sathyanarayanan G, Vengadavaradan A, Bharadwaj B. Role of Yoga and Mindfulness in Severe Mental Illnesses: A Narrative Review. Int J Yoga. 2019;12(1):3-28.
  255. Morres ID, Hatzigeorgiadis A, Stathi A, et al. Aerobic exercise for adult patients with major depressive disorder in mental health services: A systematic review and meta-analysis. Depression and anxiety. 2019;36(1):39-53.
  256. Korman N, Armour M, Chapman J, et al. High Intensity Interval training (HIIT) for people with severe mental illness: A systematic review & meta-analysis of intervention studies- considering diverse approaches for mental and physical recovery. Psychiatry research. 2020;284:112601.
  257. Miller KJ, Gonçalves-Bradley DC, Areerob P, Hennessy D, Mesagno C, Grace F. Comparative effectiveness of three exercise types to treat clinical depression in older adults: A systematic review and network meta-analysis of randomised controlled trials. Ageing Res Rev. 2020;58:100999.
  258. Zou L, Yeung A, Li C, et al. Effects of Meditative Movements on Major Depressive Disorder: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. J Clin Med. 2018;7(8).
  259. Firth J, Rosenbaum S, Stubbs B, Gorczynski P, Yung AR, Vancampfort D. Motivating factors and barriers towards exercise in severe mental illness: a systematic review and meta-analysis. Psychol Med. 2016;46(14):2869-2881.
  260. Zimmet P, Alberti K, Stern N, et al. The Circadian Syndrome: is the Metabolic Syndrome and much more! J Intern Med. 2019;286(2):181-191.
  261. Hong W, Zhang Q. Biological Rhythms Advance in Depressive Disorder. Adv Exp Med Biol. 2019;1180:117-133.
  262. Smolensky MH, Hermida RC, Reinberg A, Sackett-Lundeen L, Portaluppi F. Circadian disruption: New clinical perspective of disease pathology and basis for chronotherapeutic intervention. Chronobiology international. 2016;33(8):1101-1119.
  263. Varinthra P, Liu IY. Molecular basis for the association between depression and circadian rhythm. Ci ji yi xue za zhi = Tzu-chi medical journal. 2019;31(2):67-72.
  264. Hühne A, Welsh DK, Landgraf D. Prospects for circadian treatment of mood disorders. Ann Med. 2018;50(8):637-654.
  265. Khalifeh AH. The effect of chronotherapy on depressive symptoms. Evidence-based practice. Saudi Med J. 2017;38(5):457-464.
  266. Cunningham JEA, Stamp JA, Shapiro CM. Sleep and major depressive disorder: a review of non-pharmacological chronotherapeutic treatments for unipolar depression. Sleep Med. 2019;61:6-18.
  267. Dopierała E, Rybakowski J. Sleep deprivation as a method of chronotherapy in the treatment of depression. Psychiatria polska. 2015;49(3):423-433.
  268. Kragh M, Larsen ER, Martiny K, et al. Predictors of response to combined wake and light therapy in treatment-resistant inpatients with depression. Chronobiology international. 2018;35(9):1209-1220.
  269. Humpston C, Benedetti F, Serfaty M, et al. Chronotherapy for the rapid treatment of depression: A meta-analysis. J Affect Disord. 2020;261:91-102.
  270. Danilenko KV, Lebedinskaia MY, Gadetskaia EV, Markov AA, Ivanova YA, Aftanas LI. A 6-day combined wake and light therapy trial for unipolar depression. J Affect Disord. 2019;259:355-361.
  271. Dallaspezia S, van Jaarsveld A. Antidepressant chronotherapeutics in a group of drug free outpatients. Psychiatry research. 2016;241:118-121.
  272. Hurd D, Herrera M, Brant JM, Coombs NC, Arzubi E. Prospective, Open Trial of Adjunctive Triple Chronotherapy for the Acute Treatment of Depression in Adolescent Inpatients. J Child Adolesc Psychopharmacol. 2019;29(1):20-27.
  273. Turakitwanakan W, Pongpaplud P, Kitporntheranunt M. The Effect of Home Buddhist Mindfulness Meditation on Depressive Symptom in Major Depressive Patients. Journal of the Medical Association of Thailand = Chotmaihet thangphaet. 2017;99 Suppl 8:S171-s178.
  274. Rod K. Observing the Effects of Mindfulness-Based Meditation on Anxiety and Depression in Chronic Pain Patients. Psychiatr Danub. 2015;27 Suppl 1:S209-211.
  275. Crane C, Crane RS, Eames C, et al. The effects of amount of home meditation practice in Mindfulness Based Cognitive Therapy on hazard of relapse to depression in the Staying Well after Depression Trial. Behav Res Ther. 2014;63:17-24.
  276. Hwang WJ, Lee TY, Lim KO, et al. The effects of four days of intensive mindfulness meditation training (Templestay program) on resilience to stress: a randomized controlled trial. Psychol Health Med. 2018;23(5):497-504.
  277. Johnson JR, Emmons HC, Rivard RL, Griffin KH, Dusek JA. Resilience Training: A Pilot Study of a Mindfulness-Based Program with Depressed Healthcare Professionals. Explore (New York, NY). 2015;11(6):433-444.
  278. Ionson E, Limbachia J, Rej S, et al. Effects of Sahaj Samadhi meditation on heart rate variability and depressive symptoms in patients with late-life depression. Br J Psychiatry. 2019;214(4):218-224.
  279. Sharma A, Barrett MS, Cucchiara AJ, Gooneratne NS, Thase ME. A Breathing-Based Meditation Intervention for Patients With Major Depressive Disorder Following Inadequate Response to Antidepressants: A Randomized Pilot Study. The Journal of clinical psychiatry. 2017;78(1):e59-e63.
  280. Rao NP, Deshpande G, Gangadhar KB, et al. Directional brain networks underlying OM chanting. Asian J Psychiatr. 2018;37:20-25.
  281. Chen F, Lv X, Fang J, et al. The effect of body-mind relaxation meditation induction on major depressive disorder: A resting-state fMRI study. J Affect Disord. 2015;183:75-82.
  282. Zárate R, El Jaber-Vazdekis N, Tejera N, Pérez JA, Rodríguez C. Significance of long chain polyunsaturated fatty acids in human health. Clin Transl Med. 2017;6(1):25.
  283. Yang B, Lin L, Bazinet RP, et al. Clinical Efficacy and Biological Regulations of ω-3 PUFA-Derived Endocannabinoids in Major Depressive Disorder. Psychotherapy and psychosomatics. 2019;88(4):215-224.
  284. Messamore E, Almeida DM, Jandacek RJ, McNamara RK. Polyunsaturated fatty acids and recurrent mood disorders: Phenomenology, mechanisms, and clinical application. Prog Lipid Res. 2017;66:1-13.
  285. Yu JZ, Wang J, Sheridan SD, Perlis RH, Rasenick MM. N-3 polyunsaturated fatty acids promote astrocyte differentiation and neurotrophin production independent of cAMP in patient-derived neural stem cells. Molecular psychiatry. 2020.
  286. Grosso G, Micek A, Marventano S, et al. Dietary n-3 PUFA, fish consumption and depression: A systematic review and meta-analysis of observational studies. J Affect Disord. 2016;205:269-281.
  287. Berger M, Nelson B, Markulev C, et al. Relationship Between Polyunsaturated Fatty Acids and Psychopathology in the NEURAPRO Clinical Trial. Frontiers in psychiatry. 2019;10:393.
  288. Scola G, Versace A, Metherel AH, et al. Alterations in peripheral fatty acid composition in bipolar and unipolar depression. J Affect Disord. 2018;233:86-91.
  289. Liao Y, Xie B, Zhang H, et al. Efficacy of omega-3 PUFAs in depression: A meta-analysis. Translational psychiatry. 2019;9(1):190.
  290. Bozzatello P, Brignolo E, De Grandi E, Bellino S. Supplementation with Omega-3 Fatty Acids in Psychiatric Disorders: A Review of Literature Data. J Clin Med. 2016;5(8).
  291. Keshavarz SA, Mostafavi SA, Akhondzadeh S, et al. Omega-3 supplementation effects on body weight and depression among dieter women with co-morbidity of depression and obesity compared with the placebo: A randomized clinical trial. Clin Nutr ESPEN. 2018;25:37-43.
  292. Mazaherioun M, Saedisomeolia A, Javanbakht MH, et al. Long Chain n-3 Fatty Acids Improve Depression Syndrome in Type 2 Diabetes Mellitus. Iranian journal of public health. 2018;47(4):575-583.
  293. Chang JP, Chang SS, Yang HT, et al. Omega-3 polyunsaturated fatty acids in cardiovascular diseases comorbid major depressive disorder - Results from a randomized controlled trial. Brain Behav Immun. 2020;85:14-20.
  294. Jiang W, Whellan DJ, Adams KF, et al. Long-Chain Omega-3 Fatty Acid Supplements in Depressed Heart Failure Patients: Results of the OCEAN Trial. JACC Heart Fail. 2018;6(10):833-843.
  295. Guu TW, Mischoulon D, Sarris J, et al. International Society for Nutritional Psychiatry Research Practice Guidelines for Omega-3 Fatty Acids in the Treatment of Major Depressive Disorder. Psychotherapy and psychosomatics. 2019;88(5):263-273.
  296. DiNicolantonio JJ, O'Keefe JH. The Importance of Marine Omega-3s for Brain Development and the Prevention and Treatment of Behavior, Mood, and Other Brain Disorders. Nutrients. 2020;12(8).
  297. Woodward G, Wan JCM, Viswanath K, Zaman R. Serum Vitamin D and Magnesium levels in a psychiatric cohort. Psychiatr Danub. 2019;31(Suppl 3):221-226.
  298. Schaad KA, Bukhari AS, Brooks DI, Kocher JD, Barringer ND. The relationship between vitamin D status and depression in a tactical athlete population. Journal of the International Society of Sports Nutrition. 2019;16(1):40.
  299. Geng C, Shaikh AS, Han W, Chen D, Guo Y, Jiang P. Vitamin D and depression: mechanisms, determination and application. Asia Pac J Clin Nutr. 2019;28(4):689-694.
  300. Kim SY, Jeon SW, Lim WJ, et al. Vitamin D deficiency and suicidal ideation: A cross-sectional study of 157,211 healthy adults. Journal of psychosomatic research. 2020;134:110125.
  301. Gokalp G. The association between low vitamin D levels and suicide attempts in adolescents. Ann Clin Psychiatry. 2020;32(2):106-113.
  302. Belzeaux R, Annweiler C, Bertrand JA, et al. Association between hypovitaminosis D and cognitive inhibition impairment during major depression episode. J Affect Disord. 2018;225:302-305.
  303. Grudet C, Wolkowitz OM, Mellon SH, et al. Vitamin D and inflammation in major depressive disorder. J Affect Disord. 2020;267:33-41.
  304. Okereke OI, Reynolds CF, 3rd, Mischoulon D, et al. Effect of Long-term Vitamin D3 Supplementation vs Placebo on Risk of Depression or Clinically Relevant Depressive Symptoms and on Change in Mood Scores: A Randomized Clinical Trial. Jama. 2020;324(5):471-480.
  305. Attia P. Randomized controlled trials: when the gold standard leaves you with fool’s gold. Published 2020. Updated 09/06/2020. Accessed 10/06/2020.
  306. Vellekkatt F, Menon V. Efficacy of vitamin D supplementation in major depression: A meta-analysis of randomized controlled trials. J Postgrad Med. 2019;65(2):74-80.
  307. Jamilian H, Amirani E, Milajerdi A, et al. The effects of vitamin D supplementation on mental health, and biomarkers of inflammation and oxidative stress in patients with psychiatric disorders: A systematic review and meta-analysis of randomized controlled trials. Progress in neuro-psychopharmacology & biological psychiatry. 2019;94:109651.
  308. Omidian M, Mahmoudi M, Abshirini M, et al. Effects of vitamin D supplementation on depressive symptoms in type 2 diabetes mellitus patients: Randomized placebo-controlled double-blind clinical trial. Diabetes Metab Syndr. 2019;13(4):2375-2380.
  309. Kotb MA, Kamal AM, Aldossary NM, Bedewi MA. Effect of vitamin D replacement on depression in multiple sclerosis patients. Mult Scler Relat Disord. 2019;29:111-117.
  310. Kim CS, Shin DM. Probiotic food consumption is associated with lower severity and prevalence of depression: A nationwide cross-sectional study. Nutrition (Burbank, Los Angeles County, Calif). 2019;63-64:169-174.
  311. Sanada K, Nakajima S, Kurokawa S, et al. Gut microbiota and major depressive disorder: A systematic review and meta-analysis. J Affect Disord. 2020;266:1-13.
  312. Chao L, Liu C, Sutthawongwadee S, et al. Effects of Probiotics on Depressive or Anxiety Variables in Healthy Participants Under Stress Conditions or With a Depressive or Anxiety Diagnosis: A Meta-Analysis of Randomized Controlled Trials. Front Neurol. 2020;11:421.
  313. Amirani E, Milajerdi A, Mirzaei H, et al. The effects of probiotic supplementation on mental health, biomarkers of inflammation and oxidative stress in patients with psychiatric disorders: A systematic review and meta-analysis of randomized controlled trials. Complementary therapies in medicine. 2020;49:102361.
  314. Yong SJ, Tong T, Chew J, Lim WL. Antidepressive Mechanisms of Probiotics and Their Therapeutic Potential. Front Neurosci. 2019;13:1361.
  315. Goh KK, Liu YW, Kuo PH, Chung YE, Lu ML, Chen CH. Effect of probiotics on depressive symptoms: A meta-analysis of human studies. Psychiatry research. 2019;282:112568.
  316. Kazemi A, Noorbala AA, Azam K, Eskandari MH, Djafarian K. Effect of probiotic and prebiotic vs placebo on psychological outcomes in patients with major depressive disorder: A randomized clinical trial. Clin Nutr. 2019;38(2):522-528.
  317. Messaoudi M, Lalonde R, Violle N, et al. Assessment of psychotropic-like properties of a probiotic formulation (Lactobacillus helveticus R0052 and Bifidobacterium longum R0175) in rats and human subjects. The British journal of nutrition. 2011;105(5):755-764.
  318. Saccarello A, Montarsolo P, Massardo I, et al. Oral Administration of S-Adenosylmethionine (SAMe) and Lactobacillus Plantarum HEAL9 Improves the Mild-To-Moderate Symptoms of Depression: A Randomized, Double-Blind, Placebo-Controlled Study. Prim Care Companion CNS Disord. 2020;22(4).
  319. Akkasheh G, Kashani-Poor Z, Tajabadi-Ebrahimi M, et al. Clinical and metabolic response to probiotic administration in patients with major depressive disorder: A randomized, double-blind, placebo-controlled trial. Nutrition. 2016;32(3):315-320.
  320. Miyaoka T, Kanayama M, Wake R, et al. Clostridium butyricum MIYAIRI 588 as Adjunctive Therapy for Treatment-Resistant Major Depressive Disorder: A Prospective Open-Label Trial. Clin Neuropharmacol. 2018;41(5):151-155.
  321. Bambling M, Edwards SC, Hall S, Vitetta L. A combination of probiotics and magnesium orotate attenuate depression in a small SSRI resistant cohort: an intestinal anti-inflammatory response is suggested. Inflammopharmacol. 2017;25(2):271-274.
  322. Raygan F, Ostadmohammadi V, Asemi Z. The effects of probiotic and selenium co-supplementation on mental health parameters and metabolic profiles in type 2 diabetic patients with coronary heart disease: A randomized, double-blind, placebo-controlled trial. Clin Nutr. 2019;38(4):1594-1598.
  323. Moludi J, Alizadeh M, Mohammadzad MHS, Davari M. The Effect of Probiotic Supplementation on Depressive Symptoms and Quality of Life in Patients After Myocardial Infarction: Results of a Preliminary Double-Blind Clinical Trial. Psychosomatic medicine. 2019;81(9):770-777.
  324. Zhang L, Liu YX, Wang Z, et al. Clinical characteristic and fecal microbiota responses to probiotic or antidepressant in patients with diarrhea-predominant irritable bowel syndrome with depression comorbidity: a pilot study. Chin Med J (Engl). 2019;132(3):346-351.
  325. Pinto-Sanchez MI, Hall GB, Ghajar K, et al. Probiotic Bifidobacterium longum NCC3001 Reduces Depression Scores and Alters Brain Activity: A Pilot Study in Patients With Irritable Bowel Syndrome. Gastroenterology. 2017;153(2):448-459.e448.
  326. Prasad AS, Bao B. Molecular Mechanisms of Zinc as a Pro-Antioxidant Mediator: Clinical Therapeutic Implications. Antioxidants (Basel, Switzerland). 2019;8(6).
  327. Doboszewska U, Wlaź P, Nowak G, Radziwoń-Zaleska M, Cui R, Młyniec K. Zinc in the Monoaminergic Theory of Depression: Its Relationship to Neural Plasticity. Neural plasticity. 2017;2017:3682752.
  328. Wang J, Um P, Dickerman BA, Liu J. Zinc, Magnesium, Selenium and Depression: A Review of the Evidence, Potential Mechanisms and Implications. Nutrients. 2018;10(5).
  329. Petrilli MA, Kranz TM, Kleinhaus K, et al. The Emerging Role for Zinc in Depression and Psychosis. Frontiers in pharmacology. 2017;8:414.
  330. Li Z, Li B, Song X, Zhang D. Dietary zinc and iron intake and risk of depression: A meta-analysis. Psychiatry research. 2017;251:41-47.
  331. Siwek M, Dudek D, Schlegel-Zawadzka M, et al. Serum zinc level in depressed patients during zinc supplementation of imipramine treatment. J Affect Disord. 2010;126(3):447-452.
  332. Szewczyk B, Szopa A, Serefko A, Poleszak E, Nowak G. The role of magnesium and zinc in depression: similarities and differences. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. 2018;31(3):78-89.
  333. Solati Z, Jazayeri S, Tehrani-Doost M, Mahmoodianfard S, Gohari MR. Zinc monotherapy increases serum brain-derived neurotrophic factor (BDNF) levels and decreases depressive symptoms in overweight or obese subjects: a double-blind, randomized, placebo-controlled trial. Nutritional neuroscience. 2015;18(4):162-168.
  334. Sawada T, Yokoi K. Effect of zinc supplementation on mood states in young women: a pilot study. European journal of clinical nutrition. 2010;64(3):331-333.
  335. Ranjbar E, Shams J, Sabetkasaei M, et al. Effects of zinc supplementation on efficacy of antidepressant therapy, inflammatory cytokines, and brain-derived neurotrophic factor in patients with major depression. Nutritional neuroscience. 2014;17(2):65-71.
  336. Nowak G, Siwek M, Dudek D, Zieba A, Pilc A. Effect of zinc supplementation on antidepressant therapy in unipolar depression: a preliminary placebo-controlled study. Pol J Pharmacol. 2003;55(6):1143-1147.
  337. Siwek M, Dudek D, Paul IA, et al. Zinc supplementation augments efficacy of imipramine in treatment resistant patients: a double blind, placebo-controlled study. J Affect Disord. 2009;118(1-3):187-195.
  338. Khazdair MR, Boskabady MH, Hosseini M, Rezaee R, A MT. The effects of Crocus sativus (saffron) and its constituents on nervous system: A review. Avicenna J Phytomed. 2015;5(5):376-391.
  339. Dai L, Chen L, Wang W. Safety and Efficacy of Saffron (Crocus sativus L.) for Treating Mild to Moderate Depression: A Systematic Review and Meta-analysis. The Journal of nervous and mental disease. 2020.
  340. Khaksarian M, Behzadifar M, Behzadifar M, et al. The efficacy of Crocus sativus (Saffron) versus placebo and Fluoxetine in treating depression: a systematic review and meta-analysis. Psychology research and behavior management. 2019;12:297-305.
  341. Tóth B, Hegyi P, Lantos T, et al. The Efficacy of Saffron in the Treatment of Mild to Moderate Depression: A Meta-analysis. Planta Med. 2019;85(1):24-31.
  342. Yang X, Chen X, Fu Y, et al. Comparative efficacy and safety of Crocus sativus L. for treating mild to moderate major depressive disorder in adults: a meta-analysis of randomized controlled trials. Neuropsychiatr Dis Treat. 2018;14:1297-1305.
  343. Ghaderi A, Asbaghi O, Reiner Ž, et al. The effects of saffron (Crocus sativus L.) on mental health parameters and C-reactive protein: A meta-analysis of randomized clinical trials. Complement Ther Med. 2020;48:102250.
  344. Talaei A, Hassanpour Moghadam M, Sajadi Tabassi SA, Mohajeri SA. Crocin, the main active saffron constituent, as an adjunctive treatment in major depressive disorder: a randomized, double-blind, placebo-controlled, pilot clinical trial. J Affect Disord. 2015;174:51-56.
  345. Milajerdi A, Jazayeri S, Shirzadi E, et al. The effects of alcoholic extract of saffron (Crocus satious L.) on mild to moderate comorbid depression-anxiety, sleep quality, and life satisfaction in type 2 diabetes mellitus: A double-blind, randomized and placebo-controlled clinical trial. Complement Ther Med. 2018;41:196-202.
  346. Lopresti AL, Smith SJ, Hood SD, Drummond PD. Efficacy of a standardised saffron extract (affron®) as an add-on to antidepressant medication for the treatment of persistent depressive symptoms in adults: A randomised, double-blind, placebo-controlled study. Journal of psychopharmacology (Oxford, England). 2019;33(11):1415-1427.
  347. Akhondzadeh S, Mostafavi SA, Keshavarz SA, Mohammadi MR, Hosseini S, Eshraghian MR. A placebo controlled randomized clinical trial of Crocus sativus L. (saffron) on depression and food craving among overweight women with mild to moderate depression. J Clin Pharm Ther. 2020;45(1):134-143.
  348. Kashani L, Esalatmanesh S, Eftekhari F, et al. Efficacy of Crocus sativus (saffron) in treatment of major depressive disorder associated with post-menopausal hot flashes: a double-blind, randomized, placebo-controlled trial. Arch Gynecol Obstet. 2018;297(3):717-724.
  349. Jalali F, Hashemi SF. The Effect of Saffron on Depression among Recovered Consumers of Methamphetamine Living with HIV/AIDS. Subst Use Misuse. 2018;53(12):1951-1957.
  350. Shahmansouri N, Farokhnia M, Abbasi SH, et al. A randomized, double-blind, clinical trial comparing the efficacy and safety of Crocus sativus L. with fluoxetine for improving mild to moderate depression in post percutaneous coronary intervention patients. J Affect Disord. 2014;155:216-222.
  351. Shakiba M, Moazen-Zadeh E, Noorbala AA, et al. Saffron (Crocus sativus) versus duloxetine for treatment of patients with fibromyalgia: A randomized double-blind clinical trial. Avicenna journal of phytomedicine. 2018;8(6):513-523.
  352. Kashani L, Raisi F, Saroukhani S, et al. Saffron for treatment of fluoxetine-induced sexual dysfunction in women: randomized double-blind placebo-controlled study. Human psychopharmacology. 2013;28(1):54-60.
  353. Modabbernia A, Sohrabi H, Nasehi AA, et al. Effect of saffron on fluoxetine-induced sexual impairment in men: randomized double-blind placebo-controlled trial. Psychopharmacology (Berl). 2012;223(4):381-388.
  354. Asher GN, Gartlehner G, Gaynes BN, et al. Comparative Benefits and Harms of Complementary and Alternative Medicine Therapies for Initial Treatment of Major Depressive Disorder: Systematic Review and Meta-Analysis. Journal of alternative and complementary medicine (New York, NY). 2017;23(12):907-919.
  355. Kasper S, Gastpar M, Möller HJ, et al. Better tolerability of St. John's wort extract WS 5570 compared to treatment with SSRIs: a reanalysis of data from controlled clinical trials in acute major depression. Int Clin Psychopharmacol. 2010;25(4):204-213.
  356. Freeman MP, Mischoulon D, Tedeschini E, et al. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants. The Journal of clinical psychiatry. 2010;71(6):682-688.
  357. Rahimi R, Nikfar S, Abdollahi M. Efficacy and tolerability of Hypericum perforatum in major depressive disorder in comparison with selective serotonin reuptake inhibitors: a meta-analysis. Progress in neuro-psychopharmacology & biological psychiatry. 2009;33(1):118-127.
  358. Apaydin EA, Maher AR, Shanman R, et al. A systematic review of St. John's wort for major depressive disorder. Syst Rev. 2016;5(1):148.
  359. Herraiz T, Guillén H. Monoamine Oxidase-A Inhibition and Associated Antioxidant Activity in Plant Extracts with Potential Antidepressant Actions. Biomed Res Int. 2018;2018:4810394.
  360. Sevastre-Berghian AC, Toma VA, Sevastre B, et al. Characterization and biological effects of Hypericum extracts on experimentally-induced - anxiety, oxidative stress and inflammation in rats. Journal of physiology and pharmacology : an official journal of the Polish Physiological Society. 2018;69(5).
  361. Schmidt M, Butterweck V. The mechanisms of action of St. John's wort: an update. Wien Med Wochenschr. 2015;165(11-12):229-235.
  362. Nicolussi S, Drewe J, Butterweck V, Meyer Zu Schwabedissen HE. Clinical relevance of St. John's wort drug interactions revisited. Br J Pharmacol. 2020;177(6):1212-1226.
  363. Pennisi M, Lanza G, Cantone M, et al. Acetyl-L-Carnitine in Dementia and Other Cognitive Disorders: A Critical Update. Nutrients. 2020;12(5).
  364. Maldonado C, Vázquez M, Fagiolino P. Potential Therapeutic Role of Carnitine and Acetylcarnitine in Neurological Disorders. Curr Pharm Des. 2020;26(12):1277-1285.
  365. Wang SM, Han C, Lee SJ, Patkar AA, Masand PS, Pae CU. A review of current evidence for acetyl-l-carnitine in the treatment of depression. Journal of psychiatric research. 2014;53:30-37.
  366. Nasca C, Bigio B, Lee FS, et al. Acetyl-l-carnitine deficiency in patients with major depressive disorder. Proc Natl Acad Sci U S A. 2018;115(34):8627-8632.
  367. Veronese N, Stubbs B, Solmi M, Ajnakina O, Carvalho AF, Maggi S. Acetyl-L-Carnitine Supplementation and the Treatment of Depressive Symptoms: A Systematic Review and Meta-Analysis. Psychosomatic medicine. 2018;80(2):154-159.
  368. Bersani G, Meco G, Denaro A, et al. L-Acetylcarnitine in dysthymic disorder in elderly patients: a double-blind, multicenter, controlled randomized study vs. fluoxetine. Eur Neuropsychopharmacol. 2013;23(10):1219-1225.
  369. Leombruni P, Miniotti M, Colonna F, et al. A randomised controlled trial comparing duloxetine and acetyl L-carnitine in fibromyalgic patients: preliminary data. Clin Exp Rheumatol. 2015;33(1 Suppl 88):S82-85.
  370. Rossini M, Di Munno O, Valentini G, et al. Double-blind, multicenter trial comparing acetyl l-carnitine with placebo in the treatment of fibromyalgia patients. Clin Exp Rheumatol. 2007;25(2):182-188.
  371. Klinge CM, Clark BJ, Prough RA. Dehydroepiandrosterone Research: Past, Current, and Future. Vitamins and hormones. 2018;108:1-28.
  372. Stárka L, Dušková M, Hill M. Dehydroepiandrosterone: a neuroactive steroid. J Steroid Biochem Mol Biol. 2015;145:254-260.
  373. Hu Q, Zhang SY, Liu F, Zhang YL, Zhu DM, Zang YY. Clinical significance of decreased protein expression of dehydroepiandrosterone sulfate in the development of depression: a meta-analysis. J Affect Disord. 2015;174:416-423.
  374. Mocking RJ, Pellikaan CM, Lok A, et al. DHEAS and cortisol/DHEAS-ratio in recurrent depression: State, or trait predicting 10-year recurrence? Psychoneuroendocrinology. 2015;59:91-101.
  375. Bloch M, Schmidt PJ, Danaceau MA, Adams LF, Rubinow DR. Dehydroepiandrosterone treatment of midlife dysthymia. Biological psychiatry. 1999;45(12):1533-1541.
  376. Schmidt PJ, Daly RC, Bloch M, et al. Dehydroepiandrosterone monotherapy in midlife-onset major and minor depression. Archives of general psychiatry. 2005;62(2):154-162.
  377. Wolkowitz OM, Reus VI, Keebler A, et al. Double-blind treatment of major depression with dehydroepiandrosterone. The American journal of psychiatry. 1999;156(4):646-649.
  378. Strous RD, Maayan R, Lapidus R, et al. Dehydroepiandrosterone augmentation in the management of negative, depressive, and anxiety symptoms in schizophrenia. Arch Gen Psychiatry. 2003;60(2):133-141.
  379. Rabkin JG, McElhiney MC, Rabkin R, McGrath PJ, Ferrando SJ. Placebo-controlled trial of dehydroepiandrosterone (DHEA) for treatment of nonmajor depression in patients with HIV/AIDS. The American journal of psychiatry. 2006;163(1):59-66.
  380. Tardy AL, Pouteau E, Marquez D, Yilmaz C, Scholey A. Vitamins and Minerals for Energy, Fatigue and Cognition: A Narrative Review of the Biochemical and Clinical Evidence. Nutrients. 2020;12(1).
  381. Mikkelsen K, Stojanovska L, Apostolopoulos V. The Effects of Vitamin B in Depression. Curr Med Chem. 2016;23(38):4317-4337.
  382. Young LM, Pipingas A, White DJ, Gauci S, Scholey A. A Systematic Review and Meta-Analysis of B Vitamin Supplementation on Depressive Symptoms, Anxiety, and Stress: Effects on Healthy and 'At-Risk' Individuals. Nutrients. 2019;11(9).
  383. Almeida OP, Ford AH, Flicker L. Systematic review and meta-analysis of randomized placebo-controlled trials of folate and vitamin B12 for depression. International psychogeriatrics. 2015;27(5):727-737.
  384. Mech AW, Farah A. Correlation of clinical response with homocysteine reduction during therapy with reduced B vitamins in patients with MDD who are positive for MTHFR C677T or A1298C polymorphism: a randomized, double-blind, placebo-controlled study. The Journal of clinical psychiatry. 2016;77(5):668-671.
  385. Tsujita N, Akamatsu Y, Nishida MM, Hayashi T, Moritani T. Effect of Tryptophan, Vitamin B(6), and Nicotinamide-Containing Supplement Loading between Meals on Mood and Autonomic Nervous System Activity in Young Adults with Subclinical Depression: A Randomized, Double-Blind, and Placebo-Controlled Study. J Nutr Sci Vitaminol (Tokyo). 2019;65(6):507-514.
  386. Roberts E, Carter B, Young AH. Caveat emptor: Folate in unipolar depressive illness, a systematic review and meta-analysis. Journal of psychopharmacology (Oxford, England). 2018;32(4):377-384.
  387. Martone G. Enhancement of recovery from mental illness with l-methylfolate supplementation. Perspect Psychiatr Care. 2018;54(2):331-334.
  388. Syed EU, Wasay M, Awan S. Vitamin B12 supplementation in treating major depressive disorder: a randomized controlled trial. Open Neurol J. 2013;7:44-48.
  389. Ghaleiha A, Davari H, Jahangard L, et al. Adjuvant thiamine improved standard treatment in patients with major depressive disorder: results from a randomized, double-blind, and placebo-controlled clinical trial. European archives of psychiatry and clinical neuroscience. 2016;266(8):695-702.
  390. Jones LA, Sun EW, Martin AM, Keating DJ. The ever-changing roles of serotonin. Int J Biochem Cell Biol. 2020:105776.
  391. Kałużna-Czaplińska J, Gątarek P, Chirumbolo S, Chartrand MS, Bjørklund G. How important is tryptophan in human health? Crit Rev Food Sci Nutr. 2019;59(1):72-88.
  392. Friedman M. Analysis, Nutrition, and Health Benefits of Tryptophan. Int J Tryptophan Res. 2018;11:1178646918802282.
  393. Savitz J. Role of Kynurenine Metabolism Pathway Activation in Major Depressive Disorders. Curr Top Behav Neurosci. 2017;31:249-267.
  394. Strasser B, Gostner JM, Fuchs D. Mood, food, and cognition: role of tryptophan and serotonin. Current opinion in clinical nutrition and metabolic care. 2016;19(1):55-61.
  395. Ramírez LA, Pérez-Padilla EA, García-Oscos F, Salgado H, Atzori M, Pineda JC. A new theory of depression based on the serotonin/kynurenine relationship and the hypothalamicpituitary- adrenal axis. Biomedica. 2018;38(3):437-450.
  396. Dell'Osso L, Carmassi C, Mucci F, Marazziti D. Depression, Serotonin and Tryptophan. Curr Pharm Des. 2016;22(8):949-954.
  397. Ramos-Chávez LA, Roldán-Roldán G, García-Juárez B, et al. Low Serum Tryptophan Levels as an Indicator of Global Cognitive Performance in Nondemented Women over 50 Years of Age. Oxid Med Cell Longev. 2018;2018:8604718.
  398. Ogawa S, Fujii T, Koga N, et al. Plasma L-tryptophan concentration in major depressive disorder: new data and meta-analysis. The Journal of clinical psychiatry. 2014;75(9):e906-915.
  399. Lieberman HR, Agarwal S, Fulgoni VL, 3rd. Tryptophan Intake in the US Adult Population Is Not Related to Liver or Kidney Function but Is Associated with Depression and Sleep Outcomes. J Nutr. 2016;146(12):2609s-2615s.
  400. Lindseth G, Helland B, Caspers J. The effects of dietary tryptophan on affective disorders. Arch Psychiatr Nurs. 2015;29(2):102-107.
  401. Kikuchi AM, Tanabe A, Iwahori Y. A systematic review of the effect of L-tryptophan supplementation on mood and emotional functioning. J Diet Suppl. 2020:1-18.
  402. Young SN. The effect of raising and lowering tryptophan levels on human mood and social behaviour. Philosophical transactions of the Royal Society of London Series B, Biological sciences. 2013;368(1615):20110375.
  403. Gibson EL. Tryptophan supplementation and serotonin function: genetic variations in behavioural effects. The Proceedings of the Nutrition Society. 2018;77(2):174-188.
  404. Jangid P, Malik P, Singh P, Sharma M, Gulia AK. Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode. Asian J Psychiatr. 2013;6(1):29-34.
  405. Birdsall TC. 5-Hydroxytryptophan: a clinically-effective serotonin precursor. Altern Med Rev. 1998;3(4):271-280.
  406. Jacobsen JPR, Krystal AD, Krishnan KRR, Caron MG. Adjunctive 5-Hydroxytryptophan Slow-Release for Treatment-Resistant Depression: Clinical and Preclinical Rationale. Trends Pharmacol Sci. 2016;37(11):933-944.
  407. Das YT, Bagchi M, Bagchi D, Preuss HG. Safety of 5-hydroxy-L-tryptophan. Toxicol Lett. 2004;150(1):111-122.
  408. Deepmala, Slattery J, Kumar N, et al. Clinical trials of N-acetylcysteine in psychiatry and neurology: A systematic review. Neuroscience and biobehavioral reviews. 2015;55:294-321.
  409. Berk M, Dean OM, Cotton SM, et al. The efficacy of adjunctive N-acetylcysteine in major depressive disorder: a double-blind, randomized, placebo-controlled trial. The Journal of clinical psychiatry. 2014;75(6):628-636.
  410. Porcu M, Urbano MR, Verri WA, Jr., et al. Effects of adjunctive N-acetylcysteine on depressive symptoms: Modulation by baseline high-sensitivity C-reactive protein. Psychiatry research. 2018;263:268-274.
  411. Cullen KR, Klimes-Dougan B, Westlund Schreiner M, et al. N-Acetylcysteine for Nonsuicidal Self-Injurious Behavior in Adolescents: An Open-Label Pilot Study. J Child Adolesc Psychopharmacol. 2018;28(2):136-144.
  412. Fernandes BS, Dean OM, Dodd S, Malhi GS, Berk M. N-Acetylcysteine in depressive symptoms and functionality: a systematic review and meta-analysis. J Clin Psychiatry. 2016;77(4):e457-466.
  413. Ross SM. Rhodiola rosea (SHR-5), Part 2: A standardized extract of Rhodiola rosea is shown to be effective in the treatment of mild to moderate depression. Holistic nursing practice. 2014;28(3):217-221.
  414. Limanaqi F, Biagioni F, Busceti CL, Polzella M, Fabrizi C, Fornai F. Potential Antidepressant Effects of Scutellaria baicalensis, Hericium erinaceus and Rhodiola rosea. Antioxidants (Basel, Switzerland). 2020;9(3).
  415. Concerto C, Infortuna C, Muscatello MRA, et al. Exploring the effect of adaptogenic Rhodiola Rosea extract on neuroplasticity in humans. Complement Ther Med. 2018;41:141-146.
  416. Mao JJ, Xie SX, Zee J, et al. Rhodiola rosea versus sertraline for major depressive disorder: A randomized placebo-controlled trial. Phytomedicine. 2015;22(3):394-399.
  417. Darbinyan V, Aslanyan G, Amroyan E, Gabrielyan E, Malmström C, Panossian A. Clinical trial of Rhodiola rosea L. extract SHR-5 in the treatment of mild to moderate depression. Nord J Psychiatry. 2007;61(5):343-348.
  418. Gao L, Wu C, Liao Y, Wang J. Antidepressants effects of Rhodiola capsule combined with sertraline for major depressive disorder: A randomized double-blind placebo-controlled clinical trial. J Affect Disord. 2020;265:99-103.
  419. Amsterdam JD, Panossian AG. Rhodiola rosea L. as a putative botanical antidepressant. Phytomedicine. 2016;23(7):770-783.
  420. Lemon Balm. TRC Natural Medicines.,-herbs-supplements/professional.aspx?productid=437. Updated 03/09/2020. Accessed 09/30/2020.
  421. Araj-Khodaei M, Noorbala AA, Yarani R, et al. A double-blind, randomized pilot study for comparison of Melissa officinalis L. and Lavandula angustifolia Mill. with Fluoxetine for the treatment of depression. BMC Complement Med Ther. 2020;20(1):207-207.
  422. López V, Martín S, Gómez-Serranillos MP, Carretero ME, Jäger AK, Calvo MI. Neuroprotective and neurological properties of Melissa officinalis. Neurochem Res. 2009;34(11):1955-1961.
  423. Haybar H, Javid AZ, Haghighizadeh MH, Valizadeh E, Mohaghegh SM, Mohammadzadeh A. The effects of Melissa officinalis supplementation on depression, anxiety, stress, and sleep disorder in patients with chronic stable angina. Clinical nutrition ESPEN. 2018;26:47-52.
  424. Ranjbar M, Firoozabadi A, Salehi A, et al. Effects of Herbal combination (Melissa officinalis L. and Nepeta menthoides Boiss. & Buhse) on insomnia severity, anxiety and depression in insomniacs: Randomized placebo controlled trial. Integr Med Res. 2018;7(4):328-332.
  425. Lavender. TRC Natural Medicines.,-herbs-supplements/professional.aspx?productid=838. Updated 09/11/2020. Accessed 09/30/2020.
  426. Bazrafshan MR, Jokar M, Shokrpour N, Delam H. The effect of lavender herbal tea on the anxiety and depression of the elderly: A randomized clinical trial. Complementary therapies in medicine. 2020;50:102393.
  427. Kasper S, Volz HP, Dienel A, Schläfke S. Efficacy of Silexan in mixed anxiety-depression--A randomized, placebo-controlled trial. Eur Neuropsychopharmacol. 2016;26(2):331-340.
  428. Uehleke B, Schaper S, Dienel A, Schlaefke S, Stange R. Phase II trial on the effects of Silexan in patients with neurasthenia, post-traumatic stress disorder or somatization disorder. Phytomedicine. 2012;19(8-9):665-671.
  429. Akhondzadeh S, Kashani L, Fotouhi A, et al. Comparison of Lavandula angustifolia Mill. tincture and imipramine in the treatment of mild to moderate depression: a double-blind, randomized trial. Progress in neuro-psychopharmacology & biological psychiatry. 2003;27(1):123-127.
  430. Sharma A, Gerbarg P, Bottiglieri T, et al. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research. J Clin Psychiatry. 2017;78(6):e656-e667.
  431. TRC Natural Medicines Database. SAMe. TRC.,-herbs-supplements/professional.aspx?productid=786. Updated 09/16/2020. Accessed 09/30/2020.
  432. Williams AL, Girard C, Jui D, Sabina A, Katz DL. S-adenosylmethionine (SAMe) as treatment for depression: a systematic review. Clinical and investigative medicine Medecine clinique et experimentale. 2005;28(3):132-139.
  433. Bressa GM. S-adenosyl-l-methionine (SAMe) as antidepressant: meta-analysis of clinical studies. Acta Neurol Scand Suppl. 1994;154:7-14.
  434. Hardy ML, Coulter I, Morton SC, et al. S-adenosyl-L-methionine for treatment of depression, osteoarthritis, and liver disease. Evid Rep Technol Assess (Summ). 2003(64):1-3.
  435. Sarris J, Murphy J, Stough C, et al. S-Adenosylmethionine (SAMe) monotherapy for depression: an 8-week double-blind, randomised, controlled trial. Psychopharmacology. 2020;237(1):209-218.
  436. Sarris J, Byrne GJ, Bousman C, et al. Adjunctive S-adenosylmethionine (SAMe) in treating non-remittent major depressive disorder: An 8-week double-blind, randomized, controlled trial<sup/>. Eur Neuropsychopharmacol. 2018;28(10):1126-1136.
  437. Galizia I, Oldani L, Macritchie K, et al. S-adenosyl methionine (SAMe) for depression in adults. The Cochrane database of systematic reviews. 2016;10(10):Cd011286.
  438. Mischoulon D, Price LH, Carpenter LL, et al. A double-blind, randomized, placebo-controlled clinical trial of S-adenosyl-L-methionine (SAMe) versus escitalopram in major depressive disorder. The Journal of clinical psychiatry. 2014;75(4):370-376.
  439. Sarris J, Price LH, Carpenter LL, et al. Is S-Adenosyl Methionine (SAMe) for Depression Only Effective in Males? A Re-Analysis of Data from a Randomized Clinical Trial. Pharmacopsychiatry. 2015;48(4-5):141-144.
  440. Sharma A, Gerbarg P, Bottiglieri T, et al. S-Adenosylmethionine (SAMe) for Neuropsychiatric Disorders: A Clinician-Oriented Review of Research. The Journal of clinical psychiatry. 2017;78(6):e656-e667.
  441. Karas Kuželički N. S-Adenosyl Methionine in the Therapy of Depression and Other Psychiatric Disorders. Drug Dev Res. 2016;77(7):346-356.
  442. Kious BM, Kondo DG, Renshaw PF. Creatine for the Treatment of Depression. Biomolecules. 2019;9(9).
  443. Bakian AV, Huber RS, Scholl L, Renshaw PF, Kondo D. Dietary creatine intake and depression risk among U.S. adults. Translational psychiatry. 2020;10(1):52.
  444. Lyoo IK, Yoon S, Kim TS, et al. A randomized, double-blind placebo-controlled trial of oral creatine monohydrate augmentation for enhanced response to a selective serotonin reuptake inhibitor in women with major depressive disorder. The American journal of psychiatry. 2012;169(9):937-945.
  445. Yoon S, Kim JE, Hwang J, et al. Effects of Creatine Monohydrate Augmentation on Brain Metabolic and Network Outcome Measures in Women With Major Depressive Disorder. Biological psychiatry. 2016;80(6):439-447.
  446. Kious BM, Sabic H, Sung YH, Kondo DG, Renshaw P. An Open-Label Pilot Study of Combined Augmentation With Creatine Monohydrate and 5-Hydroxytryptophan for Selective Serotonin Reuptake Inhibitor- or Serotonin-Norepinephrine Reuptake Inhibitor-Resistant Depression in Adult Women. Journal of clinical psychopharmacology. 2017;37(5):578-583.
  447. Kondo DG, Sung YH, Hellem TL, et al. Open-label adjunctive creatine for female adolescents with SSRI-resistant major depressive disorder: a 31-phosphorus magnetic resonance spectroscopy study. J Affect Disord. 2011;135(1-3):354-361.
  448. Nemets B, Levine J. A pilot dose-finding clinical trial of creatine monohydrate augmentation to SSRIs/SNRIs/NASA antidepressant treatment in major depression. International clinical psychopharmacology. 2013;28(3):127-133.
  449. Colodny L, Hoffman RL. Inositol--clinical applications for exogenous use. Alternative medicine review : a journal of clinical therapeutic. 1998;3(6):432-447.
  450. Zheng H, Zhang L, Li L, et al. High-frequency rTMS treatment increases left prefrontal myo-inositol in young patients with treatment-resistant depression. Progress in neuro-psychopharmacology & biological psychiatry. 2010;34(7):1189-1195.
  451. Moore CM, Breeze JL, Kukes TJ, et al. Effects of myo-inositol ingestion on human brain myo-inositol levels: a proton magnetic resonance spectroscopic imaging study. Biological psychiatry. 1999;45(9):1197-1202.
  452. Levine J, Barak Y, Gonzalves M, et al. Double-blind, controlled trial of inositol treatment of depression. The American journal of psychiatry. 1995;152(5):792-794.
  453. Mukai T, Kishi T, Matsuda Y, Iwata N. A meta-analysis of inositol for depression and anxiety disorders. Human psychopharmacology. 2014;29(1):55-63.
  454. Levine J, Mishori A, Susnosky M, Martin M, Belmaker RH. Combination of inositol and serotonin reuptake inhibitors in the treatment of depression. Biological psychiatry. 1999;45(3):270-273.
  455. Nemets B, Mishory A, Levine J, Belmaker RH. Inositol addition does not improve depression in SSRI treatment failures. Journal of neural transmission (Vienna, Austria : 1996). 1999;106(7-8):795-798.
  456. Botturi A, Ciappolino V, Delvecchio G, Boscutti A, Viscardi B, Brambilla P. The Role and the Effect of Magnesium in Mental Disorders: A Systematic Review. Nutrients. 2020;12(6).
  457. Tarleton EK, Kennedy AG, Rose GL, Crocker A, Littenberg B. The Association between Serum Magnesium Levels and Depression in an Adult Primary Care Population. Nutrients. 2019;11(7).
  458. Sun C, Wang R, Li Z, Zhang D. Dietary magnesium intake and risk of depression. J Affect Disord. 2019;246:627-632.
  459. Phelan D, Molero P, Martínez-González MA, Molendijk M. Magnesium and mood disorders: systematic review and meta-analysis. BJPsych Open. 2018;4(4):167-179.
  460. Tarleton EK, Littenberg B, MacLean CD, Kennedy AG, Daley C. Role of magnesium supplementation in the treatment of depression: A randomized clinical trial. PLoS One. 2017;12(6):e0180067.
  461. Rajizadeh A, Mozaffari-Khosravi H, Yassini-Ardakani M, Dehghani A. Effect of magnesium supplementation on depression status in depressed patients with magnesium deficiency: A randomized, double-blind, placebo-controlled trial. Nutrition (Burbank, Los Angeles County, Calif). 2017;35:56-60.
  462. Vink R. Magnesium in the CNS: recent advances and developments. Magnesium research : official organ of the International Society for the Development of Research on Magnesium. 2016;29(3):95-101.
  463. Sun Q, Weinger JG, Mao F, Liu G. Regulation of structural and functional synapse density by L-threonate through modulation of intraneuronal magnesium concentration. Neuropharmacology. 2016;108:426-439.
  464. Zhou X, Huang Z, Zhang J, et al. Chronic Oral Administration of Magnesium-L-Threonate Prevents Oxaliplatin-Induced Memory and Emotional Deficits by Normalization of TNF-α/NF-κB Signaling in Rats. Neuroscience bulletin. 2020.
  465. Kim YS, Won YJ, Lim BG, Min TJ, Kim YH, Lee IO. Neuroprotective effects of magnesium L-threonate in a hypoxic zebrafish model. BMC neuroscience. 2020;21(1):29.
  466. Shen Y, Dai L, Tian H, et al. Treatment Of Magnesium-L-Threonate Elevates The Magnesium Level In The Cerebrospinal Fluid And Attenuates Motor Deficits And Dopamine Neuron Loss In A Mouse Model Of Parkinson's disease. Neuropsychiatr Dis Treat. 2019;15:3143-3153.
  467. Huang Y, Huang X, Zhang L, et al. Magnesium boosts the memory restorative effect of environmental enrichment in Alzheimer's disease mice. CNS Neurosci Ther. 2018;24(1):70-79.
  468. Jia S, Liu Y, Shi Y, et al. Elevation of Brain Magnesium Potentiates Neural Stem Cell Proliferation in the Hippocampus of Young and Aged Mice. J Cell Physiol. 2016;231(9):1903-1912.
  469. Sadir S, Tabassum S, Emad S, et al. Neurobehavioral and biochemical effects of magnesium chloride (MgCl2), magnesium sulphate (MgSO4) and magnesium-L-threonate (MgT) supplementation in rats: A dose dependent comparative study. Pakistan journal of pharmaceutical sciences. 2019;32(1(Supplementary)):277-283.
  470. Ochoa-de la Paz L, Zenteno E, Gulias-Cañizo R, Quiroz-Mercado H. Taurine and GABA neurotransmitter receptors, a relationship with therapeutic potential? Expert Rev Neurother. 2019;19(4):289-291.
  471. Cui T, Qiu HM, Huang D, et al. Abnormal levels of seven amino neurotransmitters in depressed rat brain and determination by HPLC-FLD. Biomed Chromatogr. 2017;31(8).
  472. Caletti G, Olguins DB, Pedrollo EF, Barros HM, Gomez R. Antidepressant effect of taurine in diabetic rats. Amino Acids. 2012;43(4):1525-1533.
  473. Caletti G, Almeida FB, Agnes G, Nin MS, Barros HM, Gomez R. Antidepressant dose of taurine increases mRNA expression of GABAA receptor α2 subunit and BDNF in the hippocampus of diabetic rats. Behavioural brain research. 2015;283:11-15.
  474. Wu GF, Ren S, Tang RY, et al. Antidepressant effect of taurine in chronic unpredictable mild stress-induced depressive rats. Sci Rep. 2017;7(1):4989.
  475. O'Donnell CP, Allott KA, Murphy BP, et al. Adjunctive Taurine in First-Episode Psychosis: A Phase 2, Double-Blind, Randomized, Placebo-Controlled Study. The Journal of clinical psychiatry. 2016;77(12):e1610-e1617.
  476. Cussotto S, Clarke G, Dinan TG, Cryan JF. Psychotropics and the Microbiome: a Chamber of Secrets…. Psychopharmacology. May 2019;236(5):1411-1432. doi:10.1007/s00213-019-5185-8
  477. Macedo D, Filho A, Soares de Sousa CN, et al. Antidepressants, antimicrobials or both? Gut microbiota dysbiosis in depression and possible implications of the antimicrobial effects of antidepressant drugs for antidepressant effectiveness. J Affect Disord. Jan 15 2017;208:22-32. doi:10.1016/j.jad.2016.09.012
  478. McGovern AS, Hamlin AS, Winter G. A review of the antimicrobial side of antidepressants and its putative implications on the gut microbiome. The Australian and New Zealand journal of psychiatry. Dec 2019;53(12):1151-1166. doi:10.1177/0004867419877954
  479. Ait Chait Y, Mottawea W, Tompkins TA, Hammami R. Unravelling the antimicrobial action of antidepressants on gut commensal microbes. Sci Rep. Oct 21 2020;10(1):17878. doi:10.1038/s41598-020-74934-9
  480. Sun L, Zhang H, Cao Y, et al. Fluoxetine ameliorates dysbiosis in a depression model induced by chronic unpredicted mild stress in mice. Int J Med Sci. 2019;16(9):1260-1270. doi:10.7150/ijms.37322
  481. Siopi E, Chevalier G, Katsimpardi L, et al. Changes in Gut Microbiota by Chronic Stress Impair the Efficacy of Fluoxetine. Cell reports. Mar 17 2020;30(11):3682-3690.e6. doi:10.1016/j.celrep.2020.02.099
  482. Lukić I, Getselter D, Ziv O, et al. Antidepressants affect gut microbiota and Ruminococcus flavefaciens is able to abolish their effects on depressive-like behavior. Translational psychiatry. Apr 9 2019;9(1):133. doi:10.1038/s41398-019-0466-x
  483. Lyte M, Daniels KM, Schmitz-Esser S. Fluoxetine-induced alteration of murine gut microbial community structure: evidence for a microbial endocrinology-based mechanism of action responsible for fluoxetine-induced side effects. PeerJ. 2019;7:e6199. doi:10.7717/peerj.6199
  484. Ticinesi A, Milani C, Lauretani F, et al. Gut microbiota composition is associated with polypharmacy in elderly hospitalized patients. Sci Rep. Sep 11 2017;7(1):11102. doi:10.1038/s41598-017-10734-y
  485. Falony G, Joossens M, Vieira-Silva S, et al. Population-level analysis of gut microbiome variation. Science. Apr 29 2016;352(6285):560-4. doi:10.1126/science.aad3503
  486. Tomizawa Y, Kurokawa S, Ishii D, et al. Effects of Psychotropics on the Microbiome in Patients with Depression and Anxiety: Considerations in a Naturalistic Clinical Setting. The international journal of neuropsychopharmacology / official scientific journal of the Collegium Internationale Neuropsychopharmacologicum (CINP). Sep 25 2020;doi:10.1093/ijnp/pyaa070
  487. Fontana A, Manchia M, Panebianco C, et al. Exploring the Role of Gut Microbiota in Major Depressive Disorder and in Treatment Resistance to Antidepressants. Biomedicines. Aug 27 2020;8(9)doi:10.3390/biomedicines8090311
  488. Bharwani A, Bala A, Surette M, Bienenstock J, Vigod SN, Taylor VH. [Not Available]. Can J Psychiatry. Apr 2020;65(4):278-280. Gut Microbiome Patterns Associated With Treatment Response in Patients With Major Depressive Disorder. doi:10.1177/0706743719900464
  489. Yang J, Zheng P, Li Y, et al. Landscapes of bacterial and metabolic signatures and their interaction in major depressive disorders. Science advances. 2020;6(49).
  490. Mukherjee A, Lordan C, Ross RP, Cotter PD. Gut microbes from the phylogenetically diverse genus Eubacterium and their various contributions to gut health. Gut Microbes. 2020;12(1):1802866.